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ABSTRACT 
The exposure of cells to environmental stresses, including heat shock, 
heavy metals, alcohols or oxidative stress results in the cellular accumulation of 
a number of chaperones, commonly known as heat shock proteins (Hsps). Hsps 
maintains the correct folding and conformation of proteins and are vital in 
regulating the stability between protein synthesis and degradation. Hsps are not 
only fundamental in the cellular stress response but are also important in 
regulating numerous important normal functions, such as cell proliferation and 
apoptosis. The results presented in the thesis focus on Hsp90 in nematodes, its 
possible roles in acquired drug resistance and further characterisation of Brugia 
pahangi Hsp90. 
Hsp90 plays a key role in the cellular stress response by interacting with 
proteins after their native conformation has been altered by stress.  Hsp90 is 
essential in all eukaryotes and plays a central role in multiple cellular processes. 
Since knock-out of hsp90 is lethal to most eukaryotes, inhibitors of Hsp90 have 
been widely used to study its function. The most widely used inhibitor is 
geldanamycin (GA). GA binds to the N-terminal/ATP binding site of Hsp90 which 
results in conformational changes and the degradation of client proteins. 
Although the gene encoding hsp90 has been characterized, little is known 
regarding its function in parasitic nematodes. Previous studies have shown that 
Caenorhabditis elegans Hsp90 is unique amongst eukaryotes because it fails to 
binds GA. This was suggested as an example of ‘adaptive evolution’ because C. 
elegans inhabits the same ecological niche of the soil as the Streptomyces 
species which produces GA. In contrast B. pahangi Hsp90 does bind to GA. The 
first objective of this project was to determine whether the resistance of C. 
elegans Hsp90 to GA is the norm or the exception amongst nematodes and to 
determine whether GA binding is associated with particular clades of 
nematodes. The results showed that the ability of Hsp90 to bind GA is associated 
with the life-cycle of the nematode. Free-living species or those that have a 
free-living larval stage in the soil do not bind GA, while those species which are 
obligate parasites (Trichinella and the filarial worms), or which are enclosed 
within a protective egg shell while in the environment (Ascarids), possess an 
Hsp90 that binds GA. These data support the adaptive evolution hypothesis. 
iv 
Further characterisation of B. pahangi Hsp90 showed that it was 
expressed in all life-cycle stages but in the pull-down assay, only adult B. 
pahangi Hsp90 bound to GA, not Hsp90 from L3 or Mf. The inability to detect L3 
or Mf Hsp90 binding to GA beads could perhaps reflect a lack of sensitivity of the 
assay, or alternatively may suggest that Hsp90 from these stages is processed in 
such way that it fails to bind to GA. In addition, only a small amount (6.3%) of B. 
pahangi Hsp90 bound to GA after a series of pull-down assays. Whether these 
data represents an accurate reflection of the amount of Hsp90 that can bind to 
GA is not known, but if correct, the results suggest that it might be necessary to 
inhibit only a small percentage of total Hsp90 to kill the worm.  
Attempts were make to identify proteins that associate with Hsp90 by 
comparing the proteome of GA-treated adult B. pahangi with control worms. In 
this analysis, several proteins with structural functions were identified. These 
proteins were down-regulated after exposure to GA at 1.0 µM. Comparison of 
Hsp90 levels in B. pahangi and C. elegans showed that Hsp90 was expressed at 
relatively higher levels in B. pahangi (p<0.05) but there was no significant 
difference in the affinity of B. pahangi or C. elegans for Hsp90 binding to ATP 
beads. Results in Chapter 4 showed that the binding of Hsp90 to GA beads was 
competed by free GA or ATP. In addition, novobiocin, another Hsp90 inhibitor 
which binds at C-terminal domain of Hsp90 also inhibited binding of B. pahangi 
Hsp90 to GA beads, suggesting an interaction between the N-terminal and C-
terminal of Hsp90.    
Hsp90 has also been shown to be involved in the acquisition of drug 
resistance in fungi. A previous study on fungi showed that the emergence of 
fluconazole resistance depended on high levels of Hsp90 and was abolished when 
Hsp90 expression was reduced. So, given the conservation of Hsp90 it is possible 
that Hsp90 may be involved in the acquired resistance of nematodes to 
anthelmintic. The analysis carried out did not produce any correlation between 
expression levels of Hsp90 and drug resistance in nematodes. RNAi experiments 
were carried out to reduce Hsp90 levels in C. elegans and to investigate whether 
Hsp90 may play a role in the tolerance of ivermectin-resistant C. elegans to 
drug. Results showed that reducing Hps90 levels altered the sensitivity of 
ivermectin-resistant C. elegans to drug.   
v 
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Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
Chapter 1  2  
1 Introduction 
1.1 Heat shock proteins 
In 1962, Ritossa reported the effects of evelated temperature on the 
puffing patterns of the salivary gland chromosomes of Drosophila busckii 
(Ritossa, 1962). An increase in incubation temperature resulted in the 
development of a defined set of new transcription loci on the polytene 
chromosomes. Similar effects were also observed after treatment with 2,4-
dinitrophenol and sodium salicylate in Drosophila melanogaster larvae (Ritossa, 
1963). These observations indicated that elevated temperatures and chemical 
compounds induced the expression of certain genes. However, the term ‘heat 
shock protein’ only emerged in 1974 when Tissieres and co-workers identified 
the first gene products representing this protein group in the salivary glands of 
D. melanogaster. These proteins not only appeared in salivary glands of D. 
melanogaster but also in the brain, Malphighian tubules and wing imaginal disc, 
indicating that the response was not tissue specific. Besides that, a similar 
effect of ecdysterone treatment was also observed in salivary glands but the 
induction was much less compared to that following heat shock. These unique 
proteins were referred to as heat shock proteins because of the nature of the 
stimulus that caused their induction. The remarkable discovery of heat shock 
proteins (Hsps) led to numerous subsequent studies in which Hsps were shown to 
be present in all species tested and to be well conserved (as reviewed by 
Lindquist & Craig, 1988).  
As their name implies, Hsps respond to an increase in temperature but they 
are also induced when a cell undergoes various types of other stresses. Almost 
any abrupt change in cellular environment will induce the synthesis of heat 
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shock, or stress, proteins (Csermely et al., 1998). Some Hsp members are 
constitutively expressed while some are only expressed after stress (Samali & 
Orrenius, 1998). There are a number of conditions that can induce the heat 
shock response in cells including environmental stresses, toxins, 
pathophysiological and disease states. In addition, Hsps can be induced under 
non-stress conditions such as cell growth and development and at particular 
phases of the cell cycle etc. (Morimoto, 1998)(Figure 1.1).  
A consequence of exposure to stress is the accumulation of misfolded or 
denatured proteins. Hsps bind to damaged polypeptides and either help to refold 
them or facilitate their degradation by the ubiquitin-proteasome pathway. Hsp 
induction requires the activation of heat shock factor (HSF)(Lis & Wu, 1993; 
Morimoto, 1993; Morimoto, 1998). HSF is a transcription factor that is 
responsible for regulating Hsp expression (Yamamoto et al., 2009). Up to now 
four HSFs have been characterised from animals namely, HSF-1, HSF-2, HSF-3 
and HSF-4 (Morimoto, 1998). HSF-3 was shown to be only present in avian 
species while, HSF-1, HSF-2 and HSF-4 were shown to be present in human, 
mouse and chicken. There are multiple HSFs in plants.  HSF-1 is the major 
regulator of Hsps (Sreedhar & Csermely, 2004). Following activation, HSF-1 binds 
to heat shock elements (HSEs), stress-responsive promoter elements essential for 
heat shock inducibility. These contain multiple adjacent inverted arrays of the 
binding site (5’-nGAAn-3’)(Fernandes et al., 1994), and binding of HSF-1 
activates the transcription of Hsps (Wu, 1995; Morimoto, 1998). The induction of 
Hsps helps to repair damaged proteins and assists in the recovery of the cells. 
Then, when the stress is removed, Hsp levels drop back to normal. This 
adaptation is vital for cells to restore homeostasis and improves survival. 
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Figure 1.1: Conditions that induce the heat shock response (after Morimoto, 1998). 
  
Hsps respond to environmental stress, pathophysiological stress and non-stress conditions 
following activation of heat shock factor (HSF) that binds to heat shock elements (HSEs) 
and activates transcription of Hsps. 
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Fever and inflammation 
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Neuronal injury 
Ischemia 
Oxidant injury 
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Tissue injury and repair 
Viral and bacterial 
infection 
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Heat shock 
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Oxygen-free radicals 
Transition of heavy metal 
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1.1.1 The heat shock protein family and their functions 
The major function of all Hsps is in molecular chaperoning. According to 
Hartl (1996), molecular chaperones can be defined as ‘proteins that bind to and 
stabilize an otherwise unstable conformer of another protein-and by controlled 
binding and release, facilitate its correct fate in vivo: be it folding, oligomeric 
assembly, transport to a particular sub-cellular compartment, or disposal by 
degradation’. Molecular chaperones assist or mediate the correct assembly of 
other polypeptides but are not a component of the final fold (Ellis & 
Hemmingsen, 1989). As molecular chaperones, Hsps help in protein folding, 
refolding and in the stabilization of unstable proteins. After cells are exposed to 
stresses such as heat shock, proteins become less stable and may become locally 
unfolded or misfolded. In response to the stress, transcription of Hsps is induced 
to protect cells from further damage. Hsps facilitate the unfolded/misfolded 
proteins to acquire their native state. This mechanism helps to maintain the 
protein levels in response to stresses. Hsps are also involved in the translocation 
of protein across intracellular membranes (Phillips & Silhavy, 1990; Hannavy et 
al., 1993). The other important aspect of Hsps as molecular chaperones is their 
function to prevent the aggregation of proteins. This function is vital to ensure 
proper folding of polypeptides especially for newly synthesised polypeptides.  
Hsps are classified into different families, based on their molecular 
weight, structure and function.  Those families include Hsp100, Hsp90, Hsp70, 
Hsp60, Hsp40 and the small heat shock protein family (sHsp) (reviewed by 
Johnson & Craig, 1997). Table 1.1 shows the major families of heat shock 
proteins and their functions. Hsp100 is a member of the AAA (ATPase associated 
with various cellular activities) superfamily (Neuwald et al., 1999). The AAA 
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superfamily is a diverse family of enzymes that act on other macromolecules and 
catalyze processes (Maurizi & Xia, 2004). Hsp90 is a member of the gyrase-
Hsp90-histidine kinase-MutL (GHKL) family of ATPases (Ban et al., 1999). It is 
essential in eukaryotes and involved in multiple cellular processes especially in 
maturation of substrate or client proteins engaged in signalling pathways 
(reviewed by Pearl & Prodromou, 2006). Hsp90 is discussed further in Section 
1.2.  
Hsp70 has various functions in cells. It assists in protein folding, refolding 
aggregated proteins, assembly of newly synthesized proteins, and is involved in 
the transportation of proteins across membranes (Fujihara & Nedler, 1999). In 
the free-living nematode, Caenorhabditis elegans, hsp70 constitutes a multi-
gene family (Heschl & Baillie, 1989) with different temporal and spatial 
expression patterns. In addition, some Hsp70s have been characterised from 
various parasitic nematodes, including Brugia malayi (Selkirk et al., 1989) and 
Parastrongyloides trichosuri (Newton-Howes et al., 2006). However, the exact 
function of the hsp70 gene family in parasitic nematodes remains uncertain. 
Hsp60 is considered to be a typical mitochondrial chaperone (also known 
as Cpn60) and in eukaryotes, can be found in mitochondria, the cytosol and at 
the cell surface. In plants, Hsp60 is localised to the chloroplast (Cappello et al., 
2008). Hsp60 plays an essential role in the transportation and maintenance of 
mitochondrial proteins (Koll et al., 1992) as well as the transmission and 
replication of mitochondrial DNA (Smiley et al., 1992) The intracellular Hsp60, 
which resides in mitochondria and chloroplasts, was shown to interact with 
Hsp10 (or Cpn10) to assist newly synthesised proteins to achieve their native 
conformation (Cheng et al., 1989; Richardson et al., 2001). Besides that, Hsp60 
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was shown to be present on the surface of normal (Soltys & Gupta, 1997) and 
tumour cells (Piselli et al., 2000; Feng et al., 2002; Shin et al., 2003) and has 
been suggested to be a danger signal for the immune system for the activation 
of anti-tumour T-cell responses (Feng et al., 2002; Osterloh et al., 2004). In 
addition, mutations in GroEL (a homologue of Hsp60 in bacteria) blocked the 
export of some proteins (Kusukawa et al., 1989), which suggested a role for 
Hsp60 in protein transportation. In the parasitic nematode, Trichinella spiralis, 
the induction of Hsp60 was suggested to be involved in maintenance of tolerance 
to the toxic oxidant H2O2 (Martinez et al., 2002).  
Hsp40 is categorized based on homology to the founding member in 
Escherichia coli, DnaJ (Ohtsuka et al., 1990; Hattori et al., 1993; Ohtsuka, 
1993). The key factor of Hsp40 function resides in the J-domain. This well 
conserved domain is thought to promote the function of Hsp40 by recruiting an 
Hsp70 (Sugito et al., 1995; Minami et al., 1996).   
Small Hsps (sHsps) are a varied group and widely distributed in both 
prokaryotes and eukaryotes. sHsps range in size from 12 to 43 kDa with the 
majority between 14 and 27 kDa (Garofalo et al., 2009). Different organisms 
have different numbers of sHsps, ranging from one in Saccharomyces cerevisiae 
(Petko & Lindquist, 1986) to 30 in higher plants (Mansfield & Key, 1987).  In 
plants, the sHsps are localized to the chloroplast, cytoplasm, nucleus, 
endoplasmic reticulum and mitochondria (Garofalo et al., 2009). sHsps are 
involved in stabilization of misfolded proteins and thermotolerance. 
Furthermore, a well conserved domain in sHsps, known as the α-crystallin 
domain is an important component of the eye lens which functions for the 
lifespan of an organism and is essential for vision (Ingolia & Craig, 1982). hsp16 
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is a multi-gene family in the free-living nematode C. elegans. Over-expression of 
hsp16.2, the most-stress inducible of the family, resulted in increased longevity 
and resistance to a variety of stresses (Walker & Lithgow, 2003). According to 
Halaschek-Wiener et al (2005), genes of the hsp16 family were shown to be very 
highly up-regulated in long-lived daf-2 mutants.  
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Table 1.1: Hsp families and their major functions 
 
Hsp families Major functions 
 
 
 
Hsp100 
 
Hsp90 
 
 
Hsp70 
 
Hsp60 
 
Hsp40 
 
Small Hsp 
 
Protein disaggregation, thermotolerance 
 
Regulatory interactions with signaling proteins, stabilization 
of misfolded proteins 
 
Protein folding, membrane transport of proteins 
 
Protein folding (limited substrates in eukaryotic cytoplasm) 
 
Protein folding, co-chaperone for Hsp70 
 
Stabilization of misfolded proteins, thermotolerance, eye 
lens structural proteins 
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1.2 Hsp90 
 The 90 kDa heat shock protein (Hsp90) is one of the most abundant 
proteins in the cytosol of both eukaryotic and prokaryotic cells. It can constitute 
up to 1-2% of the cellular protein under normal conditions (Welch & Feramisco, 
1982). The concentration of Hsp90 increases even more upon sudden 
temperature upshifts. Hsp90 is a unique molecular chaperone that is involved in 
cellular regulatory processes. To date members of the Hsp90 family have been 
found in the cytosol, the endoplasmic reticulum and chloroplasts (Rebbe et al., 
1987; Felts et al., 2000; Krishna & Gloor, 2001). Hsp90 is essential in all cells 
because of the nature of the proteins which it chaperones. Unlike other Hsps, 
Hsp90 chaperones specific client proteins that associate together for folding and 
degradation. Hsp90 keeps proteins on the correct folding pathway and at the 
same time prevents possible non-specific interactions with other proteins. 
Because of the importance of Hsp90 in cells it has been extensively studied, but 
much of the information on Hsp90 interactions comes from studies on 
mammalian cell lines and yeast.   
1.2.1 Hsp90 structure and conformation 
 Hsp90 is a hydrophobic protein and its hydrophobicity further increases 
after heat shock (Iwasaki et al., 1989; Yamamoto et al., 1991).  The first report 
of the crystallization of the full-length yeast Hsp90 was published nearly 14 
years ago by Prodromou et al (1996).  Based on proteolysis data (Nemoto et al., 
1997; Young et al., 1997), Hsp90 consists of three domains: a 25 kDa N-terminal, 
a 35 kDa middle domain (M) and a 12 kDa C-terminal domain (see Figure 1.3 for 
outline drawing representing the Hsp90 structural domains). The N-terminal 
domain is linked to the M-domain by a charged region (CR). The 25 kDa N-
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terminal domain of Hsp90 is the binding site for ATP (Prodromou et al., 1997) 
and geldanamycin (GA)(Whitesell et al., 1994) and is highly conserved across all 
species.  GA is a specific inhibitor of Hsp90 (Prodromou et al., 1997; Whitesell et 
al., 1994; Roe et al., 1999)(Section 1.3.1). The N-terminus is the binding site for 
another Hsp90 inhibitor, radicicol (Soga et al., 1998). The N-terminal domain 
contains an unusual adenine-nucleotide binding pocket known as a Bergerat fold 
(Dutta & Inouye, 2000). It is unusual because it has no similarity to ATP-binding 
domains found in other kinases or the chaperone Hsp70 (Whitesell & Lindquist, 
2005) even though it belongs to the GHKL superfamily. The middle domain (M-
domain) of yeast Hsp90 (amino acids 272-617) was found to mediate the 
interaction with Aha1 and Hch1 (Lotz et al., 2003). Aha1 and Hch1 are two 
Hsp90-associated proteins required by Hsp90 for full activation. The M-domain is 
a major site for client protein interactions (Fontana et al., 2002). The C-
terminus functions as a dimerisation domain (Minami et al., 1994). The C-
terminal domain is also supposed to possess an alternative ATP-binding site, 
which becomes accessible when the N-terminal pocket is occupied (Marcu et al., 
2000b; Soti et al., 2002).  
CR refers to the charged region which serves as a flexible linker between 
the N-terminal and M-domains (see Figure 1.2). All cytosolic eukaryotic Hsp90 
proteins have a charged region of varying size. The CR is possibly involved in 
regulatory function and participates in the association of the protein with 
steroid receptors (Dao-Phan et al., 1997) and with the protein kinase CK-II 
(Miyata & Yahara, 1995). However, genetic studies show that the CR is not 
fundamental for the life-sustaining functions of Hsp90 in yeast, because deletion 
of the CR did not demonstrate any noticeable phenotypes in vivo (Louvion et al., 
1996). However, it may be involved in some “back-up” or regulatory functions 
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(Csermely et al., 1998). Figure 1.3 shows the dimer of Hsp90 and its biochemical 
functions.  
 
 
 
 
 
 
Figure 1.2: Structural domains of yeast Hsp90 (after Pearl & Prodromou, 2006) 
 
N = The N-terminal domain 
M = The middle domain 
C = The C-terminal domain 
   = The charged region links the N-terminal domain to the M-domain 
 Numbers denote the amino acid positions of different domains of yeast Hsp90. 
 
 
 
 
 
 
 
 
Chapter 1    13
 
 
 
 
 
                      
 
 
 
 
Figure 1.3: Structure of Hsp90 dimer and its biochemical functions  
 
The N-terminal domain of Hsp90 is a binding site for ATP/GA. The M-domain functions as a 
binding site for co-chaperones and client proteins. It is also required for the ATPase 
activation. The C-domain is vital for the dimerization of Hsp90. The CR links the N-domain to 
the M-domain (after Whitesell & Lindquist, 2005). 
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1.2.2 Classification of Hsp90 
Hsp90 exists in all organisms but is absent in the Archaebacteria (Tanaka 
& Nakamoto, 1999; Stechmann & Cavalier-Smith, 2004). Chen et al (2006) 
divided the Hsp90 gene family into five sub-families, namely HSP90A, HSP90B, 
HSP90C, TRAP and HTPG, which differ in their cellular localisation. The Hsp90 
homologue, HTPG (high temperature protein G) is the shortest in the Hsp90 
family, with a molecular mass between 66.7–78.0 kDa and it exists in the 
Eubacteria but not in the Archaebacteria. Deletion of HTPG in Eubacteria is not 
lethal but results in a slight growth disadvantage (Bardwell & Craig, 1988). 
HSP90A, which exists in all the eukaryotic kingdoms, can be further divided into 
two different classes in vertebrates, Hsp90-alpha (Hsp90α) and Hsp90-beta 
(Hsp90β). These both exist in the cytosol where Hsp90α is the inducible form and 
Hsp90β, the constitutive form (Rebbe et al., 1987; Hoffmann & Hovemann 1988). 
HSP90B exists in all species of Protista, Plantae and Animalia, and some species 
of Fungi. HSP90B is an Hsp90 homologue which resides in the endoplasm 
reticulum and is also known as Grp94 (94 kDa glucose-regulated protein). HSP90C 
is an Hsp90 homologue which can be found in chloroplasts and is only present in 
Plantae. HSP90C has duplicated into Hsp90C1 and Hsp90C2 in higher plants. 
TRAP (tumor necrosis factor receptor-associated protein) is an Hsp90 homologue 
which resides in the mitochondria and is most closely related to HTPG 
(Stechmann & Cavalier-Smith, 2004). Refer to Table 1.2 for details of the Hsp90 
family. 
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Table 1.2: Members of the Hsp90 molecular chaperone family 
 
Name Subgroup Characteristic 
localization 
Kingdom 
HTPG 
 
 
HtpG-A 
HtpG-B 
HtpG-C 
Cytoplasm 
 
 
Bacteria but absent in 
Archaebacteria 
 
HSP90A Hsp90α 
Hsp90β 
Cytoplasm Exists in all eukaryotic 
kingdom 
HSP90B Also known as 
Grp94 
 
Endoplasmic reticulum Exists in all eukaryotic 
kingdom 
HSP90C Hsp90C1 
Hsp90C2 
Chloroplast Plantae 
TRAP  Mitochondrial Animalia and some 
species in  Protista 
(Alveolata, 
Englenozoa) 
    
 
 
(Adapted from Chen et al., 2006). 
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1.2.3 Hsp90 functions 
 As its name implies, Hsp90 responds to environmental changes such as 
elevated temperature, oxidation, pH etc. This response is important for 
maintaining a favourable environment which is suitable for cells to cope with 
environmental changes. Hsp90 plays a fundamental role in all cells. It has been 
suggested to play a central role in the assembly (Jackson et al., 2004) and 
disassembly machine (Wegele et al., 2004). This unique chaperone works 
together with Hsp40, Hsp70 and other co-chaperones such as the TPR proteins 
etc. in activation or maturation of a wide range of client proteins and 
substrates, including some important protein kinases and transcription factors. 
Because of the nature of its client proteins, it is involved in cell cycle, growth, 
apoptosis, endocrine function, plant immunity and also in evolution (Figure 1.4).  
In vitro Hsp90 alone can prevent protein aggregation and promote 
refolding (Welch et al., 1992) but in vivo Hsp90 functions with associated 
proteins known as co-chaperones (see Table 1.3). For example the v-Src tyrosine 
kinase has been reported to form stable complexes with Hsp90 (Blankenship & 
Matsumura, 1997), where Hsp90 maintains the kinase in an inactive form and 
helps in its membrane recruitment. However, this requires association with 
other co-chaperones to complete the whole processes. Table 1.3 shows the 
important components of the Hsp90 chaperone machine (adapted from Whitesell 
& Lindquist, 2005).  
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Figure 1.4: Hsp90 has a central role in the assembly of various proteins involved in many 
cellular processes.   
 
Cytosolic Hsp90 and its homologues, Grp94, HtpG, Hsp90-α and TRAP along with co-
chaperones form the cellular assembly machine.  This assembly machine acts on a range of 
client proteins for their maturation and activation, thereby controlling multiple cellular 
processes e.g. cell cycle, apoptosis and stress recovery (after Jackson et al., 2004).  
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Table 1.3: Hsp90 and the important components of the chaperone machinery 
 
Protein Family Classification Function 
Hsp90 Chaperone Supports meta-stable protein 
conformations, especially in signal 
transducers 
Hsp70 Chaperone Helps fold nascent polypeptide chains; 
participates in assembly of multiprotein 
complexes  
Hsp40 Co-chaperone Stimulates Hsp70 ATPase activity 
HIP, HOP Adapters Mediates interaction of Hsp90 and 
Hsp70 
Cdc37/p50 Co-chaperone Modulates interactions with kinase 
AHA1 Co-chaperone Stimulates Hsp90 ATPase activity 
p23 Co-chaperone Stabilizes Hsp90 association with clients 
Immunophilin Prolyl isomerase Modulates interactions with hormone 
receptors 
   
HOP – Hsp70/Hsp90-organizing protein, HIP – Hsp70-interacting protein, Cdc37 – cell 
division cycle 37 homologue, AHA1 – activator of Hsp90 ATPase homologue.  
(Adapted from Whitesell & Lindquist, 2005) 
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In the process of protein folding by Hsp90, Hsp70-Hip will initiate the 
binding to an unstructured target protein. This process is aided by the Hsp70 co-
chaperone, Hsp40. Hsp90 then forms a structure with Hop which is responsible 
for linking Hsp70 to Hsp90. Then, immunophilins and p23 are added to the 
conformation and parallel with this, Hsp70-Hip and Hop are released from the 
mature complex (Figure 1.5). p23 binding is an important process because it 
allows the completion of folding (Dittmar et al., 1997).  According to Ali et al 
(2006), p23 is required to stabilise Hsp90 in the ATP-bound form. Furthermore, 
p23 binding is vital to extend the time Hsp90 is in the appropriate conformation 
for client protein activation. Finally the mature target protein is released to 
complete the whole process. Any disruption by Hsp90 inhibitors leads to multiple 
physiologic defects in live cells. For example, for protein kinases, Hsp90 is 
thought to stabilize the exposed catalytic domains before assembly of the kinase 
into the final signalling complex (Xu & Lindquist, 1993; Alique et al., 1994; 
Stepanova et al., 1996), and the interruption of the conformation with Hsp90 
inhibitors will lead to failure of the final fold.  
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Figure 1.5: Hsp90 in the folding process.  
 
(a) Unfolded target protein. Hsp70-Hip initiates the binding to the target protein aided by 
Hsp40.  
(b) Hsp90-Hop conformation binds to the Hsp70-Hip-target protein.  
(c) The binding of immunophilin aids the maturation of the complex. The binding of p23 to 
the complex allows the completion of the folding.  
(d) Hip-Hsp70-Hop is released from the mature complex. 
(e) Target protein is released in its mature and stable conformation  
(Adapted from Csermely et al., 1998).  
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1.3 Hsp90 inhibitors 
The realisation that Hsp90 chaperones proteins required for cellular 
viability opened up a new direction in the development of drugs that alter Hsp90 
function. GA, the first Hsp90 inhibitor that was recognised, belongs to the family 
of benzoquinone ansamycins. GA binds to the N-terminal domain of Hsp90, while 
other inhibitors such as novobiocin bind to the C-terminal domain. The binding 
of inhibitor to the N-terminus or C-terminus of Hsp90 alters the conformation of 
the molecule and at the same time prevents association with client proteins that 
may be required for viability. The use of Hsp90 specific inhibitors results in a 
decline in client protein activity in vivo and in the degradation of vital signalling 
proteins that are involved in cell proliferation, cell cycle regulation and 
apoptosis (reviewed by Maloney & Workman, 2002). As an outcome of this, 
several Hsp90 inhibitors have been developed and some of them are already in 
clinical trials. Table 1.4 shows some of the Hsp90 inhibitors (reviewed by 
Sreedhar et al., 2004). 
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Table 1.4: Hsp90 inhibitors  
 
Domain targeted Inhibitors 
 
N-terminal 
 
 
 
C-terminal 
 
 
Geldanamycin and analogues (17-AAG, 17-DMAG) 
Radicicol and its analogues (aigialomycin D, pochonin D) 
Purine-scaffold Hsp90 binders, PU3 
 
Cisplatin 
Novobiocin 
 
   
  
 
(Adapted from Sreedhar et al., 2004) 
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1.3.1 Geldanamycin  
GA, which belongs to the family of benzoquinone ansamycins, is an 
antibiotic that specifically inhibit the cytosolic chaperone Hsp90 (Pratt, 1998; 
Neckers, et al., 1999) GA was first purified from the broth of Streptomyces 
hygroscopicus (DeBoer et al., 1970), a soil bacterium. GA is soluble in alcohols, 
aliphatic chlorinated solvents, acetone, benzene and ethyl acetate but poorly 
soluble in water (DeBeor et al., 1970). GA consists of a quinone ring and 
hydrophobic ansa bridge (Rinehart & Shield, 1976) (see Figure 1.6 for the 
chemical structural of GA). At first GA was thought to be an inhibitor of tyrosine 
kinases (Uehara et al., 1989), as it was shown that GA abolishes Src kinase 
activity in whole cell assays (Uehara et al., 1988). However, in other studies, GA 
was shown to be unable to directly inhibit the kinase activity of the purified 
recombinant protein (Whitesell et al., 1992). It was then suggested that GA 
indirectly inhibits Src kinase activity by binding to unrecognised Src associated 
proteins. Subsequently by an affinity isolation method using GA immobilised on 
agarose beads, it was shown that GA specifically binds to Hsp90 (Whitesell et 
al., 1994). In addition, it was observed that levels of src-Hsp90 were reduced as 
the GA concentrations were increased. This early experiment demonstrated that 
GA not only binds to Hsp90 but also interrupted the chaperone function of Hsp90 
and its associated kinase proteins.  
The first co-crystal structure of Hsp90 bound to GA was published in 1997 
(Prodromou et al., 1997). Subsequent affinity chromatography experiments 
together with co-crystal structures provided evidence that GA inhibits Hsp90 by 
binding to its N-terminal ATP binding site (Whitesell et al., 1994; Prodromou et 
al., 1997; Roe et al., 1999). These studies resulted in a re-interpretation of the 
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effect of GA on kinases.  In the presence of GA, the immature kinase undergoes 
rapid degradation as a consequence of ubiquitination and subsequent catabolism 
by the proteasome.  As a result, the depletion of the mature kinase can cause 
cell death.  
Recently, GA has been used intensively to study the effects of inhibiting 
Hsp90 in tumour cells. However, GA is poorly soluble in aqueous solution and its 
hepatotoxicity proved problematic in clinical trials (Supko et al., 1995). Studies 
by Dikalov and co-workers (2002) showed that incubation of GA with flavin-
dependent reductase enzymes transformed GA quinone into a semiquinone. The 
semiquinone reacts with molecular oxygen to produce superoxide radicals which 
can cause toxicity (Dikalov et al., 1992) and this causes cell death. By inserting a 
stronger electron-donating group into the 17-position of GA, it stabilized the 
quinone and decreased its redox-active potential (Blagg & Kerr, 2006). This new 
analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG) seems to behave 
significantly better than GA (Barzilay et al., 2005). 17-AAG has entered Phase I 
and Phase II clinical trials for cancer chemotherapy. Even though 17-AAG shows 
promising results in chemotherapy, this analogue still produces hepatotoxicity 
and its water insolubility makes it difficult to formulate (Jez et al., 2003). In 
order to improve the solubility of 17-AAG, an extra tertiary amine group was 
incorporated into 17-AAG which led to the development of 17-demethoxy-17-
N,N-dimethylamino-ethylamino-geldanamycin (17-DMAG)(Jez et al., 2003). 17-
DMAG is much more water soluble and has entered Phase I clinical trials 
(reviewed in Bagatell & Whitesell, 2004). Refer to Figure 1.6 for the chemical 
structure of GA, 17-AAG and 17-DMAG. 
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Figure 1.6: Geldanamycin and its analogues 
 
a) Geldanamycin (C29H40N2O9). As a member of the benzoquinone ansamycin family, GA 
consists of a quinone ring and hydrophobic ansa bridge. 
b) Chemical structure of 17-AAG shows the new substituted group in 17-position of GA (17-
AAG, (CH2=CHCH2NH-).  
c) 17-DMAG chemical structure shows an extra tertiary amine group inserted in 17-position of 
GA to produce 17-DMAG  (CH3)2NCH2CH2NH-) 
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1.3.2 Radicicol 
Radicicol is a macrocyclic antibiotic that was first isolated from 
Monosporium bonarden (Delmotte & Delmotte-Plaque, 1953)(see Figure 1.7). 
Kwon et al (1992a) reported that radicicol contributed to the inhibition of the 
oncogenic kinase Src.  Then, it was revealed by Kwon et al (1992b) that it is a 
specific inhibitor of Hsp90. In 1999, the crystal structure of radicicol bound to 
yeast Hsp90 was solved (Roe et al., 1999). Even though radicicol does not have a 
similar structure to GA, it also inhibits Hsp90 by binding to the N-terminal ATP 
pocket (Prodromou et al., 1997) and it binds with greater affinity compared to 
GA and 17-AAG (Roe et al., 1999). It has been shown to compete with ATP for 
the binding site of Hsp90 (Roe et al., 1999). Radicicol is also known to suppress 
the activity of various oncogenic proteins such as Ras, Raf and v-src-tyrosine 
kinase (Kwon et al., 1997). Furthermore radicicol has been shown to be active 
against retinoblastoma cells that are resistant to 17-AAG (Yamamoto et al., 
2003). However, radicicol lacks anti-tumour activity in vivo in experimental 
models because of its instability (Vogen et al., 2002). Besides that there are two 
analogues of radicicol that show a good affinity for binding to Hsp90 namely, 
aigialomycin D (Yang et al., 2004) and pochonin D (Moulin et al., 2005).                                                                                
                       
1.3.3 Novobiocin 
Novobiocin is a coumarin antibiotic that has been isolated from 
Streptomyces strains and has a potent activity against Gram-positive bacteria 
(Yu et al., 2004)(see Figure 1.7). It has been shown to inhibit the enzyme-
catalyzed hydrolysis of ATP and binds to type II topoisomerases including DNA 
gyrase (Lewis et al., 1996; Holdgate et al., 1997) and because of that it has 
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been used for the treatment of bacterial infection. Novobiocin consists of three 
distinct parts namely the benzamide side chain, the coumarin core and the 
noviose sugar (Donnelly & Blagg, 2008). The observation that novobiocin inhibits 
Hsp90 was proposed by Marcu et al (2000a). They showed that cell lysates 
incubated with novobiocin-Sepharose bound to Hsp90, and demonstrated that 
the novobiocin binding site correlated to residues 538-728 of Hsp90. Removal of 
amino acids 657-677 from the 538-728 peptide fragment of chicken Hsp90, 
resulted in a decline in novobiocin binding which demonstrated that residues 
657-677 were essential for novobiocin binding. However, subsequent studies 
suggested that the binding of Hsp90 to novobiocin-Sepharose was non-specific 
(Whitesell pers. comm. to E. Devaney). Novobiocin was shown to disrupt Hsp90 
functions (Marcu et al., 2000b) and cause the destabilization and proteolytic 
degradation of a number of proteins.  Allan and co-workers proposed that 
novobiocin may lead to substrate release by inducing a conformational change 
that result in separation of homodimeric C-terminal domains (Allan et al., 2006). 
In vitro, incubation of SkBr3 (human breast cancer cells) with increasing 
concentrations of novobiocin caused the degradation of Hsp90 client proteins 
(Marcu et al., 2000b). 
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(a) 
 
 
 
(b) 
Figure 1.7: Chemical structure of selected Hsp90 inhibitors  
 
a) Chemical structure of radicicol (C18H17ClO6).  
b) Chemical structure of novobiocin (C31H36N2O11) consists of three distinct parts; the 
benzamide side chain, the coumarin core and the noviose sugar. 
 
Noviose 
Coumarin Benzamide 
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1.3.4 Hsp90 inhibitors: Mode of action 
Under normal circumstances, Hsp90 acts as a chaperone, aiding the 
maturation of important client proteins. The binding and hydrolysis of ATP is the 
key factor for Hsp90 function (Meyer et al., 2003; Pearl & Prodromou, 2006). 
According to Prodromou et al (2000), the Hsp90 N-terminal domains transiently 
binds ATP so that the ATPase cycle is intimately coupled to the opening and 
closing of a molecular clamp (Figure 1.8). For the N-terminal hydrolysis of ATP, 
dimerization of Hsp90 is required. According to Pearl & Prodromou (2006), the 
two halves of the Hsp90 dimer cooperate to achieve a conformation that is able 
to hydrolyse ATP. ATP binds to Hsp90 and it stabilizes ‘a tense conformation’ 
and the functional state of Hsp90, because Hsp90 depends on the presence of 
the γ-phosphate of ATP. Energy produced by ATP hydrolysis is used to facilitate 
a conformational change within Hsp90 that clamps Hsp90 around the bound 
client proteins which leads to proper folding of the client proteins. Hydrolysis of 
bound ATP releases the polypeptide by opening up the Hsp90 dimer (Young et 
al., 2001).  According to Young & Hartl (2000), GA can inhibit the chaperone-
mediated folding of Hsp90 client proteins by blocking their ATP-dependent 
dissociation from Hsp90. It has also been suggested that by binding to inhibitors 
the formation of closed clamps around the bound client proteins is inhibited 
(Blagg & Kerr, 2006). As a result, client proteins are released from Hsp90 
without achieving their active or mature conformation. These unprocessed 
chaperone-client protein complexes accumulate within the cell leading to 
recruitment of E3 ubiquitin ligases that target Hsp90 client proteins for 
degradation in the proteasome (Sepp-Lorenzino et al., 1995; Mimnaugh et al., 
1996).          
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Figure 1.8: Schematic of current model for the conformational changes that accompany 
binding and hydrolysis of ATP (adapted from Pearl & Prodromou, 2006).  
 
N represents N-terminal, M for M-domain and C for C-terminal domain. Red represents client 
proteins. 
a) Open conformation of Hsp90 clamp. Client proteins can bind to Hsp90 without the 
presence of ATP. However to achieve the full activation it requires ATP hydrolysis. 
b) Closed conformation of Hsp90 dimer in the presence of ATP. In the presence of inhibitor, 
in the ATP binding pocket, Hsp90 cannot form a closed clamp around bound client proteins 
leading to degradation of client proteins. 
 
 
 
 
(a) 
(b) 
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1.4 Hsp90 as a target for anti-tumour drugs 
Presently, there is growing evidence that Hsp90 plays a fundamental role in 
the progress of malignant diseases. Previous studies have shown that Hsp90 was 
expressed at two- to 10-fold higher levels in tumour cells (lung carcinomas, 
melanomas and hepatoma) compared to normal cells (peripheral-blood 
lymphocytes, human umbilical endothelial cells and fibroblasts) and Hsp90 was 
suggested to play an important role in tumour cell survival (Ferrarini et al., 
1992). Hsp90 and its homologue, Grp94, were shown to be over-expressed in 
human breast cancer (Jameel et al., 1992; Haverty et al., 1997). Furthermore, 
in tumour cells Hsp90 co-chaperones were observed to be over-expressed, 
suggesting that a greater amount of Hsp90 in tumour cells might be engaged in 
active chaperoning (Kamal et al., 2003).  
There are several Hsp90 client proteins that are important as possible 
anti-cancer targets. Most of these require Hsp90 association for their activation. 
They are mutated p53 (Blagosklonny et al., 1995), Src family kinases (Hatson and 
Matts, 1994), Wee1 kinase (Alique et al., 1994), transmembrane receptor 
tyrosine kinases (Chavany et al., 1996), Raf-1 kinase, CK-II (Miyata & Yahara, 
1995), Cdk4/Cdk6 (Stepanova et al., 1996), subunits of trimeric GTP-binding 
proteins (Inanobe et al., 1994), tumour necrosis factor receptor, retinoblastoma 
protein and focal adhesion kinase (Song et al., 1995; Chen et al., 1996). In 
addition, certain client proteins that interact with Hsp90 for their stability are 
oncogenic e.g. ErbB2 transmembrane kinase, Bcr-Abl kinase, Akt kinase, PLK-1, 
hypoxia-inducible factor 1α and C-RAF (Powers and Workman, 2006). Most of 
these client proteins represent a group which contribute to the hallmark of 
cancer (Hanahan & Weinberg, 2000; Powers & Workman, 2006)(Figure 1.9). For 
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example, Akt kinase is one protein associated with Hsp90. It was shown to be 
involved in a signal transduction pathway which is responsible for the growth 
signal, evasion of apoptosis and sustained angionesis (Donnelly & Blagg, 2008). 
Akt kinase acts as a modulator for phosphatidylinositol 3-kinase (PI-3K) which is 
responsible for the cell survival signal pathway and the interaction between Akt 
kinase and PI-3K has been targeted by various anti-cancer drugs (Tsurou et al., 
2003).   
 
 
 
Figure 1.9: Hsp90 and six hallmark traits of cancer. 
 
Hsp90 is essential for stability and function of oncogenic client proteins, which contribute 
to the hallmark of cancer.  
 
(After Power & Workman, 2006). 
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In tumour cells, Hsp90 was found to accumulate in multiprotein 
complexes bound to client and partner proteins while in normal cells Hsp90 was 
found as a homodimeric protein unbound to partner proteins (Kamal et al., 
2003). In addition, Hsp90 in tumour cells has a high ATPase activity and a high 
affinity for inhibitors such as GA compared to normal cells (Kamal et al., 2003). 
This high affinity of tumour Hsp90 may be because tumour cells are highly 
dependent on Hsp90 for growth in the aggressive tumour environment (Blagg & 
Kerr, 2006). The use of Hsp90 specific inhibitors results in a decline in client 
protein activity in vivo and in the degradation of vital signaling proteins that are 
involved in cell proliferation, cell cycle regulation and apoptosis (Maloney & 
Workman, 2002). As a result, unfolded proteins become part of an unproductive 
heteroprotein complex, which leads to their degradation by the ubiquitin-
proteasome pathway (Connell et al., 2001). Targeting a single molecule leads to 
the degradation of many other proteins, which is why Hsp90 has been suggested 
as a unique target for cancer therapeutics.   
Studies by Hostein et al (2001) on human colon cell lines showed that 17-
AAG inhibited the RAS-RAF-MEK-ERK1/2 and PI-3K-AKT/PKB pathway by targeting 
Hsp90 molecules. Subsequently, this was accompanied by cytostasis, cell cycle 
arrest and cell-line dependent apoptosis. Both signalling pathways require 
activation by tyrosine kinase ErbB2, which was shown to be an important Hsp90 
client protein (Yarden & Sliwkowski, 2001; Citri et al., 2004). Studies by Smith 
et al (2002) showed that ErbB2 over-expression caused a five-fold increase in 
sensitivity to GA and 17-AAG. These observations suggest the potential use of 17-
AAG as an agent for chemotherapy. In phase 1 clinical trials, treatment of two 
patients with advanced metastatic malignant melanoma showed that B-RAF 
mutants were very sensitive to 17-AAG-mediated proteosomal degradation (da 
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Rocha Dias et al., 2005) which may suggest a possible mechanism for the clinical 
activity of 17-AAG in melanoma. In addition, Pacey et al (2006) observed some 
clinical activity using 17-AAG in breast and prostate cancer. The activity of 17-
AAG was shown to be reduced in the presence of P-glycoprotein (P-gp)(Kelland 
et al., 1999) and it was metabolized by the cytochrome P450, CYP3A4 (Egorin et 
al., 1998). A second generation of GA derivatives, 17-DMAG has also entered 
Phase 1 clinical trials. In patients with chemotherapy-refractory acute 
myelogenous leukaemia, a complete response to treatment in 3 out of 17 
patients was observed (Lancet et al., 2010). These results indicate the potential 
of Hsp90 as a drug target in cancer chemotherapy.   
1.5 Hsp90 in nematodes 
Nematodes are very diverse organisms and are classified under the phylum 
Nematoda. According to Blaxter et al (1998) nematodes have evolved to be 
parasitic on multiple occasions and have successfully adapted to non-vertebrate, 
vertebrate and plant hosts. Despite the tremendous medical and economic 
importance of nematodes, the great majority of nematodes are free-living. 
Initially, nematodes were classified based on morphological characteristics 
derived primarily from light microscopy. Recently, attempts have been made to 
use molecular methods to classify nematodes. The analysis of small subunit 
ribosomal RNA genes (SSU rRNA) by Blaxter et al (1998) showed that nematodes 
can be divided into three major clades: Dorylaimia (clade I), Enoplia (clade II), 
and Chromadorea which also includes the Rhabditida. The Rhabditida can be 
further divided into Sprurina (clade III), Tylenchina (clade IV) and Rhabditina 
(clade V). Clade I consists of Dorylaimida, Mermithida, Mononchida, 
Dioctophymatida and Trichinellida. This clade includes the free-living 
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microbivores, plant, insect and animal parasitic nematodes. Clade II contains 
plant parasitic enoplids and triplonchids but no animal parasites. Clade III 
consists of parasitic species including spirurids, ascaridids, oxyurids and 
rhigonematids. B. pahangi resides in clade III together with Toxocara cati and 
Parascaris equorum. Clade IV comprises plant and animal parasites and some 
free-living species. Globodera sp. was placed in this clade together with the 
vertebrate parasitic Strongyloidoidae. Clade V the Rhabditia, consists of free-
living and animal parasitic species. C. elegans belongs to clade V with some 
others important parasitic species such as Haemonchus contortus and 
Teladorsagia circumcincta. Figure 1.10 shows a classification of nematodes in 
different clades based on SSU rRNA (Blaxter et al., 1998; De Ley & Blaxter, 
2002). 
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Figure 1.10: Nematode species from different clades of nematode (after Blaxter et al., 1998).  
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1.5.1 Nematodes life-cycles 
Nematodes show a great deal of diversity in their life-cycles with many 
free-lving species while others are parasitic in animals and plants. Genarally, 
nematodes have five developmental stages in their life-cycle; L1, L2, L3, L4 and 
adult. Free-living species such as C. elegans exhibit a direct life-cycle 
developing from egg to adult (see Figure 1.11a). However, under certain 
conditions such as an absence of food or over crowding, C. elegans can choose 
an alternative developmental pathway leading to the dauer larva (Cassada & 
Russell, 1975). In the dauer stage, worms do not feed but can survive under 
extreme conditions for several months. When conditions become more 
favourable, development is resumed. The nematodes exit the dauer larval stage 
and develop into the normal L4 stage before becoming adults. For parasitic 
species such as the Trichostrongyles, e.g H. contortus, part of the life-cycle 
takes place in the environment. Eggs are passed in the host faeces and L1, L2 
and L3 stages develop in the environment. The infective L3 is ingested and L4 
and adult stages develop in the definitive host (see Figure 1.11b).   
For obligate parasitic nematodes, such as filarial worms, the life-cycle is 
more complex and requires an intermediate host. Mf to L3 development occurs 
in the mosquito, while L3 to adult stages takes place in the definitive host. The 
infection is initiated by the bite of a mosquito which harbours L3 stage parasites. 
The L3 are released and enter the body of the definitive host. In the definitive 
host, the L3 undergo two moults before become an adult in the afferent 
lymphatics. After mating, females produce Mf that circulate in the bloodstream 
which are then available for a mosquito to ingest with a blood meal (see Figure 
1.12).        
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Figure 1.11: Life-cycles of free-living and parasitic nematodes. 
 
a) C. elegans life-cycle. As a free-living nematode, the C. elegans life-cycle takes place in the 
environment. Eggs hatch and develop from L1, L2, L3 and L4 before undergo a final moult to 
adult. Under certain conditions (such as crowded or limitated food source) dauer stages 
develop. Dauer stages are resistant and non-feeding. When the conditions revert to normal, 
dauer stages develop into L4 before becoming adult.  
b) Parasitic Trichostrongyle life-cycle e.g H. contortus, T. circumcincta.  Eggs are passed in the 
faeces and hatch. The L1, L2 and L3 develop in the environment. The infection occurs when the 
definitive host grazes and eat grass containing infective L3. In the definitive host, the L3 
develop into L4 and to adult. (Image courtesy of Virginia State University 
http://pubs.ext.vt.edu/410/410-027/410-027.html)   
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(b) 
 
Chapter 1    41
 
 
 
Figure 1.12: Filarial worm life-cycle.  
 
Filarial worms (such as B. pahangi or B. malayi) require a mosquito to complete the life-
cycle. During a blood meal, an infected mosquito introduces L3 filarial larvae onto the skin 
of the definitive host, where they penetrate into the bite wound. L3 develop into L4 and 
adults that commonly reside in the lymphatics. After mating, female worms produce Mf. The 
Mf migrate into lymph and then circulate in the bloodstream. A mosquito ingests the Mf 
during a blood meal. The Mf develop into L2 and subsequently into L3. The L3 can infect 
another human when the mosquito takes a blood meal. (Image courtesy of Medscape 
http://emedicine.medscape.com/article/998011-overview) 
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1.5.2 What do we know about Hsp90 in nematodes? 
Much of the information on Hsp90 in nematodes comes from studies on C. 
elegans, a free living nematode that is often used as a model for parasitic 
species. The C. elegans genome contains a single hsp90 gene (daf-21) located on 
chromosome V, which is 74% and 76% identical to human hsp90α and hsp90β 
respectively (Birnby et al., 2000). daf-21 has a molecular weight of 
approximately 83 kDa as seen by Western blotting. By in situ hybridization, daf-
21 mRNA in L1 was shown to be expressed in the germline precursor cells and 
the head region of C. elegans (Inoue et al., 2003). In adult males, daf-21 was 
distributed mainly in germline cells similar to hermaphrodites. The over-
expression of daf-21 in the germline suggests that it may be involved in the 
maintenance and maturation of germline precursors. A strong signal was also 
observed in spermatocytes but no signal was observed in mature sperm (Inoue et 
al., 2003). In the same studies, Inoue and co-workers showed that under stress 
conditions, daf-21 mRNA was expressed all over the body of C. elegans. 
Interestingly the localization of daf-21 mRNA and DAF-21 protein are not the 
same in the L1 and adult stages. daf-21 mRNA was detected only in germline 
cells at both the L1 larva and adult stages, whilst the DAF-21 protein was 
localized not only in germline cells but also in somatic cells at both stages (Inoue 
et al., 2003).            
 The transcription of hsp90 in C. elegans is increased 10-15-fold in dauer 
larvae compared to other life cycle stages (Dalley & Golomb, 1992). The dauer 
stage is an alternate third stage larva in C. elegans that enhances survival of the 
organism under harsh conditions. In the dauer stage, larvae do not eat because 
their oral orifice is blocked by an internal plug (Riddle et al., 1981). The reason 
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why daf-21 mRNA is highly abundant in dauer stages compared with other life 
cycle stages remains unknown. It may provide additional chaperone activity 
under stressful conditions. However, the expression of daf-21 mRNA decreased 
sharply within the first 75 minutes of recovery after worms had been stimulated 
to emerge from the dauer stage (Dalley & Golomb, 1992). It has been suggested 
that Daf-21/Hsp90 is involved in the formation of dauers in C. elegans acting in 
the same pathway as daf-11 (a transmembrane guanylyl cyclase) in regulating 
chemosensory transduction in several types of sensory neurons (Thomas et al., 
1993). Furthermore, the dauer is a long-lived stage of C. elegans and other 
studies have also shown that daf-21 is highly expressed in long-lived mutants of 
C. elegans (Morley & Morimoto, 2004). 
Two mutations have been characterised in C. elegans hsp90 namely, daf-
21(p673) and daf-21(nr2081) (Birnby et al., 2000). daf-21(p673) is a point 
mutation (E292 to K) that causes relatively limited phenotypes. This is not a null 
mutation and may result in a protein that specifically fails to stabilize 
chemosensory transduction components because mutants have a range of 
sensory defects and reduced fertility (Birnby et al., 2000). daf-21(nr2801) is a 
true null mutation and has an 860 bp deletion with a 3-bp insertion. daf-
21(nr2081) arrests growth at the L2 to L3 stage (Birnby et al., 2000), indicating 
the importance of Hsp90 in C. elegans. RNAi studies on daf-21 revealed the 
necessity for Hsp90 in adult worms. Studies by Piano et al (2000) showed that 
injection of dsRNA into hermaphrodite worms results in an embryonic lethal 
phenotype in the progeny and a defect in egg production, which again suggests, 
the important roles of Hsp90 in C. elegans. 
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Hsp90 in the filarial parasite B. pahangi, is 82% identical to C. elegans 
Hsp90, 67% identical to D. melanogaster Hsp90 and 69% identical to human 
Hsp90 (Thompson et al., 2001). However, the expression of Hsp90 in B. pahangi 
is constitutive and no significant increase in the level of Hsp90 was observed in 
any life cycle stage of B. pahangi exposed to elevated temperatures (Devaney et 
al., 2005). These results suggest that in B. pahangi, Hsp90 is not a major heat-
inducible protein. B. pahangi Hsp90 contains all five features of Hsp90s that are 
common to others eukaryotic proteins. However, B. pahangi Hsp90 has a long 
charged region encompassing the amino acids 235–320 (Thompson et al., 2001).  
B. pahangi Hsp90 contains two putative ATP-binding domains (amino acids 93–99 
and 135–142) and a large number of potential phosphorylation sites. Analysis by 
Southern blots showed that B. pahangi hsp90 is a single copy gene (Thompson et 
al., 2001), as in C. elegans.  
Skantar and Carta (2004) showed that the plant parasitic nematodes, 
Heterodera glycines and Meloidogyne javanica, contain a single hsp90 gene 
similar to C. elegans (Birnby et al., 2000) and B. pahangi Hsp90 (Thompson et 
al., 2001). H. glycines Hsp90 was shown to be 83% indentical to B. pahangi 
Hsp90, 82% to C. elegans and 73% to D. melanogaster. Despite the high level of 
conservation and homology between C. elegans Hsp90 and other eukaryotes, C. 
elegans Hsp90 is resistant to GA treatment and failed to bind to GA (David et al., 
2003; Devaney et al., 2005). The structure of Hsp90 is well-conserved between 
B. pahangi and C. elegans, the only major feature of significance being the 
shorter CR in C. elegans compared to B. pahangi.    
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1.5.3 C. elegans as a model for the study of parasitic nematodes 
C. elegans is a small free-living nematode usually found in the soil in 
temperate climates all around the world. It has a direct life-cycle and is very 
easy to maintain in the laboratory. It is only 1 mm long.   The first paper on the 
use of C. elegans for genetic studies was published in 1974 (Brenner, 1974) and 
since then, it has become one of the most interesting model organisms to study, 
especially in developmental biology (reviewed by Gilleard, 2004). A major 
problem faced by researchers working on parasitic nematode is the lack of in 
vitro culture systems and the requirement to propagate life-cycles in vivo. As a 
result, the technology and genomic resources for parasitic nematode are still 
lagging behind those available for C. elegans.  
In addition, there are no reverse genetic methods available to study 
parasitic nematode gene function (Gilleard, 2004). One of the powerful methods 
to study gene function is RNA-mediated interference (RNAi)(Fire et al., 1998). 
This mechanism of gene-silencing was shown to be very reliable and effective in 
many organisms including insects, planarians, protozoa and mammalian cells 
(Britton & Murray, 2006). In C. elegans RNAi can be achieved by injection of 
double-stranded RNA (dsRNA) into the adult worm body, by soaking in dsRNA or 
by feeding the worms with E. coli expressing dsRNA (Kamath et al., 2003). Using 
RNAi to knock-down a gene can result in an observable phenotype. Based on the 
phenotypes observed it can give a starting point for studying the gene of interest 
in greater detail. The known phenotypes of RNAi in C. elegans can be assessed 
through the Wormbase website (http://www.wormbase.org/db/searches/basic). 
In parasitic nematodes, there are several reported successful applications of 
RNAi e.g. in Nipponstrongylus brasiliensis (Hussein et al., 2002), Heterodera 
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glycines and G. pallida (Urwin et al., 2002), Meloloidogyne incognita (Bakhetia 
et al., 2005), B. malayi (Aboobake & Blaxter, 2003), Onchocerca volvulus 
(Lustigman et al., 2004), Trichostrongylus colubriformis (Issa et al., 2005) and 
H. contortus (Kotze & Bagnall, 2006; Samarasinghe et al., 2010). The success of 
RNAi in these parasitic nematodes suggests that the RNAi pathway does exist in 
some parasitic species and that some genes can be silenced by dsRNAi (Britton & 
Murray, 2006; Samarasinghe et al., 2010). Furthermore, the level of target 
transcript or sites of gene expression influence susceptibility to RNAi by soaking 
(Samarasinghe et al., 2010). However, the success of RNAi varies enormously 
with parasite species, life cycle used and genes targeted. RNAi studies by 
Geldhof et al (2005) revealed that the success of RNAi approaches is variable in 
H. contortus. Under certain circumstances, it is possible to suppress gene 
expression but RNAi only works on a limited number of genes and the effect is 
often small and hard to reproduce.      
C. elegans was the first multi-cellular organism to have its genome 
completely sequenced in 1998. This provided a very important resource for 
bioinformatics and functional analysis of C. elegans genes. As more genomes for 
parasitic nematodes become available, it will be possible to identify important 
genes which can provides a good reference for understanding the molecular basis 
of the evolutionary adaptations of nematodes. In addition it will provide further 
understanding of the many adaptations associated with parasitic life-cycles 
(Wasmuth et al., 2008).  The draft sequence of the B. malayi genome has been 
published (Ghedin et al., 2007) and sequencing the H. contortus genome is on-
going. There also several sequencing projects for other species of veterinary 
importance which can be accessed through the website 
(http://sanger.ac.uk/Projects/helminths/).  
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C. elegans can provide a useful platform to study gene function particularly 
in parasitic nematodes (Gilleard, 2004). A parasite gene of interest can be 
expressed in C. elegans which then provides a tool to study its function. One of 
the methods is to introduce the gene of the interest into a C. elegans mutant 
strain to ask whether it can restore the wild type phenotype. The majority of 
the successful interspecies rescue experiments reported to date come from work 
using H. contortus (Britton & Murray, 2006). For example, H. contortus isotype 1 
β-tubulin (tub-1) was the first parasitic gene to be functionally expressed in C. 
elegans (Kwa et al., 1995). In C. elegans, a mutation in the β-tubulin gene, ben-
1 conferred resistant to benzimidazole compounds (Driscoll et al., 1989). By 
expressing the H. contortus tub-1 susceptible gene in C. elegans ben-1 mutants, 
the resistance phenotype was reversed. In contrast expressing the H. contortus 
tub-1 resistant gene in the mutant had no effect on the susceptibility of the 
mutant to benzimidazole (Kwa et al., 1995). This experiment proved that 
interspecies mutant rescue can be used to study the function of a parasite gene.   
1.6 Hsp90 and its role in drug resistance  
1.6.1 The ability of Hsp90 to ‘buffer’ mutations has important 
implications 
Recently, a number of studies have suggested that Hsp90 may be involved 
in facilitating rapid evolutionary changes in organisms such as D. melanogaster 
(Rutherford & Lindquist, 1998; Sollars et al., 2003), and Arabidopsis thaliana 
(Queitsch et al., 2002). The study of Rutherford & Lindquist (1998) showed that 
back-crossing a D. melanogaster hsp90 mutant with a standard laboratory strain 
resulted in morphological abnormalities in the offspring e.g. deformed eyes or 
legs, bristle duplications, change in wing shape or venation etc. In addition, 
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when the wild-type D. melanogaster strain was raised on food containing GA, 
similar abnormalities were produced as observed for the D. melanogaster hsp90 
mutants. It was proposed that these cryptic mutations are not observed when a 
sufficient amount of Hsp90 is normally expressed. In the plant, A. thaliana, 
Hsp90 was also suggested to act as a buffer for genetic variation (Queitsch et 
al., 2002). That study extended the early concept of Hsp90 buffering of 
morphological traits to environmental responses. In Arabidopsis they showed 
that inhibition of Hsp90 function by treatment with GA revealed several 
phenotypes which were heritable even in the absence of GA. This effect may be 
conserved in other organisms, potentially influencing the pace and nature of 
evolution.   
1.6.2 Hsp90 and its role in drug resistance in infectious agents 
Recent studies on Hsp90 have shown that it is required in Saccharomyces 
cerevisiae to survive the acute stress of drug exposure and also for some types of 
drug resistance.  The original study of Cowen & Lindquist (2005) demonstrated 
that Hsp90 was important for the acquisition of resistance to azole compounds in 
S. cerevisiae. The azole target Erg11 which is involved in the biosynthesis of 
ergosterol, a component of fungal membranes (Sanglard, 2002, Odds et al., 
2003). Compromising Hsp90 functions with GA or radicicol was sufficient to 
restore azole sensitivity to otherwise resistant S. cerevisae. The emergence of 
fluconazole resistance under rapid selection was shown to be highly dependent 
on elevated levels of Hsp90 and this resistance was abrogated when Hsp90 
expression was reduced (Cowen & Lindquist, 2005). In that system, inhibition of 
an Hsp90 client protein, calcineurin, mimicked Hsp90 inhibition suggesting that 
Hsp90 might act via calcineurin. Importantly, the role of Hsp90 in drug 
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resistance in S. cerevisiae was also conserved in a number of medically 
important pathogenic fungi such as C. albicans and Aspergillus fumigatus (Cowen 
et al., 2009, Singh et al., 2009). Calcineurin is a serine/threonine protein 
phosphatase (Dobson et al., 1999) and according to Singh et al (2009), in 
Candida albicans, Hsp90 inhibition blocks calcineurin activation, which leads to 
increased sensitivity to the novel anti-fungal compound, echinocandin. These 
results suggest a role for Hsp90 in acquired drug resistance in fungi. 
In Leishmania donovani Hsp83, the orthologue of Hsp90, was shown to be 
expressed at higher levels in isolates from patients unresponsive to pentavalent 
antimonials, compared to isolates from patients responsive to these drugs 
(Vergness et al., 2007). The mechanism by which pentavalent antimonials kill 
the parasite is not well understood, but they may interact with trypanothione, 
the main reduced cellular thiol of the parasite (Wyllie et al., 2004). L. donovani 
isolates from unresponsive patients were not only resistant to pentavalent 
antimonials but also exhibited cross-resistance to miltefosine and amphotericin 
B. Furthermore, transfection of the hp83 gene from an L. donovani resistant 
strain into an L. donovani sensitive strain resulted in an increased resistance to 
trivalent antimonials. The sensitive isolates overexpressing Hsp83 were shown to 
be more than two-fold resistant to trivalent antimonials compared to control 
parasites and also showed cross-resistant to metefosine. The parasites over-
expressing Hsp83, were protected from programmed cell death after treatment 
with trivalent antimonials, suggesting that Hsp83 might increase drug resistance 
compared to the control group.  
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1.6.3 Hsp90 and drug resistance in tumour cells 
In tumour cells, Hsp90 is an important target for chemotherapy because it 
is required for the stability and function of many molecules that are important 
for tumour cell growth. In tumours, Hsp90 interacts with a variety of protein 
including steroid hormone receptors, Ser/Thr and Tyr kinases and proteins with 
various other functions (Maloney & Workman, 2002). Several studies in tumour 
cells suggest that Hsp90 is involved in drug resistance. For example, a breast 
cancer cell line was shown to be resistant to docetexal chemotherapy due to 
involvement of the PI-3K pathway which is modulated by Hsp90 (Xing et al., 
2008). Another interesting example of Hsp90 involvement in drug resistance in 
tumour cells comes from studies on malignant melanomas. According to Banerji 
(2009), malignant melanoma is relatively resistant to most conventional forms of 
cancer treatment such as chemotherapy and radiotherapy. Studies by Davies et 
al (2002), showed that an Hsp90 client protein, BRAF, is highly mutated in 
malignant melanoma. Hsp90 inhibition resulted in degradation of the mutant 
BRAF compared to wild-type BRAF, which suggests that Hsp90 might mediate 
resistance in malignant melanoma through BRAF. In addition, Hsp90 expression 
was found to be higher in metastasic melanomas (Faingold et al., 2008; 
McCarthy et al., 2008). The higher expression level of Hsp90 in resistant tumour 
cells suggests that Hsp90 may be one mechanism by which tumour cells acquire 
drug resistance. 
A study by Costantino et al (2009) on TRAP1, an homologue of Hsp90 which 
resides in the mitochondria, in drug resistant HT-29 human colorectal carcinoma 
cells showed that TRAP1 was up-regulated after treatment with three 
chemotherapeutic agents namely, 5-fluoracil, oxaliplatin and irinotecan 
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compared to wild-type HT-29 cells. In addition, they also showed that over-
expression of TRAP1 leads to 5-fluoracil, oxaliplatin and irinotecan resistant 
phenotypes in HT-29 cells.  In contrast the inhibition of TRAP1 using sperherdin 
increased the sensitivity of resistant HT-29 to oxaliplatin and irinotecan but not 
to 5-fluoracil. These results suggest that TRAP1 may be involved in a multi-drug 
resistant phenotype in vitro.  
A common mechanism of drug resistance in many tumour cell types is over-
expression of drug transporters such as P-gp or detoxification systems. According 
to Bertram et al (1996), Hsp90β is associated with P-gp in multi-drug resistant 
colon carcinoma (LoVo) cells and in a murine cell line (S180). These cell lines 
were shown to be resistant to doxorubicin. In that study, they showed that 
Hsp90β was expressed constitutively in the resistant LoVo cell line but not in 
sensitive LoVo cells. In addition, in the doxorubicin resistant murine cell line, 
S180, Hsp90β was also expressed at higher levels compared to a sensitive cell 
line. In a subsequent study, it was demonstrated that Hsp90β and P-gp co-
precipated in the lysates of resistant LoVo cells, which suggests a direct 
interaction between P-gp and Hsp90. Furthermore, reducing the Hsp90β levels by 
antisense oligonucleotides resulted in a reduced half-life of P-gp which increased 
the doxorubicin sensitivity of resistant LoVo cells by two-fold (Betram et al., 
1996). These results suggest an intracellular co-operation between Hsp90β and 
P-gp and the involvement of Hsp90β in doxorubicin resistance. 
1.6.4 Could Hsp90 have a role in anthelmintic resistance in 
nematodes? 
In nematodes anthelmictic resistance is one of the major problems that 
affects livestock production worldwide. Up to now, the industry has been 
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dependent on anthelmintic drugs from three different groups (benzimidazoles, 
imidazothiazoles and macrocylic lactones) for control of infection. Anthelmintic 
resistance can be defined as a decrease in anthelmintic efficiency against a 
parasite which is normally susceptible to that drug (Sangster & Gill, 1999). 
Resistance is a heritable character, therefore many of these nematodes will 
have inherited their parent’s ability to survive exposure to drug (Prichard et al., 
1980).  The use of anthelmintic drugs to control gastrointestinal nematode put a 
massive selection pressure on nematode populations which led to emergence of 
anthelmintic resistance. According to Gilleard (2006), current understanding of 
the mechanism of benzimidazole resistance is more highly developed, but for 
imidazothiazole or macrocylic lactones, the underlying mechanisms are not well 
defined. Studying the mechanisms of anthelmintic resistance in parasitic 
nematodes is difficult because of the complexity of the life-cycles and because 
it is not possible to genetically manipulate these organisms. Because of that, C. 
elegans has been used as a model to study the mechanisms of drug resistance in 
parasitic nematodes.  
Benzimidazoles exert their roles by binding to tubulin. Tubulin is a major 
component of microtubules which play an important role in sustaining the 
cellular homeostasis in eukaryotic cells. By binding to tubulin, benzimidazoles 
cause disruption of microtubule structure and function which lead to cell death. 
Benzimidazole resistance in nematodes appears to be associated with an 
alteration in ß-tubulin genes, which reduces the high affinity binding of drug to 
tubulin (Lacey, 1988). In C. elegans, sensitivity to benzimidazole is associated 
with a single gene, ben-1, which encodes β-tubulin isotype-1 (Driscoll et al., 
1989). Deletion or mutation of ben-1 in C. elegans does not impair the 
development of C. elegans but it leads to benzimidazole resistance (Driscoll et 
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al., 1989). In the study of Kwa et al (1995), the wild-type β-tubulin isotype-1 
gene from H. contortus was expressed in benzimidazole-resistant C. elegans and 
restored the sensitivity of C. elegans to benzimidazole compunds.  
 Anthelmintics of the imidazothiazole group were introduced to the 
market in 1968. The most widely used are levamisole, pyrantel and morantel. 
Levamisole is a nicotinic acetylcholine (nACh) receptor agonist (Aceves et al., 
1970; Aubry et al., 1970) with a selective action on nematode receptors. 
Levamisole binds to nACh receptors and mimics this neurotransmitter resulting in 
paralysed worms (Sangster, 1999) and spastic paralysis and egg-laying defects in 
C. elegans (Holden-Dye & Walker, 2007). This muscle paralysis is thought to be 
caused by activation of the excitatory nACh receptors on the nematode body 
wall muscle (Martin et al., 1996).). In C. elegans, at least four subunits, unc-38, 
unc-29, unc-63 and lev-1 contribute to the levamisole receptor (Culetto et al., 
2004). All these genes were suggested to be associated with levamisole 
resistance in C. elegans. Development of levamisole resistance in parasitic 
nematodes is also likely to be polygenic as reported in H. contortus (Sangster et 
al., 1991) and Oesophagostomum dentatum (Varady et al., 1997, Robertson et 
al., 1999). However the potential genes involved in levamisole resistance have 
not yet been identified in parasitic nematodes.    
The macrocylic lactones that have been used commercially to combat 
nematode infections are ivermectin, moxidectin and abemectin. Ivermectin is a 
fermentation product of the micro-organism Streptomyces avermilitis (Holden-
Dye & Walker, 2007). Ivermectin causes paralysis of worm somatic musculature 
(Kass et al., 1980; Kass et al., 1982) and inhibits feeding of the nematode by 
blocking pharyngeal pumping (Geary et al., 1993; Martin et al., 1996; Sangster & 
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Gill, 1999), causing starvation and worm death. The mechanism of ivermectin 
resistance is thought to be associated with alterations in the GluCl receptor in C. 
elegans (Cully et al., 1994). As reviewed by Gilleard (2006), the mechanism of 
ivermectin resistance is complex and multigenic. For example, in C. elegans it 
was shown that resistance to ivermectin requires mutations in at least three 
genes which are members of the GluCl family, namely in glc-1, avr-14 and avr-15 
(Dent et al., 2000, Holden-Dye & Walker, 2007). Mutation of any two of these 
genes did not confer ivermectin resistance on C. elegans (Dent et al., 2000). 
Furthermore, recent studies in parasitic species suggest the involvement of P-gp 
in ivermectin resistance in H. contortus (Xu et al., 1998). Expression of P-gp 
mRNA was shown to be higher in ivermectin-selected than unselected strains of 
H. contortus, which suggests that ivermectin resistance in H. contortus may be 
associated with a more efficient drug efflux system.  
In tumour cells and fungi, the emergence of drug resistance was 
suggested to be associated with Hsp90 and its co-chaperones. However, the 
mechanisms underlying the development of drug resistance in parasitic 
nematodes are not well understood. Because of that, research addressing the 
mechanisms of anthelmintic resistance must therefore be a main concern in this 
field.       
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1.7 Aims of thesis 
The specific aims are detailed below. 
• Although the sequence of daf-21 (Hsp90) in C. elegans is highly conserved, 
it is unique amongst eukaryotes because it fails to bind to GA. In contrast, 
previous studies have shown that B. pahangi Hsp90 can bind GA. The first 
aim of the project is to determine whether the failure of C. elegans Hsp90 
to bind to GA is the norm or the exception amongst nematodes and to 
determine whether GA binding is associated with particular clades of 
nematodes. 
• B. pahangi is known to be susceptible to Hsp90 inhibition, but no 
information exists to explain why GA kills the worm. A second aim of the 
thesis is to characterise B. pahangi Hsp90 in more detail with a view to a 
better understanding of the function of Hsp90 in nematodes. 
• Nematode resistance to anthelmintics threatens the viability of the small 
ruminant industry in many countries all over the world. In tumours and 
fungi, Hsp90 is known to be involved in drug resistance. So the third aim 
of the thesis is to investigate whether Hsp90 plays a role in drug 
resistance in nematodes.  
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2 Materials and methods 
2.1 GA-binding assay 
2.1.1 Nematodes  
24 species of nematode from different clades were used for the analysis 
of GA-binding. These included both free–living and parasitic species. Some 
nematode strains were received from the Caenorhabditis elegans Genetics 
Centre (CGC, USA) including C. elegans Bristol N2, C. elegans JT6130, a daf-21 
mutant, C. briggsae, Oscheius tipuleae and Pristionchus pacificus, while others 
were obtained from relevant laboratories (Appendix 1). Parasitic species 
analysed included Trichinella spiralis and Trichuris muris (both clade I). Clade III 
nematodes included the filarial species (Brugia pahangi, Dirofilaria immitis, 
Onchocerca ochengi, Acanthocheilonema viteae), Ascarid species (Toxocara cati, 
Ascaris suum, Parascaris equorum), Anisakids (Anisakis simplex, 
Pseudoterranova decipiens) and Anguillicola crassus. Clade IV species included 
Strongyloides ratti, Globodera rostochiensis and G. pallida and the free-living 
species Panagrellus redivivus. Clade V species included Haemonchus contortus, 
Teladorsagia circumcincta, Nipponstrongylus brasiliensis and Heligmosomoides 
polygyrus. Mixed life-cycle stages were used for all free-living nematodes, while 
for parasitic species, usage was determined by availability of particular life-
cycle stages. In most cases adult males and females were analysed with the 
following exceptions: H. contortus, L3; T. spiralis, L1 muscle stage larvae; S. 
ratti adults were free-living rather than parasitic females; Globodera spp. J2 
stages; O. ochengi only males were used; A. simplex and P. decipiens L3 were 
used.  
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2.1.2 Maintenance of nematodes 
2.1.2.1 Maintenance of free-living species  
C. elegans N2, C. elegans JT6130  (a daf-21 mutant which carries a point 
mutation in daf-21, E292 to K)(Birnby et al., 2000), C. briggsae, O. tipuleae and 
P. pacificus were cultured at 20oC on NGM agar (Appendix 4.3) inoculated with 
Escherichia coli strain OP50 as a food source as described previously (Brenner, 
1974). Free-living worms were washed with M9 (Appendix 5.2) several times, 
concentrated by centrifugation at 2000 rpm for 2 min and stored at -80oC before 
use. 
P. redivivus was received from Prof. Aaron G. Maule (Queen’s University 
Belfast, UK) and was cultured on cooked oats in Petri dishes. 100 g of oats 
(Quaker Oats) were cooked in some water and poured into Petri dishes (6 x 9 
cm). Worms were then poured over the surface of the cold cooked oats and were 
maintained at room temperature. As the population of the worms bloom, the 
worms will crawl onto the lid from where they were colleted by washing off the 
lid with M9. Worms were pelleted by centrifugation at 2000 rpm at 4oC and kept 
at -80oC before use.  
2.1.2.2 Maintenance of parasitic species 
For parasitic species, adult stages were obtained from relevant 
laboratories from their respective hosts and were frozen as soon as possible at -
800C (see Appendix 1). L3 Larval stages of A. simplex and P. decipiens were 
obtained from infected fish (kindly provided by Dr. S. Martin and Dr. I. Coombs 
respectively). T. spiralis L1 (kindly provided by Dr. C. Lawrence), muscle stages 
were obtained by digestion of infected mouse muscle using standard methods 
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(Wakelin & Wilson, 1977; Knight et al., 2000).  H. contortus L3 were obtained by 
harvesting the eggs from infected sheep faeces and culturing to the L3 stage 
(received from Prof. D. Knox).       
The cysts of G. rostochiensis (obtained from Dr. J. Jones) and G. pallida 
(Dr. C. Fleming) containing infective stage juveniles (J2) were placed in large 
Petri dishes half filled with tap water and left for 5 days at room temperature. 
After 5 days, the water was replaced with tomato root diffusate (TRD) (kindly 
provided by Dr. J. Jones, Scottish Plant Breeding Institute, UK). The J2 begin to 
hatch a few days after TRD has been applied. The larval stages of Globodera 
spp. were colleted and cleaned by floating them on a sucrose gradient. The 
larvae were suspended in 5 ml ddH2O in a 15 ml conical tube and 5 ml of sucrose 
solution (Appendix 5.3) was added. 500 µl of ddH2O was overlaid on top of the 
surface of sucrose solution which was then centrifuged for 5 min at 2000 rpm. 
The nematodes will float at the interface between the sucrose and the water 
overlay. The nematodes were collected and rinsed several times in clean water 
and kept in -80oC before use.  
2.1.3 Protein extraction for GA-binding experiments 
Extracts of worms were prepared in ice-cold TNES buffer (Appendix 
2.1.1), with protease inhibitors added prior to use (1 tablet per 10 ml TNES) 
(Complete Mini Protease Inhibitor Cocktail, Roche Diagnostics, UK). Liquid 
Nitrogen was poured into a mortar, the worm pellet was added and ground to a 
fine powder using the pestle. The worm extract was then re-suspended in 1.0 ml 
TNES containing protease inhibitors and the mortar washed out with 0.5 ml 
TNES. Following incubation on ice for 15 min, the extract was pelleted at 13200 
rpm at 4oC for 15 min and the supernatant was retained. In some cases, where 
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the worm material was very limiting, e.g. D. immitis and O. ochengi, the lysates 
were prepared using small glass homogenisers. 100 µl of ice-cold TNES with 
protease inhibitors was added and the worms were ground. The supernatant was 
then prepared as described previously.  
2.1.4 Protein concentration estimation 
Protein concentrations were estimated using the Bio-Rad protein assay in 
a 96 well microtitre format. Usually samples were diluted 1:50 and then 
different amount added to the assay e.g. 5, 10, 15, 20 µl.  Samples and bovine 
serum albumin (BSA) standards were incubated in the working reagent (Bio-Rad, 
UK) for 8 min at room temperature, allowing a colorimetric reaction to occur. 
The optical density (OD) at 562 nm was measured using OpsysMR (Dynex 
Technologies) and the protein concentration of the sample (in duplicate) 
determined through comparison with a standard curve prepared using BSA. 
2.1.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Soluble extracts of worms were analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using the Mini-Protean Cell 
System (Bio-Rad, UK). Protein separation was carried out in 10% polyacrylamide 
gels (Appendix 2.2.8). Approximately, equal amounts of worms extract (2-4 µg) 
was mixed with SDS-PAGE sample cocktail (Appendix 2.2.1), boiled for 3 min, 
centrifuged at 13200 rpm for 3 min and applied to the gel. Following 
electrophoresis at 200 volts for 60 min in running buffer (Appendix 2.2.4), gels 
were stained with Coomassie blue (Appendix 2.3.1) for 60 min and destained in 
the destaining solution (Appendix 2.3.3). In some cases, worms were directly 
solubilised with appropriate volume of SDS-PAGE sample cocktail and boiled for 
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3 min followed by centrifugation at 13200 rpm for 3 min. After gel 
electrophoresis, gels were incubated with gentle agitation in Coomassie blue R-
250 (Sigma, UK)(Appendix 2.3.1) for 60 min at room temperature. Gels were 
then destained in 10% acetic acid solution (Appendix 2.3.3). 
2.1.6 Western blotting 
Proteins separated by SDS-PAGE were transferred onto nitrocellulose 
HybondTM-c extra (NCP) membranes (Amersham, UK) using the Mini Trans-Blot 
Electrophoretic Transfer Cell System (Bio-Rad, UK) at a constant voltage of 100V 
for 60 min. The transfer set up consisted of pre-wetting the NCP membrane in 
transfer buffer (Appendix 2.2.5). The transfer sandwich was created with a fibre 
pad pre-soaked in transfer buffer. Then one pre-soaked filter paper was laid on 
top, followed by the equilibrated NCP membrane. The SDS-PAGE gel, having 
been equilibrated in transfer buffer for 15 min, was then laid on the NCP 
membrane. Another pre-soaked filter paper was laid on the gel and finally, a 
pre-soaked fibre pad completing the transfer sandwich. The completed cassette 
was placed in the module. The same procedure was repeated for a second gel (if 
required). Following protein transfer, the NCP membrane was stained with 
Ponceau S (Appendix 2.3.5) for 5 min with agitation to check that the transfer of 
protein to the NCP membrane was complete. The NCP membrane then was 
incubated in blocking solution (Appendix 2.2.10) for 60 min at room temperature 
with gentle agitation.  
2.1.7 Antibody detection of transferred proteins 
Two antibodies were used in this study to detect Hsp90. The first antibody 
was raised in rabbits to a recombinant protein equivalent to the C-terminal 238 
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amino acids of B. pahangi (Devaney et al., 2005). The second antibody used was 
a well-characterised monoclonal antibody AC88, raised to Hsp90 from the water 
mould, Achlya ambisexualis, which recognises Hsp90 from many different 
species. AC88 was kindly provided by Dr. David Toft (Mayo Clinic College of 
Medicine, Rochester, USA). 
Following the blocking incubation, the NCP membrane was washed 3 x 5 
min with washing buffer (Appendix 2.2.11) at room temperature. The primary 
antibody (B. pahangi anti-Hsp90 or AC88 monoclonal anti-Hsp90 antibody) was 
diluted at appropriate concentration in incubation solution (Appendix 2.2.10) 
and applied to the membrane overnight at 4oC with gentle agitation. Following 
overnight incubation, the membrane was washed 3 x 5 min with washing buffer 
before incubation in either HRP-conjugated anti-rabbit IgG (1:10,000) or HRP-
conjugated anti-mouse IgG (1:10,000) (both Sigma, UK) for a further 60 min at 
room temperature. The NCP membrane was then washed 3 x 5 min in washing 
buffer. In some experiments, blots were probed with an antibody to actin 
(Sigma, UK), as a loading control, at a dilution of 1:1000 and followed by anti-
mouse IgG as a secondary antibody. 
The Enhanced Chemiluminescence (ECL) Plus System was employed 
(Pierce, UK) to detect any bound antibody by autoradiography. The 
autoradiograph was subjected to quantitation by scanning and analysing using 
FluorChemTM IS-5500 software. The Integrated Density Value (IDV) was measured 
for each sample and subsequently used to calculate the ratio of the signal 
relative to the loading control (actin). 
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2.1.8 Preparation of geldanamycin solid support 
GA was derivatised as described by Whitesell et al (1994). 1.0 mg GA 
(InvivoGen, UK) was dissolved in 180 µl chloroform. 1,6-Hexamethylenediamine 
(Sigma, UK) was weighed out and dissolved in chloroform to give a final 
concentration of 28.7 mg/ml. 71 µl of the 1,6-Hexanediamine in chloroform was 
added to the GA solution. The mixture was rocked for 4 h at room temperature 
in the dark to yield 17-hexamethylenediamine-17 demethoxygeldanamycin. A 
yellow to purple colour change is evidence of this reaction. The mixture was 
extracted with 1.0 ml of 0.01 M NaOH by centrifugation at 2000 rpm for 2 min. 
These steps were repeated three times. The mixture was dried under nitrogen 
and the powder stored at -20oC at this point.   
 
400 µl of DMSO was added to 1.0 mg derivatised GA. Simultaneously, 400 
µl of Affi-Gel 10 beads (Bio-Rad, UK) were washed with 1.0 ml cold iso-propanol. 
The beads were centrifuged at 2000 rpm for 2 min and the supernatant was 
removed. These steps were repeated four times. Then, the beads were washed 
with 1.0 ml of DMSO and dried. At this point, the bead volume looks much 
smaller. 400 µl of ~5 mM 17-hexamethylenediamine-17 demethoxygeldanamycin 
prepared as described previously was mixed with the beads and agitated for 4 h 
at room temperature in the dark. At this point the beads were expected to be 
purple. The supernatant was removed and the beads were washed with 1.0 ml 
DMSO followed by three washes with 1.0 ml TNES. The beads were rocked 
overnight in 1.0 ml 1.0 M ethanolamine, pH 8.3 to block non-specific binding. 
Finally the beads were re-suspended at 50% v/v in TNES. The beads can be 
stored at 4oC at this point. The same procedures were applied for control beads, 
reacted with DMSO alone.                   
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2.1.9 GA pull-down assay 
50 µl of GA beads were blocked in 1% BSA in TNES (Appendix 2.1.1) for 60 
min at room temperature. The beads were then washed 3 x 5 min with 1.0 ml 
TNES on a rocker and were then centrifuged at 2000 rpm for 2 min. The 
supernatant was removed and the beads were retained for the binding assay. 
300-500 µg of worm protein in a volume 300 µl was mixed with 50 µl packed 
volume of GA or control beads for 2.5 h at 4oC. The beads were then washed 5 x 
10 min with 1.0 ml of TNES buffer by centrifugation. Bound proteins were eluted 
in 40 µl SDS-PAGE sample cocktail by boiling for 3 min followed by centrifugation 
at 13200 rpm for 3 min. Proteins eluted from GA beads and control beads were 
loaded on a 10% SDS-PAGE gel and were analysed by Western blotting as 
described previously.  
2.1.10 The specificity of Hsp90 binding to GA beads 
For selected nematode species which showed positive results in pull-down 
assays, the experiments were repeated in the presence of excess GA to block the 
binding sites in order to determine the specificity of the binding. Worm extracts 
were pre-incubated with soluble GA at 2.0 µM or 20.0 µM for 60 min at room 
temperature then used in a pull-down assay exactly as described above. 
2.2 Further characterisation of Brugia Hsp90 
2.2.1 Analysis of different life-cycle stages of B. pahangi 
Three different life-cycle stage of B. pahangi were available for the 
analysis of Hsp90 expression levels. Adults and Mf were obtained from gerbils 
while L3 were obtained from mosquitoes (Aedes aegpti) using standard methods 
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(Devaney & Jecock, 1991). Gerbils were killed by CO2 inhalation. Worms were 
obtained by repeated peritoneal lavage with Hanks Balanced Salt Solution (HBSS, 
Gibco, UK) at 37oC. Adults were washed in HBSS and were kept at -80oC until 
they were required for the preparation of parasite extracts. The Mf were 
collected by washing out the peritoneal cavity with HBSS medium at 37oC. The 
combined washes were centrifuged 1000 rpm for 5 min. The Mf pellet was then 
purified to remove red blood cell contamination by adding 1.0 ml sterile ddH2O, 
and the Mf were collected by centrifugation at 1000 rpm for 5 min. To separate 
Mf from contaminating white blood cells, Mf were centrifuged on Histopaque 
(Sigma, UK). 1.0 ml of Mf suspension was carefully layered onto 5.0 ml of 
Histopaque and centrifuged at 1200 rpm for 10 min. White blood cells float at 
the interface, while Mf were colleted from the pellet.  The number of Mf in a 20 
µl aliquot was counted and the number of Mf in the total volume calculated. The 
Mf were kept at -80oC until use. 
2.2.2 B. pahangi Hsp90 expression level following exposure to 
heat shock or GA 
Heat shock proteins respond to changes in the environment including 
elevated temperatures and chemical compounds. In order to investigate Hsp90 
expression levels after exposure to heat shock or to GA, adult B. pahangi were 
recovered from gerbils as described previously. 10 adult females were cultured 
in 10 ml RPMI-1640 culture medium (Appendix 4.5) Worms were heat shocked by 
incubating in a water bath at 41oC for 60 min and were allowed to recover at 
37oC for a further 2 h. The control group for the experiment was incubated in a 
water bath at 37oC for 3 h. Worms were then directly solubilised by boiling in 
100 µl SDS-PAGE sample cocktail for 3 min and the supernatant collected by 
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centrifugation at 13200 rpm for 3 min. 5 µl of supernatant were loaded onto 10% 
gel and analysed by SDS-PAGE and Western blotting.     
In other experiments, 10 B. pahangi adult females were cultured in the 
presence of GA. 1 mg GA was dissolved in 171 µl DMSO to give a stock of 10 mM 
GA which was then diluted in RPMI-1640 culture medium to give a final 
concentration of 1.0 µM GA. Adult worms were then incubated in RPMI-1640 
containing GA at 37oC in an atmosphere of 5% CO2 in air for 24 h. The control 
group for the analysis was incubated in RPMI-1640 culture medium containing 
DMSO alone for 24 h at 37oC. Worms were directly solubilised in 100 µl of SDS 
sample cocktail and were centrifuged at 13200 rpm for 3 min. Equal volumes (5 
µl) were analysed by SDS-PAGE and Western blotting as described previously 
using actin as a control. 
2.2.3 Estimating the proportion of B. pahangi Hsp90 that binds to 
GA beads 
The aim of this experiment was to investigate the percentage of the 
cytosolic Hsp90 that could bind to GA beads. Here, the supernatant from one GA 
pull-down was applied to a second GA pull down, for a total of five times. 50 µl 
of GA-beads prepared as described in Section 2.1.8 were mixed with 300 µg of B. 
pahangi extract in a volume of 300 µl for 2.5 h at 4oC. The supernatant from the 
pull-down was retained for the next pull-down. Simultaneously, the beads for 
the first pull-down were processed as described previously in Section 2.1.9. 
These steps were repeated five times. Equal volumes of supernatant (20 µl) were 
loaded onto 10% SDS-PAGE gels and bound protein was analysed by SDS-PAGE and 
Western blotting. The bands on the autoradiograph were scanned and band 
densities were obtained using FlourChemTM IS-5500 software. 
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2.2.4 Detection of Hsp90 in ES products of Mf and adult Brugia  
In B. malayi, Hsp90 was reported to be secreted as an ES product (Kumari 
et al., 1994). In order to investigate whether B. pahangi secretes Hsp90, two 
different stages of B. pahangi were analysed. Mf and adult B. pahangi were 
recovered from infected gerbils at approximately 120 days post-infection. Adult 
worms were washed several times in HBSS. After a final wash, approximately 100 
B. pahangi female and male adult worms were cultured in 40 ml of RPMI-1640 
culture medium (Appendix 4.5) at 37oC in an atmosphere of 5% CO2 in air for 48 
h. Medium was changed every 24 h. Spent medium, containing ES products, was 
passed through a 0.45 µm sterile syringe filter (Iwaki, Japan) to remove Mf and 
ES was stored at -20oC until analysis. A total of 80 ml spent culture medium was 
concentrated to approximately 150 µl in a 10,000 Mr cut off Viva Spin 15R 
Hydrasart (Sartorius Biolab Products, UK) by centrifugation at 3000 g for 45 min. 
The Mf were collected as described previously in Section 2.2.1. Approximately 
1.05 x105 Mf were incubated in RPMI-1640 medium as described previously at 37-
oC in an atmosphere of 5% CO2 in air for 48 h. The medium containing ES 
products was centrifuged at 1000 rpm for 5 min to remove Mf and the 
supernatant was processed as described above for adults. To detect the 
presence of Hsp90 in B. pahangi ES products, 10 µl of concentrated ES products 
were added to 10 µl of SDS-PAGE sample cocktail. The mixture was boiled for 3 
min and centrifuged for further 3 min at 13200 rpm. Samples were then analysed 
by SDS-PAGE and Western blotting.  
Gels were initially analysed by Coomassie blue staining but no bands were 
observed, so a silver staining protocol was used. Following electrophoresis, the 
gel was incubated in fixative enhancer solution (Appendix 2.3.4.1, Bio-Rad, UK) 
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for 20 min with gentle agitation. The gel was then rinsed in 400 ml of ddH2O for 
3 x 10 min. ddH2O was discarded and the gel was stained with staining solution 
(Appendix 2.3.4.2) for approximately 20 min or until the desired staining 
intensity was reached. Finally, the gel was placed in stop solution (Appendix 
2.3.4.3) containing 5% acetic acid. The gel was then rinsed in ddH2O for a 
further 5 min.         
2.2.5 Identification of B. pahangi Hsp90-associated proteins 
Hsp90 is the central component of a complex chaperone system. In most 
organisms, Hsp90 associates with a large set of co-chaperones to mediate the 
activation and maturation of client proteins. Inhibition of Hsp90 function will 
lead to the disassociation of these co-chaperones and the destabilisation of 
client proteins. GA was shown to be toxic to B. pahangi, but it is not known how 
inhibition of Hsp90 function kills the worm. In an attempt to address this point, 
two different approaches were carried out. In the first approach, proteomic 
analysis of B. pahangi adult worms cultured in vitro in the presence or absence 
of GA was carried out. In the second approach, attempts were made to purify 
Hsp90-associated proteins using a modified pull-down approach (Neef et al., 
2010). This modified pull-down relies upon the binding of biotin-labelled GA to 
Hsp90 protein complexes. The complexes are then isolated using Neutravidin-
agarose beads as described below.    
2.2.5.1 GA-biotin 
B. pahangi protein extracts were prepared in biotin-binding buffer with 
protease inhibitors added prior to use as described by Neef et al (2010).  1.0 mg 
of worm extract was incubated with 100 µl of GA-biotin (InvivoGen, UK) for 15 h 
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at 4oC. Hsp90 associated proteins were captured by incubating the mixture with 
Neutravidin-agarose beads for 90 min at 4oC. The beads were pelleted and the 
supernatant was discarded and beads were then washed 3 x 1.0 ml in biotin-
binding buffer and bound proteins were eluted in SDS-PAGE sample cocktail by 
boiling for 5 min. Bound proteins were analysed by Coomassie blue staining.  
2.2.5.2 Protein lysate preparation for proteomic analysis 
B. pahangi adult worms were recovered and processed as described 
previously in Section 2.2.1. 60 adult worms were cultured in RPMI-1640 culture 
medium as described previously, containing 1.0 µM GA at 37oC for 24 h. The 
control group was cultured under identical conditions in the presence of an 
equivalent volume of DMSO. Both samples were kept at -80oC until required for 
preparation of the parasite extracts.  
Worm extracts were prepared using a mortar and pestle in 2D 
electrophoresis lysis buffer (Appendix 3.1) with protease inhibitors added prior 
to use (Roche Diagnostics, UK) exactly as described in 2.1.3. The supernatant 
was retained for protein precipitation. 4x sample volume of 80% cold acetone 
was added and incubated on ice for 30 min, following which the extract was 
pelleted at 13200 rpm at 4oC for 15 min and the supernatant was discarded. The 
protein pellet was dried for approximately 5 min at room temperature and then 
re-suspended in 50 µl lysis buffer and the protein concentration estimated using 
the protein assay as described in Section 2.1.4. Lysis buffer was added to a give 
final protein concentration of 5 mg/ml.  
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2.2.5.3 Isoelectric Focusing (IF) 
50 µg in 10 µl volume of GA-treated B. pahangi lysate was labelled with 
1.0 µl Cy3 and 50 µg in 10 µl volume of untreated group was labelled with Cy5 by 
incubating the mixture for 30 mins on ice in the dark. Cy3 and Cy5 dye were 
provided by GE Healthcare Bio-Sciences, UK. 1.0 µl of 10 mM lysine was added to 
each tube and incubated for 10 mins in the dark. The labelled protein lysates 
were then mixed together and added to 430 µl rehydration buffer (Appendix 3.3) 
containing Bromophenol blue and DDT. The sample was incubated for 30 min at 
room temperature in the dark followed by centrifugation at 13200 rpm for 3 
min. 450 µl of sample was loaded into an Immobilised pH Gradient (IPG) strip 
holder using a Gilson pipette. The samples were distributed along the bed of the 
strip holder. 
A 24 cm IPG strip, ph 4-7 (GE Healthcare Bio-Sciences, UK) was removed 
from the protective package using forceps. The IPG strip was laid into the IPG 
holder with the sticky surface facing down to make contact with the sample 
solution. The barcode was placed toward the pointed end of the IPG strip 
holder. The strip was then overlaid with 1.0 ml mineral oil, sufficient to cover 
the entire strip to avoid evaporation. The IPG strip was placed on the electrode 
bed of an IPGphor Isoelectric Focusing System (GE Healthcare Bio-Sciences, UK) 
with the pointed end of the holder oriented towards the anode. IF was 
performed at 20oC for approximately 25 h at a limited current of 50 µAmp/IPG 
strip and accumulated volts from 70000-80000 Vhs. After IF, the IPG strip was 
removed for analysis or alternatively could be stored at -20oC. 
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2.2.5.4 Second dimension SDS-PAGE  
 
Prior to SDS-PAGE, the IPG strip was equilibrated in equilibration buffer. 
The IPG strip was removed from the strip holder and transferred to a cylindrical 
tube containing the first equilibration buffer (Appendix 3.4) supplemented with 
100 mg DTT/10 ml. The IPG strip was incubated for 15 min on a rocker at room 
temperature. The solution was then poured off and the IPG strip was incubated 
with a second equilibration buffer (Appendix 3.5) containing 250 mg 
iodoacetamide/10 ml on a rocker for 15 min at room temperature.  
The second dimension 12% gel was prepared using standard recipes 
(Appendix 3.6). The equilibrated strip was laid onto the top of the SDS-PAGE gel 
so that there was complete contact between gel and strip, and 1.0 ml of 0.5% 
agarose in SDS-PAGE running buffer with Bromophenol blue was added to overlay 
the strip. Electrophoresis was performed using an Ettan DALTtwelve 
electrophoresis unit (Amersham Bio-Sciences, UK) in running buffer at constant 
voltage of approximately 6V for 25 h at 25oC or until the dye front reached the 
base of the gel. Following electrophoresis, gels were scanned using Typoon 9400 
scanner and the images were analysed using the Differential In-Gel Analysis (DIA) 
software module of the DeCyder batch processor (Amersham Bio-Sciences, UK).  
In a further experiment, GA-treated and control worms were analysed 
separately by 2D-gel electrophoresis. Approximately 50 µg of each worm lysate 
in 50 µl volume was added to 400 µl rehydration buffer (Appendix 3.3) containing 
Bromophenol blue and DTT. The sample was incubated for 30 min at room 
temperature in the dark followed by centrifugation at 13200 rpm for 3 min. 450 
µl of each sample was loaded into different IPG strips. The samples were 
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distributed along the bed of the strip holder, and were processed as described 
above for IF and second dimension SDS-PAGE. Following electrophoresis, the gels 
were stained with Coomassie blue G-250 (Appendix 2.3.2) then washed with 
ddH2O to remove the blue residue off the staining tray. The gels were then 
incubated with 10% acetic acid solution (Appendix 2.3.3) with gentle agitation 
until the desired staining intensity was reached. 
The Ettan Spot handling workstation (Amersham Bio-Sciences) was used to 
spot the differences between the GA-treated and control group. Spots of 
interest were excised and placed in 1.5 ml eppendorf tubes. The samples were 
then subjected to in-gel trypsin digest. 
2.2.5.5 In-gel trypsin digest 
The gel pieces were washed for 60 min in 500 µl 100 mM ammonium 
bicarbonate followed by a further wash in 50% acetonitrile/100 mM ammonium 
bicarbonate for 60 min at room temperature. The supernatant was discarded and 
gel pieces were washed in 500 µl 50% acetonitrile/100 mM ammonium 
bicarbonate with shaking for 60 min, followed by 50 µl of acetonitrile for 10 min. 
After 10 min, the solvent was removed and the gel pieces were dried in a 
vacuum centrifuge. 20 µl of 0.2 µg/µl sequencing grade modified Porcine Trypsin 
(Promega, UK) in 25 mM ammonium bicarbonate was added to rehydrate each 
gel piece. 25 mM ammonium bicarbonate was added to cover the gel pieces (~20 
µl) and then left overnight at 37oC for digestion. The following day, the tube was 
centrifuged to pellet the gel pieces. Supernatant in the tube was then 
transferred to the 96-well plate. 20 µl of 5% formic acid was added to the tube 
and incubated for 20 min followed by incubation in 20 µl acetonitrile for a 
further 20 min with gentle shaking. The tube was centrifuged and supernatant 
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was then transferred into the same well as the first extract. The combination 
extracts were dried completely in a Speedvac. The dried digested samples were 
then subjected to analysis by mass spectrometry where all peptides samples 
were separated on a liquid chromatography-electrospray (LC) system before 
analysing by ionization/multi-stage mass spectrometry (ESI-MS).     
2.2.6 Post-translational modification of Hsp90  
Post-translational modifications of Hsp90 are known to be essential in 
regulating Hsp90 chaperoning functions (Rose et al., 1987; Scroggins et al., 
2007). In order to investigate whether post-translational modification could 
influence the ability of Hsp90 to bind to GA, recombinant human Hsp90α 
(rHsp90α) and Hsp90 isolated from the breast cancer cell line (SkBr3) were 
compared. Ideally, purified B. pahangi Hsp90 would have been used but was not 
available. The rHsp90α (StressMarq, Biosciences Inc., UK) used in the study was 
expressed in E. coli, and therefore had no post-translational modifications. SkBr3 
cells were obtained from Dr. Tina Rich (Faculty of Veterinary Medicine, 
University of Glasgow, UK). SkBr3 cells were extracted in extraction buffer 
(Appendix 2.1.2) by adding 1.0 ml of buffer containing protease inhibitors. The 
mixture was shaken gently to lyse the cells following which the supernatant was 
collected by centrifugation at 13200 rpm for 3 min at 4oC. The supernatant was 
assayed for protein concentration as described previously in Section 2.1.4. 
Approximately, equal amounts of SkBr3 extract (2-4 µg) was mixed with SDS-
PAGE sample cocktail, boiled for 3 min, centrifuged at 13200 rpm for 3 min and 
loaded onto the 10% gel and analysed by SDS-PAGE and Western blotting. For the 
pull-down assay, 5 µg of rHsp90α and 500 µg of SkBr3 lysates were used, exactly 
as described in Section 2.1.9.  In order to demonstrate that the binding of 
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Hsp90α and SkBr3 to GA beads was specific, both samples were subjected to 
competition assay with free soluble GA. Protein extracts were pre-incubated 
with soluble GA at 1.0 µM or 2.0 µM for 60 min at room temperature followed by 
pull-down. Bound proteins were analysed as described previously. 
2.2.7 Competition assays with B. pahangi Hsp90 
2.2.7.1 Competition assay with GA, ATP and novobiocin 
In order to investigate whether the binding of B. pahangi Hsp90 to GA 
beads could be competed with other compounds that bind to Hsp90, a variety of 
experiments were carried out. Compounds used included Adenosine Tri-
Phosphate (ATP) which is known to compete for GA binding, and Novobiocin, a 
drug which binds at the 3’ end of Hsp90, but which can alter the ability of the 5’ 
end of Hsp90 to bind to GA/ATP (Grenert et al., 1997, Garnier et al., 2002). For 
the competition assay with GA beads, 500 µg of worm extract was pre-incubated 
with competitors at different concentrations (Table 2.1) for 60 min at room 
temperature with gentle agitation. The control tube contained only worm 
extract and control beads. 50 µl of packed volume of GA or control beads, 
prepared as described previously, was then added to the mixture and incubated 
for 2.5 h at 4oC. The beads were then washed 5 x 10 min with 1.0 ml of TNES 
buffer by centrifugation. Bound proteins were eluted in SDS-PAGE sample 
cocktail by boiling for 3 min and were centrifuged at 13200 rpm for 3 min. 
Proteins eluted from GA beads and control beads were run on a 10% SDS-PAGE 
gel and were analysed by Western blotting with antibody as described 
previously.    
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2.2.7.2 B. pahangi Hsp90 binding to ATP beads 
ATP binds to Hsp90 at the N-terminal domain in the same binding site as 
for GA (Grenert et al., 1997, Garnier et al., 2002, David et al., 2003). These 
experiments were carried out in order to investigate whether free GA could 
compete the binding of Hsp90 to ATP beads. For the competition assays with ATP 
beads, 500 µg of worm extract was pre-incubated with free GA over a range of 
concentration from 250 nM to 2000 nM for 60 min at room temperature with 
gentle agitation. 100 µl volume of ATP beads (Sigma, UK) was added to the 
mixture and incubated for 1.5 h at 4oC. The beads were then washed 5 x 10 min 
with 1.0 ml of ATP binding buffer (Appendix 2.1.4). Bound proteins were eluted 
in SDS-PAGE sample cocktail by boiling for 3 min and were centrifuged at 13200 
rpm for 3 min. Proteins eluted from GA beads and control beads were run on a 
10% SDS-PAGE gel and were analysed by Western blotting with antibody as 
described previously.     
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Table 2.1: Concentration of compounds used in competition assays with GA-beads 
 
Competitor Concentration 
Soluble GA 0.0  
25 nM 
50 nM 
100 nM 
200 nM 
1000 nM 
ATP 5.0 mM 
10.0 mM 
15.0 mM 
20.0 mM 
Novobiocin 2.5 mM 
5.0 mM 
10.0 mM 
20.0 mM 
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2.2.8 Comparison of B. pahangi and C. elegans Hsp90 
2.2.8.1 Hsp90 expression levels in B. pahangi and C. elegans 
Hsp90 is a well conserved protein in most organisms. C. elegans Hsp90 
was shown to be resistant to GA treatment and failed to bind to GA beads in 
pull-down assays (David et al., 2003; Devaney et al., 2005). In order to 
investigate the differences in Hsp90 sequence of B. pahangi and C. elegans, both 
sequences were compared using a Clustal W alignment.    
In addition, Hsp90 expression levels between B. pahangi and C. elegans 
were compared in adult stages. B. pahangi adult worms were collected as 
described in Section 2.2.1, while C. elegans adult worms were collected by 
washing NGM plates with M9. Protein extracts of adult B. pahangi and C. elegans 
were prepared as described in Section 2.1.3 and assayed for protein 
concentration. Equal amounts of protein (2-4 µg) were loaded onto 10% SDS-
PAGE gel and analysed by SDS-PAGE and Western blotting using actin as a loading 
control. The autoradiograph was scanned and analysed using FluorChemTM IS-
5500 software. Hsp90 expression levels in B. pahangi and C. elegans were scored 
based on the ratio of Hsp90 to actin.       
2.2.8.2 B. pahangi and C. elegans Hsp90 binding to ATP beads  
ATP was shown to bind to the N-terminal domain of Hsp90, which is the 
same binding site for GA. ATP binding affinity can differ from one organism to 
another. It order to investigate the affinity of Hsp90 binding to ATP beads, B. 
pahangi and C. elegans extract were compared. Approximately 300 µg of worm 
lysates were incubated with 100 µl ATP beads (Sigma, UK) for 60 min at room 
temperature with gentle agitation. The beads were then washed 5 x 10 min in 
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ATP binding buffer. The bound proteins were eluted by boiling for 3 min in 30 µl 
of SDS-PAGE sample cocktail followed by centrifugation at 13200 rpm for 3 min. 
Samples were analysed by SDS-PAGE and Western blotting. Any band on the 
autoradiograph was scanned and analysed as described previously.  
2.3 Hsp90 and drug resistance 
In order to determine whether Hsp90 may play a role in drug resistance in 
nematodes, a number of experiments were carried out. Hsp90 levels were 
examined in anthelmintic resistant and susceptible Teleodorsagia circumcincta. 
In addition, Hsp90 expression in various strains of C. elegans was assessed. 
Finally, attempts were made to reduce Hsp90 levels in ivermectin-resistant C. 
elegans to investigate the effect of Hsp90 reduction on susceptibility to 
ivermectin. 
2.3.1 Hsp90 expression levels in drug resistant and susceptible 
worms 
In a previous study on tumour cells, Hsp90 was shown to be expressed at 
higher level in drug resistant cell lines compared to wild-type cell lines (Bertram 
et al., 1996, Banerji, 2009; Constantino et al., 2009). However, in nematodes no 
such information is available. In order to determine the Hsp90 expression levels 
in resistant and susceptible nematodes, three groups of resistant nematodes 
were analysed. A T. circumcincta resistant isolate (Tci5) and a susceptible 
isolate (Tci2) were obtained from Prof. David Knox (Moredun Research Institute, 
UK). Tci5 worms are known to be resistant to anthelmintics from all three broad 
spectrum families (benzimidazole, ivermectin and levamisole)(Bartley et al., 
2005). In contrast the Tci2 isolate is susceptible to all broad spectrum 
Chapter 2  79 
anthelmintic families. Both of the strains were originally field isolates. T. 
circumcincta resistant and susceptible worms were extracted and assayed as 
described previously in Section 2.1.3. Approximately equal amounts of protein 
(2-4 µg) were analysed by SDS-PAGE and Western blotting, using actin as a 
loading control as described previously.  
C. elegans CB3474 and C. elegans DA1316 were obtained from the C. 
elegans Genetics Centre (CGC, USA) for analysis. The C. elegans CB3474 strain 
shows resistance to benzimidazoles conferred by a mutation in the ben-1 gene 
(β-tubulin isotype-1) (Driscoll et al., 1989). C. elegans DA1316 contains 
mutations in avr-14, avr-15 and glc-1 and exhibits high level resistance to 
ivermectin (Dent et al., 2000). Worms were maintained on standard NGM plates 
as described in Section 2.1.2.1. For C. elegans CB3474 and C. elegans DA1316 
mixed stages were analysed. Worms were directly solubilised in SDS-PAGE 
sample cocktail by boiling for 3 min and extracts were collected by 
centrifugation at 13200 rpm for 3 min. 5 µl samples were loaded onto 10% gels 
and analysed SDS-PAGE and Western blotting.   
Two additional lines of ivermectin-resistant C. elegans were also 
available, IVM-6 and IVM-10. In contrast to C. elegans DA1316 and CB3474 which 
are the product of mutagenesis screen, IVM-6 and IVM-10 worm were selected by 
growth on increasing levels of ivermectin over a period of time. Therefore, these 
worms may be more similar to field isolates of drug resistant parasitic 
nematodes. IVM-6 worms are resistant to ivermectin at 6 ng/ml and IVM-10, to 
10 ng/ml (James & Davey, 2009). These strains were obtained from the Institute 
for Biotechnology of Infectious Diseases, University of Technology Sydney, 
Australia. IVM-6 and IVM-10 worms were cultured on ivermectin plates containing 
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drug at 6 ng/ml or 10 ng/ml respectively (Appendix 4.7). For C. elegans IVM-6 
and IVM-10 worms, adult stages were used for the analysis of Hsp90 levels. 30 
worms were solubilised in 30 µl SDS-PAGE sample cocktail by boiling for 3 min 
and extracts were collected by centrifugation at 13200 rpm for 3 min. 5 µl of 
samples were loaded onto 10% gels and analysed SDS-PAGE and Western blotting.   
2.3.2 C. elegans methods 
2.3.2.1 Synchronisation of C. elegans cultures 
For ivermectin sensitivity assays and RNAi feeding experiments, L4 stage 
worms were used. In order to get worms at the same stage of development, 
gravid adult worms were lysed in bleach solution containing 15% sodium 
hypochlorite solution (Appendix 5.1). Bleaching also cleans the worms of any 
bacterial contamination from the plates. Worms were cultured on standard NGM 
plates with E. coli OP50 as a food source and were allowed to grow for 3 to 4 
days at 20oC so that the plates contained many gravid adults. Gravid adults were 
collected by washing in M9 buffer in 15 ml conical centrifuge tubes and worms 
were pelleted at 2000 rpm at 4oC for 2 min. The supernatant was removed 
without disturbing the worm pellet and 0.5 ml bleach solution was then added to 
the tube. The mixture was shaken gently for 3-5 min to help to lyse the gravid 
adults. Eggs were then pelleted by centrifugation at 2000 rpm for 2 min and the 
supernatant was discarded. Following four washes in M9 buffer, eggs were 
incubated in M9 and allowed to hatch overnight at 20oC in an incubator.  L1 
hatched in M9 arrest development. The synchronised L1 stage worms were 
spotted onto standard NGM plates seeded with OP50 and were allowed to 
develop to early L4 stage at 20oC before use in ivermectin sensitivity assays or in 
RNAi experiments.  
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2.3.2.2 Ivermectin sensitivity assays 
Two assays were used for this analysis; a drug cytotoxicity assay and a 
motility assay. In the drug cytotoxicity assay, the growth of C. elegans from egg 
to gravid adult was scored, while in the motility assays, the motility of worms 
after exposure to ivermectin at different concentrations for 24 h and 48 h was 
scored. The drug cytotoxicity assay was applied as described previously by Hart 
(2006). C. elegans N2 and IVM-10 resistant worms were bleached as described 
previously in Section 2.3.2.1. Eggs were then re-suspended in M9 and 10 µl of the 
suspension was spotted onto plates containing containing 1 ng/ml, 5 ng/ml, 10 
ng/ml ivermectin or DSMO as a control in triplicate and were incubated at 20oC. 
The worms were allowed to grow for 3-4 days and growth was scored (egg to 
adult). The motility assay was applied as described previously (Arena et al., 
1995). Five L4 stage worms of C. elegans N2 or IVM-10 resistant worms were 
incubated in 24 well plates. Six replicates were made for each dilution of 
ivermectin. IVM-10 resistant worms were incubated in M9 culture containing 1 
ng/ml, 5 ng/ml or 10 ng/ml ivermectin and DMSO as a control in 24 well plates. 
OP50 was added as a food source. Plates were incubated for 24 h and 48 h at 
20oC and worm motility was scored based on the percentage of worms that were 
still thrashing in the different wells. The activity of the worms was scored (see 
Table 2.2) and the score was converted to a numerical value. 
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Table 2.2: Scoring system for motility assay 
 
 Activity* Score 
Thrashing  
Slow 
Paralysed 
Dead 
3 
2 
1 
0 
  
* All scores based on the movement or activity of the worm after 24 h and 48 h in liquid 
culture system containing ivermectin at different concentration (ng/ml). Each worm was 
observed for 10 sec. 
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2.3.2.3 Reducing Hsp90 levels by RNA mediated interference (RNAi) 
There are a variety of RNAi approaches that can be applied to C. elegans 
including injection of dsRNA into the hermaphrodite gonad, feeding the worms 
on lawns of bacteria expressing dsRNA, soaking worms in dsRNA or expressing 
dsRNA from a transgene (Kamath et al., 2001, 2003). The experiments presented 
in this thesis involved the feeding of bacteria expressing dsRNA to C. elegans. 
hsp90(RNAi) constructs used in this thesis was prepared previously by Dr. 
Victoria Gillan (University of Glasgow, UK). Two different constructs was used; a 
300 bp and a 75 bp construct, as described in Gillan et al (2009). Figure 2.2a 
shows a schematic time frame of a single experiment using RNAi by feeding.   
2.3.2.4 Preparation of plates for hsp90(RNAi), bacteria preparation and 
induction 
For the RNAi feeding experiment, worms were cultured on RNAi plates 
containing IPTG and ampicillin. IPTG and ampicillin were added to standard NGM 
agar (Appendix 4.3) to give a final concentration of 1.0 mg/ml and 25 µg/ml, 
respectively. Plates were prepared 4-7 days before use and kept at room 
temperature to allow the plates to dry. RNAi plates must be dried before 
seeding with bacteria because wet plates will affect the efficiency of RNAi 
(Kamath et al., 2001).  
HT115 (DE3) cells containing the RNAi construct of interest, or containing 
an empty vector were used in these studies. Bacteria from glycerol stocks were 
spotted onto L-Broth agar plates (Appendix 4.2) containing 50 µg/ml ampicillin 
and 15 µg/ml tetracycline. Plates were incubated overnight at 37oC. Next day, 
one large colony of bacteria was picked and inoculated into L-Broth (Appendix 
4.1) containing 50 µg/ml ampicillin and grown overnight with shaking at 37oC in 
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an orbital incubator. The bacteria were then seeded onto RNAi plates as 
described above and incubated overnight at room temperature to allow the 
bacteria to grow and to begin induction by IPTG. The same procedures were 
applied to the control group, which consisted of bacteria expressing empty 
vector as a food source.       
2.3.2.5 Optimising the conditions for hsp90(RNAi)  
In order to determine the optimal conditions for hsp90(RNAi) and to 
estimate the reduction of Hsp90 levels in RNAi worms, L4 stages of C. elegans N2 
were incubated at different temperature or were fed for different time periods. 
Synchronised L4 were incubated at 16oC, 20oC or 25oC for 24 h feeding time. To 
determine the reduction of Hsp90 expression levels after 24 h on RNAi or control 
plates, 30 worms were solubilised in 30 µl of SDS-sample cocktail by boiling for 3 
min and collected by centrifugation at 13200 rpm for 3 min. 5 µl of worm extract 
were loaded on a 10% SDS-PAGE gel and the Hsp90 expression levels were 
analysed by SDS-PAGE and Western blotting. In other experiments, L4 were 
incubated at 20oC for 6 h, 12 h or 24 h on RNAi or control plates. Hsp90 
expression levels were analysed by SDS-PAGE and Western blotting. Any bands on 
the autoradiograph were scanned and analysed using FluorChemTM IS-5500 
software as described previously in Section 2.1.7. For all experiments, actin was 
used as a loading control. These experiments were carried out using both the 
300 bp and 75 bp hsp90(RNAi) constructs. 
2.3.2.6 Scoring the efficiency of hsp90(RNAi) by counting progeny 
To investigate the efficiency of hsp90(RNAi), adult worms were fed on the 
300 bp or 75 bp hsp90(RNAi) construct for a 24 h period and then the number of 
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progeny were counted. After 24 h on hsp90(RNAi) plates, 3 adults were 
transferred onto each of three fresh NGM plates and were allowed to lay eggs for 
24 h at 20oC. Adults were then removed from the plates. The number of eggs 
laid by adults was counted and plates were incubated for further 24 h at 20oC. 
Embryonic lethality, early larval phenotypes and post-embryonic phenotypes 
were scored using a dissecting microscope. 
2.3.2.7 Ivermectin sensitivity assays following hsp90(RNAi) 
  C. elegans N2 and IVM-10 resistant worms were fed on the 75 bp 
hsp90(RNAi) construct or the control empty vector for 24 h at 20oC. After 24 h on 
RNAi plates, worms were subjected to the drug cytotoxicity assay on plates 
containing ivermectin at 1, 5 or 10 ng/ml or DSMSO alone as a control. For the 
motility assay, five worms were transferred into 24 well plates in six replicates. 
The medium contained 1, 5, or 10 ng/ml of ivermectin or DMSO alone as a 
control. OP50 was added as food source and the plates were incubated at 20oC 
for 24 h or 48 h.  Figure 2.2b and 2.2c shows a schematic time frame of a single 
experiment using RNAi by feeding.  
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Figure 2.1: Schematic time-frame of RNAi feeding experiment.  
 
a) Feeding time-line. 
b) Schematic of the time-frame of experiment using RNAi followed by ivermectin 
cytotoxicity assay. 
c) Schematic of the time-frame of experiment using RNAi followed by ivermectin motility 
assay. 
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(a) 
 
(b) 
 
(c) 
Adapted from Kamath et al (2003) 
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2.4 Statistical analysis   
The Student t-test and Mann-Whitney U-test was used to determine the 
statistical of significance differences between groups. Differences between 
groups were considered significant at p<0.05. 
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3 Hsp90 and the biology of nematodes 
3.1 Introduction 
Hsp90 is a unique molecular chaperone which is involved in chaperoning 
important proteins such as kinases, telomerase, helicases and transcription 
factors. Because it is involved in multiple cellular processes, knock-out of hsp90 
is lethal to most organisms, so the functions of Hsp90 have been studied using 
inhibitors. One of the best characterised Hsp90 inhibitors is geldanamycin (GA) 
which is synthesised by Stremptomyces hygroscopicus. By binding to Hsp90, GA 
prevents the binding of ATP, resulting in the destabilisation of client proteins (as 
reviewed in Chapter 1). The sequence of Hsp90 is highly conserved and in most 
eukaryotes Hsp90 is inhibited in the presence of GA, the exception to date being 
Caenorhabditis elegans. C. elegans Hsp90 failed to bind GA while retaining the 
ability to bind ATP (David et al., 2003). In that study no discernable effects on 
larval viability, dauer development, adult fertility and life span were observed 
despite continuous passage of worms for three generations on plates saturated 
with GA at 178 µM. Furthermore, C. elegans showed no ill-effect when 
maintained on a lawn of S. hygroscopicus secreting GA. In contrast, studies on 
the filarial nematode Brugia pahangi, revealed the importance of Hsp90 in these 
worms (Devaney et al., 2005). After being exposed to GA at 1.0 µM (the 
concentration known to inhibit mammalian Hsp90 activity), there was a 
significant decrease in microfilariae release from adult worms. Similar results 
were obtained at 500 nM GA but not at 100 nM GA. The female worms appeared 
flaccid and become progressively more lethargic until, by day 7-8, 100% were 
dead, while the male worms were more sensitive to GA with 100% dying by day 
5-6. This finding suggests that GA has a direct macrofilaricidal effect on Brugia. 
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Moreover, in solid phase pull-down assays, Hsp90 of B. pahangi bound to GA as 
analysed by Western blotting using an antiserum to B. pahangi Hsp90. Thus, the 
effect of GA on filarial worms contrasts with its lack of activity on C. elegans.  
The failure of C. elegans Hsp90 to bind GA was suggested to be an example of 
adaptive evolution, as C. elegans shares the same ecological niche of the soil 
with the Streptomyces species that elaborates GA (David et al., 2003). Given the 
different results with the GA binding assay using extracts of B. pahangi and C. 
elegans, some questions arise. Why does Hsp90 of C. elegans not bind to GA 
while Hsp90 of B. pahangi does?  Is the ability of Hsp90 to bind to GA associated 
with a particular nematode life-cycle or with a specific clade of nematodes? Is 
GA resistance or susceptibility the norm amongst nematodes? What are the 
differences between the structure of non-binding and binding of Hsp90s?  
Many nematodes are important parasites of humans, animals and plants 
and are responsible for significant economic losses worldwide. Nematodes can 
be grouped into five separate clades based on the phylogenetic analysis of small 
subunit ribosomal RNAs (as reviewed in Introduction). Nematode life-cycles are 
very diverse between species. Some species have a free-living larval stage within 
the environment, e.g. the Trichostrongyles, while some species, e.g. filarial 
worms, are obligate parasites transmitted by the bite of an infected 
intermediate host. Furthermore other species are permanently parasitic and 
transmitted by ingestion of infected tissues, such as Trichinella spiralis, a clade 
I species.  
 At the start of this study only two species of nematode had been 
examined for GA binding, B. pahangi, a clade III parasitic nematode and the 
free-living clade V species C. elegans. The aim of the studies described in this 
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chapter was to examine a range of other nematode species for GA binding 
capacity and to determine whether the ability of Hsp90 to bind GA is associated 
with a particular clade of nematodes or particular nematode life cycles.   
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3.2 Results 
3.2.1 Do other clade V species bind GA? 
Initial studies involved analysing extracts of a variety of nematodes to 
detect the expression of Hsp90 using the B. pahangi anti-Hsp90 antibody or the 
AC88 monoclonal antibody by immuno-blotting. B. pahangi lysate was used as a 
positive control in all experiments because it reacted with both of the 
antibodies. Any species which showed no reactivity with the B. pahangi anti-
Hsp90 antibody was tested with the AC88 monoclonal antibody. Nine species of 
clade V nematode were used for the analysis, of which five were free-living 
species and four were parasitic. Free-living species were wild-type C. elegans 
N2, C. elegans JT6130, a daf-21 mutant (which carries a point mutation in daf-
21(E292 to K), Caenorhabditis briggsae, Pristionchus pacificus and Oscheius 
tipulae. For these worms, mixed life-cycle stages were analysed. All free-living 
species reacted positively with the B. pahangi anti-Hsp90 antibody (see Figure 
3.1). The strongest signal was obtained with B. pahangi extracts, with O. 
ochengi and P. pacificus extracts showing a relatively weak signal. The 
autoradiograph shown in Figure 3.1b was developed for 10 sec. The signal for O. 
tipulae and P. pacificus improved with increased time of exposure (results not 
shown).   
 The parasitic species from Clade V analysed were Haemonchus contortus, 
Nipponstrongylus brasiliensis, Teladorsagia circumcincta and Heligmosomoides 
polygyrus. In all cases, adult males and females were used.  All these parasitic 
species tested reacted with the B. pahangi anti-Hsp90 antibody (see Figure 3.2) 
except for H. contortus adults. The anti-Hsp90 monoclonal antibody (AC88) also 
failed to detect Hsp90 in H. contortus adult worms (results not shown). A new 
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extract of H. contortus adult worms was prepared by directly solubilising in SDS-
PAGE sample cocktail by boiling for 3 minutes. The soluble supernatant was run 
on a 10% gel (see Figure 3.3a) and was analyzed by western blot (Figure 3.3b). 
From the blot it was clear that Hsp90 from H. contortus adult worms that were 
directly solubilised in SDS-PAGE sample cocktail reacted well with the B. pahangi 
anti-Hsp90 antibody, but no signal was obtained from the TNES-soluble extract 
of H. contortus adults. In an attempt to overcome this problem, different 
protease inhibitors from SIGMA (containing AEBSF, Aprotinin, Bestatin 
hydrochloride, E-64, Leupeptin hemisulfate salt and pepstatin A) and the 
Complete Mini Protease Inhibitor from ROCHE (formulation not available) were 
compared using the standard extraction methods as described before. Then the 
extracts were run on a 10% gel and analyzed by Western blot. Even using the 
new protease inhibitor cocktail there was still no signal from H. contortus adult 
TNES-soluble lysates using the B. pahangi anti-Hsp90 antibody. This result 
suggested that the TNES-soluble extract of H. contortus adults may be degraded 
during the preparation of the extract, despite the presence of protease 
inhibitors. Examination of the Coomassie blue stained gel shown in Figure 3.3a 
(Lane 3) suggested that this explanation may be correct. Adult worms extracted 
directly into SDS-sample cocktail show a range of bands of different molecular 
weight (Lane 2), while the TNES-soluble extract of adult worms shows few bands 
and an abundance of material at the bottom of the gel (Lane 3). As H. contortus 
adults are known to be rich in proteases (Knox et al., 1993), attempts were 
made to identify Hsp90 in TNES-soluble extracts of H. contortus L3. A TNES-
soluble extract of H. contortus L3 reacted with B. pahangi anti-Hsp90 antibody 
(Figure 3.3b) and was used for subsequent pull-down assays. 
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Previous results had shown that C. elegans Hsp90 failed to bind GA. Pull-
down assays were carried out on a range of free-living species belonging to clade 
V in order to investigate the GA binding ability of Hsp90 from other free-living 
nematodes. As shown in Figure 3.4, no binding was observed to GA beads for any 
free-living species tested. Analysis of clade V parasitic species produced similar 
results, with no binding observed (Figure 3.5). B. pahangi lysate was used as a 
positive control in all experiments (see Lane 1, Figure 3.4 and Figure 3.5). In all 
cases, blots were exposed for extended periods of time, but no positive 
reactions were observed compared to the B. pahangi positive control. Each pull-
down was repeated at least twice with similar results. These data demonstrated 
that like C. elegans, Hsp90 from the other clade V free-living and parasitic 
nematodes tested do not bind GA. In all experiments, worm lysate were 
incubated with control beads in pull-downs and were analysed as for GA beads. 
Non-specific binding of Hsp90 to control beads was not observed.  
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                  (a)  
 
  (b)  
 
Figure 3.1: All clade V free-living nematodes were observed to react with the antibody to B. 
pahangi anti-Hsp90.  
 
a) Coomassie blue stained gel of different worm extracts. Approximately equal amounts of 
proteins were loaded on a 10% SDS-PAGE gel as assessed by Coomassie blue staining for 
B. pahangi (Lane 1), C. elegans (Lane 2), C. elegans (JT6130) (Lane 3), C. briggsae (Lane 4), 
O. tipulae (Lane 5) and P. pacificus (Lane 6). Mr represents the molecular weight markers.  
b) Free-living clade V nematodes reacted with the B. pahangi anti-Hsp90 antibody. A strong 
signal was observed with B. pahangi extract (Lane 1); weaker signals were observed for O. 
tipulea and P. pacificus (Lane 5 and Lane 6). Approximately, equal amounts of each extract 
were analysed on a 10% gel, which was blotted and probed with 1:5000 dilution of the B. 
pahangi anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-
rabbit IgG conjugated to HRP. The blot was developed using the Pierce Super Signal West 
Pico chemiluminescence kit. The autoradiograph shown was developed for 10 sec. 
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(a)  
 
(b)  
 
Figure 3.2: Clade V parasitic nematodes show cross reactivity with B. pahangi anti-Hsp90 
antibody. 
 
a) Coomassie blue stained gel of clade V parasites. Equal amounts of proteins were loaded 
on a 10% SDS-PAGE gel. B. pahangi (Lane 1), T. circumcincta (Lane 2), N. brasiliensis (Lane 
3), H. polygyrus (Lane 4) and H. contortus L3 (Lane 5). Mr represents the molecular weight 
markers. 
b) Clade V parasitic nematodes react with the B. pahangi anti-Hsp90 antibody. B. pahangi 
(Lane 1), T. circumcincta (Lane 2), N. brasiliensis (Lane 3), H. polygyrus (Lane 4) and H. 
contortus L3 (Lane 5). Proteins were transferred to NCP using standard methods, blocked 
o/n in 5% dried milk in PBS/0.5% Tween 20 and then the blot was probed with 1:5000 
dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit. 
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(a)  
 
(b)  
 
Figure 3.3: Analysis of H. contortus worm extracts with B. pahangi anti-Hsp90 antibody. 
 
a) Coomassie blue staining of H. contortus extracts. 10% SDS-PAGE gel with B. pahangi 
lysate as a control (Lane 1). An extract of adult H. contortus solubilised directly in SDS-
PAGE sample cocktail (Lane 2), TNES-soluble extract of H. contortus adults (Lane 3) and 
TNES-soluble extract of H. contortus L3 (Lane 4).    
b) TNES-soluble extracts of H. contortus adults are not recognised by B. pahangi anti-Hsp90 
antibody. B. pahangi extract (Lane 1), adult H. contortus solubilised in SDS-PAGE sample 
cocktail (Lane 2), TNES-soluble extracts of adult H. contortus (Lane 3), TNES-soluble extract 
of H. contortus L3 (Lane 4). Proteins were transferred to NCP using standard methods, 
blocked o/n in 5% dried milk in PBS/0.5% Tween 20 and then the blot was probed with 
1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit. 
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(a)  
 
(b)  
 
Figure 3.4: Pull-down assays demonstrate that Hsp90 from free-living clade V nematodes 
does not bind GA.  
 
a) Pull-down assays with GA beads. B. pahangi (Lane 1), C. elegans N2 (Lane 2), C. elegans 
(JT6130), C. briggsae (Lane 4), O. tipulae (Lane 5)  and P. pacificus (Lane 6).  
b) Pull-down assay with control beads. B. pahangi (Lane 1), C. elegans N2 (Lane 2), C. 
elegans JT6130 (Lane 3), C. briggsae (Lane 4), O. tipulae (Lane 5) and P. pacificus (Lane 6).  
GA pull-down assays were carried out with 500 µg of worm lysate incubated with 50 µl of GA 
beads for 2.5 h at 4o C. The beads were washed extensively in TNES and bound proteins 
were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins were analysed by 
SDS-PAGE and immuno-blotting. The blots were probed with 1:5000 dilution of the B. 
pahangi anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-
rabbit IgG conjugated to HRP. The blot was developed using the Pierce Super Signal West 
Pico chemiluminescence kit. 
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                          (a) 
 
(b)  
 
Figure 3.5: Hsp90 from clade V parasitic nematodes does not bind to GA. 
 
a) Pull-down assay with GA beads. B. pahangi (Lane 1), T. circumcincta (Lane 2), N. 
brasiliensis (Lane 3), H. polygyrus (Lane 4) and H. contortus L3 (Lane 5).  
b) Pull-down assays with control beads. B. pahangi (Lane 1), T. circumcincta (Lane 2), N. 
brasiliensis (Lane 3), H. polygyrus (Lane 4) and H. contortus L3 (Lane 5). 
Results shown here from three different pull-down assays. GA pull-down assays were 
carried out with 500 µg of worm lysate with GA beads. Lysate of worms were incubated with 
50 µl of GA beads for 2.5 h at 4o C. The beads were washed extensively in TNES and bound 
proteins were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins were 
analysed by SDS-PAGE and immuno-blotting. The blot was probed with 1:5000 dilution of 
the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution 
of anti-rabbit IgG conjugated to HRP. The blots were developed using the Pierce Super 
Signal West Pico chemiluminescence kit.  
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3.2.2 Do other clade III species bind GA? 
Hsp90 from B. pahangi, a clade III nematode, was previously shown to 
bind GA in pull-down assays and was also sensitive to GA treatment (Devaney et 
al., 2005). In order to investigate whether the ability to bind GA is shared with 
other clade III species, several other nematodes were available for analysis 
including three filarial worms, Acanthocheilonema viteae, Dirofilaria immitis 
and Ochocerca ochengi, the Ascarid species, T. cati, Ascaris suum, Parascaris 
equorum and the Anisakids, Anisakis simplex and Pseudoterranova decipiens. In 
addition a Dracunculid, species Anguilicola crassus was also tested. All filarial 
worms reacted with B. pahangi anti-Hsp90 antibody (Figure 3.6b) as did the 
ascarid and anisakid species (Figure 3.7b) but no reaction was observed with A. 
crassus (Figure 3.6c). For A. crassus, the immuno-blot was repeated using the 
AC88 monoclonal anti-Hsp90 antibody. However no reaction was observed (see 
Figure 3.6c).  
GA pull-downs assays of clade III parasites showed an interesting variation 
in results. All filarial nematodes tested were shown to bind to GA (Figure 3.7a), 
while Hsp90 from the three Ascarid species analysed also bound to GA (Figure 
3.7c). However, Hsp90 from the Anisakids (A. simplex and P. decipiens) did not 
bind to GA. The autoradiograph was left overnight for further exposure, but still 
no signal was observed. All experiments were repeated at least twice. As no 
signal was obtained with the antibody using A. crassus extracts, attempts were 
made to visualise a band in the GA pull-downs with A. crassus by Coomassie blue 
staining of a gel, but no band was observed (results not shown).  
For selected species which showed positive results in pull-down assays, 
the experiments were repeated in the presence of excess GA to block free 
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binding sites (see Figure 3.8). Two concentrations of GA were used, 2 µM and 20 
µM. The binding of A. suum Hsp90 to GA beads was blocked by pre-incubation 
with GA at 2 µM or 20 µM (Panel a, Figure 3.8). Similar results were observed for 
P. equorum (Panel b, Figure 3.8), D. immitis (Panel c, Figure 3.8), and O. 
ochengi (Panel d, Figure 3.8). These results indicate the specificity of the 
interaction. In separate experiments, male and female worms were available for 
two species A. suum and T. cati, so it was possible to compare GA binding of 
both sexes. The results demonstrate that Hsp90 from males and females of both 
nematodes bound to GA (Figure 3.9a and 3.9b).   
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Figure 3.6: Hsp90 from clade III nematode reacted with B. pahangi anti-Hsp90 antibody. 
 
a) Coomassie blue stained gel. Gel shows equivalent amounts of proteins from selected 
clade III nematodes loaded on 10% gel and analysed by Coomassie blue staining. B. 
pahangi (Lane 1), A. viteae (Lane 2), D. immitis (Lane 3), O. ochengi (Lane 4), A. simplex 
(Lane 5).  
b) Hsp90 from clade III nematodes is recognised by the B. pahangi anti-Hsp90 antibody. 
The blots were probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. B. 
pahangi (Lane 1), A. viteae (Lane 2), D. immitis (Lane 3), O. ochengi (Lane 4), T. cati (Lane 
5), A. suum (Lane 6), P. equorum (Lane 7), A. simplex (Lane 8) and P. decipiens (Lane 9). 
Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to 
HRP. The blot was developed using the Pierce Super Signal West Pico chemiluminescence 
kit. 
c) A TNES-soluble extract of A. crassus (Lane 2 and Lane 4) failed to react with the B. 
pahangi anti-Hsp90 or the AC88 anti-Hsp90 antibody. In these experiments a C. elegans 
lysate was used as a positive control (Lane 1 and Lane 3). The blots were probed with 
1:5000 dilution of the B. pahangi anti-Hsp90 antibody (Lane 1 and Lane 2). Bound antibody 
was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP.  Lane 3 and 
Lane 4 were probed with 1:500 dilution of AC88 anti-Hsp90 monoclonal antibody. Bound 
antibody was detected using a 1:10,000 dilution of anti-mouse IgG. Both blots were 
developed using the Pierce Super Signal West Pico chemiluminescence kit. 
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(a)  
 
(b)  
 
 
B. pahangi anti-Hsp90 antibody AC88 anti-Hsp90 antibody   
 
 
(c) 
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Figure 3.7: GA pull-down assays using clade III nematodes 
 
a) Immuno-blot of GA pull-down assays using extracts of filarial worms. B. pahangi (Lane 1), A. 
viteae (Lane 2), D. immitis (Lane 3) and O. ochengi (Lane 4).  
b) Immuno-blot of pull-down assays with control beads. Gel loaded as in Panel a.  
c) Immuno-blot of GA pull-down assays using extracts of ascarid and anisakid worms. B. 
pahangi (Lane 1), A. suum (Lane 2), P. equorum (Lane 3) and T. cati (Lane 4), P. decipiens (Lane 
5) and A. simplex (Lane 6).  
d) Immuno-blot of control beads for the pull-down assays. Gel loaded exactly as in Panel c.  
For pull-down assays, 500 µg of proteins extract were incubated with 50 µl of GA beads for 2.5h 
at 4oC on rocker. The blots were probed with 1:5000 dilution of the B. pahangi anti-Hsp90 
antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated 
to HRP. The blot was developed using the Pierce Super Signal West Pico chemiluminescence 
kit.  
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                      (a)  
 
(b)  
 
 
 
                                     (c) 
 
(d)  
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Figure 3.8: The binding of Hsp90 to GA is specific 
 
For selected species which showed a positive result in pull-down assay, the experiments 
were repeated in the presence of excess GA at 2.0 µM or 20.0 µM to block free binding sites. 
A. suum (Panel a), P. equorum (Panel b), D. immitis (Panel c) and O. ochengi (Panel d).  
For the competition assays, 500 µg of worm lysate were first incubated in a total volume 300 
µl with GA at 2.0 µM or 20.0 µM for 1 h at room temperature. Then 50 µl of GA beads were 
added and incubated for further 2.5 h at 4o C. The beads were washed extensively in TNES 
and bound proteins were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins 
were analysed by SDS-PAGE and immuno-blotting. The blots were probed with 1:5000 
dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit.  
 
 
 
 
(a) A. suum (b) P. equorum 
(c) D. immitis (d) O. ochengi 
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(a) (b) 
Figure 3.9: The binding of Hsp90 to GA is independent of the sex of the worm.  
 
a) Immuno-blot of GA pull-down assay using A. suum male and female worms. B. pahangi 
(Lane 1), A. suum female (Lane 2) and A. suum male (Lane 3).     
b) Immuno-blot of GA pull-down assay using T. cati male and female. B. pahangi (Lane 1), T. 
cati female (Lane 2) and T. cati male (Lane 3).     
500 µg of worm lysate of male or female worms were incubated with 50 µl of GA beads for 
2.5 h at 4o C.  The beads were washed extensively in TNES and bound proteins were eluted 
by boiling in SDS-PAGE sample cocktail. Bound proteins were analysed by SDS-PAGE and 
immuno-blotting. The blots were probed with 1:5000 dilution of the B. pahangi anti-Hsp90 
antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit.  
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3.2.3 Do nematodes from other clades bind to GA? 
Two species of clade I nematode were available for the analysis, T. 
spiralis and Trichuris muris. Equal amounts of TNES-soluble protein extracts 
were loaded onto a 10% SDS-polyacrylamide gel and were analysed to detect 
Hsp90 on the blots. However, neither species reacted with the B. pahangi anti-
Hsp90 antibody or with AC88 antibody at a range of antibody concentrations or 
exposure times (Figures 3.10a and 3.10b). Consequently, it was not possible to 
analyse GA pull-downs by immuno-blotting. GA and control pull-downs using both 
T. spiralis and T. muris were analysed by Coomassie blue staining. For T. 
spiralis, a band of 83 kDa was observed on the gel that was not present using the 
control beads (Figure 3.10c). However, for T. muris no band was observed when 
GA pull-downs were analysed by Coomassie blue staining (Figure 3.10c). The T. 
spiralis band was excised from the gel and was sent to the Sir Henry Welcome 
Functional Genomics Unit, University of Glasgow for proteomic analysis. 
Following trypsin digestion and mass spectrometry, MASCOT searches revealed 
that the T. spiralis band was likely to be Hsp90. Multiple peptide hits showed a 
high degree of similarity (p<0.05) with Hsp90s from many other species. These 
experiments were repeated in the presence of excess GA to block free binding 
sites (see Figure 3.10e). Two concentrations of GA were used, 2 µM and 20 µM. 
At 2 µM GA, the binding of T. spiralis Hsp90 to GA beads was completely 
blocked. This demonstrated the specificity of the interaction of T. spiralis Hsp90 
with GA.   
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Figure 3.10: T. spiralis Hsp90 binds to GA beads in pull-down assay. 
 
a) Immuno-blot showing that Hsp90 from clade I nematodes is not recognised by the B. 
pahangi anti-Hsp90 antibody. B. pahangi (Lane 1), T. spiralis (Lane 2) and T. muris (Lane 
3). The blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound 
antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The 
blot was developed using the Pierce Super Signal West Pico chemiluminescence kit.  
b) Immuno-blot of clade I nematodes failed to reacted with AC88 monoclonal anti-Hsp90 
antibody. C. elegans (Lane 1), T. spiralis (Lane 2) and T. muris (Lane 3). The blot probed 
with 1:500 dilution of the AC88 monoclonal anti-Hsp90 antibody. Bound antibody was 
detected using a 1:10,000 dilution of anti-mouse IgG. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit. In this experiment, C. elegans 
lysate was used as a control.  
 c) Coomassie blue stained gel of GA pull-down assay for clade I nematodes. B. pahangi 
(Lane 1), T. spiralis (Lane 2) and T. muris (Lane 3). Note the band at ~ 83 kDa in Lane 1 and 
Lane 2.  
d) Coomassie blue stained gel of control beads. Gel loaded as in Panel c. For pull-down 
assays, 500 µg of proteins extract were incubated with 50 µl of GA beads for 2.5 h at 4oC 
on rocker. The beads were washed extensively in TNES and bound proteins were eluted by 
boiling in SDS-PAGE sample cocktail. Bound proteins were analysed by SDS-PAGE and 
gel was stained using 0.1% Coomassie blue by agitation for 1h at room temperature.  
e) Panel e shows a Coomassie blue stained gel of a T. spiralis pull-down pre-incubated 
without GA (Lane 1) and with GA at 2.0 µM (Lane 2) or 20.0 µM (Lane 3) and control beads 
(Lane 4). 500 µg of worm lysate was incubated in a total volume of 300 µl containing GA at 
2.0 µM or 20.0 µM for 1 h at room temperature. Then 50 µl of GA beads were added and 
incubated for further 2.5 h at 4oC. The beads were washed extensively in TNES and bound 
proteins were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins were 
analysed by SDS-PAGE. Gel was stained with 0.1% Coomassie blue. 
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                             (a) 
 
(b)  
 
             Pull-down with GA beads Pull-down with control beads 
             (c) (d) 
 
          (e) 
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The clade IV nematode species tested were the plant parasitic 
nematodes, Globodera pallida and Globodera rostochiensis, a free-living species 
Panagrellus redivivus and the animal parasite Strongyloides ratti. The S. ratti 
adults used in the analysis were free-living rather than parasitic. Both plant 
parasitic nematodes reacted with the antibody, as did P. redivivus (see Figure 
3.11a). S. ratti reacted weakly with the B. pahangi anti-Hsp90 antibody although 
the signal obtained improved with increasing exposure times. Next, pull-down 
assays were carried out to investigate the ability of Hsp90 from clade IV 
nematodes to bind GA. From this experiment it could been seen that Hsp90 from 
the two plant parasitic nematodes failed to bind GA as did Hsp90 from the free-
living clade IV species,  P. redivivus (see Figure 3.11b). Similarly, Hsp90 from S. 
ratti did not bind to GA in pull-down assays (Figure 3.11d). Because the Hsp90 
signal in S. ratti was relatively weak using the B. pahangi anti-Hsp90 antibody, 
the pull-downs were exposed for prolonged period of time (overnight) but no 
signal was obtained. These experiments were repeated at least two occasions 
with similar results Table 3.1 shows the summary of GA pull-down assays with a 
range of nematodes from different clades.    
 
 
 
 
 
 
 
Chapter 3  113 
 
 
 
Figure 3.11: Analysis of clade IV nematodes  
 
(a) Immuno-blot of Hsp90 from clade IV nematodes probed with the B. pahangi anti-Hsp90 
antibody. G. pallida (Lane 2), G. rostochiensis (Lane 3), S. ratti (Lane 4) and P. redivivus 
(Lane 5). B. pahangi lysate was used as a positive control (Lane 1).   
b) Immuno-blot of GA pull-down assays. G. pallida (Lane 2), G. rostochiensis (Lane 3) and 
P. redivivus (Lane 4). For these experiments, D. immitis lysate was used as a positive 
control (Lane 1).  
c) Immuno-blot of pull-down assays for control beads. D. immitis (Lane 1), G. pallida (Lane 
2), G. rostochiensis (Lane 3) P. redivivus (Lane 4).   
d) Immuno-blot of GA pull-down assay with S. ratti lysate. S. ratti (Lane 2). B. pahangi 
lysate was used as a positive control (Lane 1).  
e) Immuno-blot of pull-down assays for control beads. B. pahangi (Lane 1), S. ratti (Lane 
2). 
Panel a shows a lay-up of GA pull-downs for three separate experiments. Proteins were 
transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% 
Tween 20 and then the blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 
antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit.  
For pull-down assays (Panel b,c, d and e), 500 µg of proteins extract were incubated with 
50 µl of GA beads for 2.5 h at 4oC on rocker. The beads were washed extensively in TNES 
and bound proteins were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins 
were analysed by SDS-PAGE and immuno-blotting. The blots were probed with 1:5000 
dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit.  
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Table 3.1: Summary of GA pull-down assays 
 
Species Clade Life-cycle 
stage 
Life style GA 
binding 
T. spiralis 
 
T. muris 
 
 
 
A. crassus 
A. simplex 
P. decipiens 
 
A. suum 
P. equorum 
T. cati 
 
B. pahangi 
A. viteae 
D. immitis 
O. ochengi 
 
 
S. ratti 
 
 
P. redivivus 
G. rostochiensis 
G. pallida 
 
 
C. elegans 
C. elegans daf-21 mutant 
C. briggsae 
O. tipulae 
P. pacificus 
 
H. contortus  
T. circumcincta 
H. polygyrus 
N. brasiliensis 
I 
 
I 
 
 
 
III 
III 
III 
 
III 
III 
III 
 
III 
III 
III 
III 
 
 
IV 
 
 
IV 
IV 
IV 
 
 
V 
V 
V 
V 
V 
 
V 
V 
V 
V 
L1 
 
adult 
 
 
 
adult 
L3 
L3 
 
adult 
adult 
adult 
 
adult 
adult 
adult 
adult 
 
 
adult, FL 
 
 
mixed stages 
J2 
J2 
 
 
mixed stages 
mixed stages 
mixed stages 
mixed stages 
mixed stages 
 
L3 
adult 
adult 
adult 
Obligate parasite 
 
Parasitic, egg in 
the environment 
 
 
Parasitic, Fl larvae 
Parasitic, Fl larvae 
Parasitic, Fl larvae 
 
Parasitic 
Parasitic 
Parasitic 
 
Obligate parasite 
Obligate parasite 
Obligate parasite 
Obligate parasite 
 
 
Parasitic or FL 
adult, FL larvae 
 
Free-living 
Plant parasitic 
Plant parasitic 
 
 
Free-living 
Free-living 
Free-living 
Free-living 
Free-living 
 
Parasitic, FL larvae 
Parasitic, FL larvae 
Parasitic, FL larvae 
Parasitic, FL larvae 
+ 
 
? 
 
 
 
? 
- 
- 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
 
 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
     
FL = free-living - = Negative binding  + = Positive binding ? = uncertain GA binding status 
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3.3 Discussion 
As reviewed in Chapter 1, Hsp90 plays a fundamental role in cells by 
regulating specific client proteins often involved in signalling pathways. These 
proteins depend on Hsp90 for maturation and stabilisation. Any disruption in this 
process will lead to degradation of the proteins and to cell death. An important 
characteristic of Hsp90 is its ability to bind to GA, a specific Hsp90 inhibitor (as 
reviewed in Chapter 1). According to Whitesell et al (1994), most eukaryote 
Hsp90s are susceptible to GA and will bind to GA in pull-down assays. However, 
the ability of Hsp90 to bind to GA is not shared by C. elegans (David et al., 2003) 
while Hsp90 from the parasitic nematode B. pahangi does bind GA (Devaney et 
al., 2005).The results with C. elegans were hypothesised to be an example of 
adaptive evolution as C. elegans and Streptomyces spp. shared the same 
ecological niche of the soil (David et al., 2003). In this chapter this hypothesis 
was tested by analysing the GA binding properties of a range of nematode.    
Table 3.1 summarises the GA binding assays for the nematodes tested. 
From these results some interesting conclusions can be drawn. All free-living 
nematodes tested or those parasitic species which have free-living larval stages 
in the environment failed to bind GA. Five free-living species from clade V (C. 
elegans, C. elegans daf-21 mutant, C. briggsae, O. tipulae and P. pacificus) and 
one species from clade IV (P. redivivus) were tested. The parasitic species 
tested that have free-living larval stages in the environment belong to clade V 
(H. contortus, N. brasilliensis, H. polygyrus and T. circumcincta) and clade IV (S. 
ratti). This group of nematodes are generally gut-dwelling parasites in the 
mammalian host and are transmitted between hosts when eggs, passed out in 
the faeces of the infected animal, hatch to release free-living larval stages. 
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These generally develop to the L3 stage in the environment before infecting a 
new host by ingestion. The clade IV species, S. ratti has a unique life-cycle, 
which has both a parasitic and a free-living phase. S. ratti can undergo two 
types of development outside of the host: homogonic and heterogonic (Viney, 
1996). In homogonic development, the eggs pass out in the faeces, hatch and 
moult through two larval stages into infective L3. While in heterogonic 
development, the eggs hatch and moult through four larval stages into dioecious 
free-living adults (Viney et al., 1993). In the analysis described here, only free-
living adult worms were available.  
Likewise, none of the clade IV plant parasitic nematodes (G. pallida and G. 
rostochiensis) tested could bind to GA. Globodera spp. are parasites of plant 
roots commonly known as potato cyst nematodes, which live in soil. The second 
stage juvenile worms (J2) are the infective stage in the soil where they 
penetrate the roots of the susceptible plant and feed on it and develop to 
adults. The cyst containing eggs remains dormant within the body of the dead 
female until the proper stimulus to hatch is received. Eggs of potato cyst 
nematodes can remain dormant and viable within the cyst for 30 years (Winslow 
& Willis, 1972). In this stage (J2), the nematodes are more resistant to 
anthelmintic drugs. 
 For the clade III nematodes, the results were more variable. Some of the 
species analysed exhibited the ability to bind to GA while some did not. Hsp90 
from all filarial worms tested in this study bound to GA. Filarial worms are 
obligate parasites and their life cycle does not involves any free-living stages in 
the environment, with arthropods acting as a intermediate hosts for transmission 
between definitive hosts. In keeping with this result, analysis of Hsp90 from 
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another obligate parasite from clade I, T. spiralis, also showed binding to GA. 
The life-cycle of T. spiralis involves two phases. The first phase is enteral, the 
worms remain in the intestine, growing from larvae to adults and reproducing. 
For the second phase known as the parenteral phase, newly hatched larvae 
migrate to the host's muscle cells and become encysted. Infection occurs when 
meat contaminated with encysted L1 larvae is eaten. 
Analysis of Hsp90 from the Ascarid species (T. cati, A. suum and P. 
equorum) shows the ability to bind to GA. For these species, the eggs are passed 
out in the faeces of the infected animal into the environment, but the larvae are 
protected within an egg. For example, infection with Toxocara occurs after 
ingestion of eggs, which hatch in the stomach of the definitive host. 
Alternatively infection can also occur by ingestion of a paratenic host, such as a 
mouse. All Ascarid parasites have an egg with a thick shell, giving protection 
against potentially harsh environmental conditions. 
The clade III Anasakid parasites, A. simplex and P. decipiens, did not bind 
to GA. These parasites have a complex life-cycle in the marine environment. 
Unembryonated eggs are excreted by mammals such as whales, seals or dolphins 
and eggs embryonate to form L2 in sea water. When eggs hatch, the larvae are 
eaten by crustaceans e.g. Eusphausids for Anisakis and cyclopod copepods for 
Pseudoterranova (Bristow & Berland, 1992). Similar to the Anasakid, A. crassus 
has a free-swimming larval stage as part of its life-cycle in the environment. A. 
crassus is a parasite of eels where the L2 stage is excreted in the water before 
being consumed by paratenic or intermediate host e.g. copepods. It develops 
into the infective stage in the intermediate host before being ingested by the 
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eel. In the eel, the infective stage moves from the intestine to the swim bladder 
and develops into an adult.  
For some species it was not possible to ascertain with certainty whether 
Hsp90 bound to GA or not. These species were A. crassus and T. muris. For both 
species and for T. spiralis from clade I no reactivity was observed with any anti-
Hsp90 antibody tested, so the pull-downs could not be analysed by immuno-
blotting. For T. spiralis, staining a gel of a pull-down with Coommasie blue was 
sufficient to detect a band running at approximately the correct molecular 
weight (83 kDa) but not for A. crassus and T. muris. The T. spiralis band was 
excised from the gel and subjected to mass spectrometry, revealing that the T. 
spiralis band was likely to be Hsp90. Although it was not possible to identify 
Hsp90 binding to GA in pull down assays using A. crassus and T. muris, it is not 
possible to definitively conclude that Hsp90 from these species does not bind to 
GA. As extracts of A. crassus and T. muris failed to react with either antibody, 
the GA-binding status of these species remains unresolved. Further experiment 
would have to be carried out using a more sensitive detection method e.g. silver 
staining or perhaps using different life-cycle stages.  
The results in this chapter so far suggested that the ability of nematode 
Hsp90 to bind to GA is correlated with particular nematode life histories. Free-
living species and species with a free-living larval stage did not bind to GA. In 
contrast, species which are permanently parasitic (filarial worms and T. spiralis) 
or species which have free-living stages in the environment enclosed within a 
protective egg-shell possess a GA-binding Hsp90. However, there are limitations 
to these results as described above. Overall, these data could be interpreted in 
the context of adaptive evolution. Adaptive evolution of C. elegans Hsp90 would 
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argue that C. elegans Hsp9O is resistant to GA because it shares the same 
ecological niche as the Streptomyces spp. which produces GA. However, whether 
C. elegans and Streptomyces spp. do actually share the same spatial and 
temporal niches within the soil is unknown. Although C. elegans can be found in 
the soil, the predominant in the wild is the dauer larvae, which is usually found 
in organic-rich environment such as compost. Dauer stages are resistant and non-
feeding and the natural food source of C. elegans in the wild is unknown 
(Kiontke & Sudhause, 2006).  
A fascinating example of the interaction between a micro-organism that 
synthesises an Hsp90 inhibitor and its host plant come from the work of McLellan 
et al (2007). They studied a fungus (Paraphaeospharia quadriseptata) that 
synthesises the Hsp90 inhibitor, Monocillin I (MON) and showed that MON could 
inhibit plant (Arabidopsis thaliana) Hsp90. Inhibition of Hsps such as Hsp70 or 
Hsp90, is known to induce a stress response in many organisms and plants 
exposed to MON were no exception. Indeed, MON was shown to induce Hsp101, a 
protein required for thermotolerence. Finally it was demonstrated that co-
association of the MON-producing fungus and A. thaliana enhanced the tolerance 
of the plant to heat-stress, suggesting an intricate association between plant and 
micro-organism.  
In order to further investigate the adaptive evolution theory, a 
collaboration with Dr. Richard Emes (University of Nottingham), analysed hsp90 
sequences from a range of nematodes to determine if there were particular 
amino acid substitutions associated with GA binding or not. This analysis 
demonstrated three separate lineages for hsp90 sequences (Branch A, B and C) 
which correlated with the ability to bind GA (Figure 3.12). Branch A represents 
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the group of GA-binding clade III species, Branch B represents the group of non 
GA-binding clade V species and Branch C represents the group of plant parasitic 
nematode hsp90 sequences. While a number of residues showed significant 
evidence of adaptive evolution, the results did not demonstrate a direct 
relationship between amino acid substitutions in Hsp90 and GA binding ability 
(Him et al., 2009). These data suggest that the evolution of hsp90 may be 
correlated to key functions other than the ability to bind GA.  
While it was not possible to identify specific amino acid sequences 
associated with GA binding or not, studies in other organisms have demonstrated 
that point mutations in hsp90 can alter sensitivity to Hsp90 inhibitors. For 
example, in yeast an increased sensitivity to GA and radicicol was observed in 
hsp90 mutants (Piper et al., 2003a). That study revealed an increased sensitivity 
to GA of A587T and T101I with T22I, G313S and E381K showing lesser effect. In 
addition, in chicken Hsp90, mutation of S113A abolished GA binding and K112A 
reduced the GA binding compared to wild type Hsp90 (Lee et al., 2004). A study 
on human Hsp90 also showed the effect of mutations in hsp90 on GA-binding 
(Onuoha et al., 2007).  Mutation of residues L106A and S107A, in the N-terminal 
of human Hsp90, was shown to be important for the isomeration of GA. As a 
result of these mutations, the binding of Hsp90 to GA was reduced. S107 is an 
important element in the catalysis of trans to cis GA (Lee et al., 2004). S107 
acts as a docking site for the binding of trans GA and catalyses the conversion to 
the cis isoform. So any mutation at this site, may affect the association and 
dissociation rates of GA binding, which may explain the differences in GA binding 
between mutant and wild-type Hsp90.  
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From Him et al. BMC Evolutionary Biology 2009 9:254  
 
Figure 3.12: Unrooted phylogenetic tree showing relationship of hsp90 sequences from 
fifteen different nematode species. 
 
Three different branches showed significant evidence of adaptive evolution. Branch A 
represents the group of GA binders (red), B (green) and C (blue) represents the group of 
non-GA binders. B, non-binding hsp90 sequences from clade V species and C the plant 
parasitic nematode hsp90 sequences.    
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As GA and related Hsp90 inhibitors, such as radicicol, are produced by 
micro-organisms, study of the micro-organism Hsp90 might be revealing as 
presumably inhibition of Hsp90 would be deletenous. In the yeast Humicola 
fuscoatra, a species that produce radicicol, a single conserved amino acid 
substitution (L33I) in Hsp90 is enough to influence the binding of radicicol 
without altering the ability to bind ATP or GA (Prodromou et al., 2009). In that 
study they showed that substitution of leucine to isoleucine alters the size of the 
hydrophobic drug-binding pocket. As a result of this, there is increased binding 
of H2O molecules and hydration of the drug. These findings demonstrate that 
small alterations in amino acid residues can have major affects on drug binding 
efficacy.   
There are also additional theories on GA binding to Hsp90 that may 
explain the differences in the ability of nematode Hsp90 to bind to GA. A 
possible explanation of the differences between B. pahangi and C. elegans Hsp90 
in GA binding is the cellular context of Hsp90; that is the degree of post-
translational modifications or the presence of specific co-chaperones in the 
Hsp90 complex. This is best exemplified by studies in tumour cells where Hsp90 
appears to exist in high affinity complexes with a number of co-chaperones 
(Kamal et al., 2003). In this configuration Hsp90 was shown to be more sensitive 
to 17-AAG than Hsp90 from normal cells, which exists in a free-uncomplexed 
state. Hsp90 complexes in tumour cells contain the co-chaperones p23 and Hop, 
and have a higher affinity for GA than Hsp90 from normal cells. p23 is thought to 
modulate Hsp90 activity in the last stages of the chaperoning pathway. Hop 
belongs to the large group of Hsp co-chaperones. It is one of the best studied co-
chaperones of the Hsp70/Hsp90-complex and it is essential to link Hsp70 and 
Hsp90 together. By forming a super-chaperone complex containing many 
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essential co-chaperones, Hsp90 becomes more active and this helps it carry out 
its function. In addition, by adding p23, Hop, Hsp70 and Hsp40 to purified Hsp90 
the affinity of Hsp90, for 17-AAG was significantly increased (Kamal et al., 
2003). These results were substantiated by the studies of Vilenchik et al (2004), 
who reported a 10- to 50-fold difference in binding of PU24FCI, a novel Hsp90 
inhibitor, to Hsp90 from tumour cells compared to normal cells.   
 Piper et al (2003a) showed that expressing the human Hsp90β in S. 
cerevisiae increased the sensitivity of the yeast to GA and radicicol whereas 
expression of C. elegans Hsp90 made the yeast more resistant to GA and 
radicicol. In yeast, complementation by human Hsp90β and C. elegans Hsp90 
requires the presence of the co-chaperones, Sti-1 and p23. Recently Sti-1 has 
been recognised as an Hsp90-interacting protein in C. elegans (Song et al., 
2009). This indicates that in the cell, Hsp90 functions in a complex rather than 
in isolation. In addition, studies from this lab (Gillan et al., 2009), showed that 
there are fundamental differences between C. elegans and B. pahangi Hsp90. 
Injection of B. pahangi hsp90 into C. elegans failed to rescue a daf-21 mutant, 
while injection of the wild-type C. elegans daf-21 rescued the mutant. 
Interestingly, injection of an H. contortus hsp90 construct provided a partial 
rescue. In these studies, wild-type C. elegans expressing a translational fusion of 
B. pahangi hsp90 gave a positive signal with GA beads in contrast to wild-type C. 
elegans hsp90, showing that even though the Brugia protein was translated in C. 
elegans, it was not functional. This suggests that in different nematodes Hsp90 
may require different co-chaperones for activity or perhaps reflect difference in 
the client proteins chaperoned by Hsp90.  
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While the differences in Hsp90 binding to GA in different species of 
nematode could be explained by the presence of different co-chaperones or 
perhaps different client proteins, it might be also relate to differences in post-
translational modification of Hsp90. Hsp90 is known to be modified significantly, 
by phosphorylation, acetylation and glycosylation (Scroggins et al., 2007; Chiosis 
et al., 2004). These post-translational modifications are known to alter its 
activity. However to date, very little known of Hsp90 modifications in 
nematodes.  
In conclusion, the results in this chapter demonstrated that C. elegans 
Hsp90 is not unique and that the non-GA binding phenotype is shared by other 
nematodes from different clades. The ability to bind to GA is associated with the 
life history of the species. Free-living nematodes and those parasitic species 
which have a free-living larval stage in the environment do not bind to GA. In 
contrast, obligate parasite or those parasitic species which have free-living 
stages enclosed within a protective egg, do bind to GA. However, while these 
observations may be consistent with the adaptive evolution theory of hsp90 
sequences as proposed by (David et al., 2003), no evidence was produced of 
specific amino acids that were associated with the binding or non-binding 
phenotype.  
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4 Further characterisation of B. pahangi Hsp90 
4.1 Introduction 
Lymphatic filariasis is a disabling and disfiguring parasitic disease caused by 
the adult and developing stages of filarial nematode parasites residing in the 
lymphatic system of a mammalian host. Nearly 120 million people are infected 
and, until the advent of the global elimination programme, the number was 
increasing in affected countries. The disease is caused by the parasitic filarial 
worms Wuchereria bancrofti, Brugia malayi or Brugia timori that are 
transmitted by the bite of the mosquitoes acting as their intermediate hosts. 
Approximately one billion people are faced with the risks of infection and 
preventing and combating lymphatic filariasis is a long term goal of World Health 
Organisation (WHO) (http://www.who.int/mediacentre/ factsheets/fs102/en/). 
However, there are no current drugs which have activity against adult worms. 
The drugs currently used in control, such as diethylcarbamazine and ivermectin, 
largely target the microfilariae (Mf). The mechanism by which 
diethylcarbamazine kills Mf is still poorly understood but it has been suggested 
that it acts as an inhibitor of arachidonic acid metabolism in Mf (Liu & Weller, 
1990) making the Mf more susceptible to host immune attack. As the inhibition 
of Hsp90 in Brugia pahangi by geldanamycin (GA) kills both adult worms and Mf 
(Devaney et al., 2005) it is relevant to ask whether Hsp90 or its client proteins 
would be suitable targets for drug development.  
In the filarial nematode B. pahangi, hsp90 is a single copy gene which is 
69% identical to human hsp90 (Thompson et al., 2001). B. pahangi Hsp90 
contains all the features of Hsp90 that are common to other eukaryotic proteins; 
the N-terminal domain, the C-terminal domain, the M-domain and a charged 
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region that links the N-terminal domain to the M-domain. In B. malayi, Hsp90 
was shown to be excreted by adult worms cultured in vitro (Kumari et al., 
1994). The quantification of excretory/secretory (ES) products released by living 
worms may be useful for detection of antibody, because these products appear 
to be more species-specific than crude somatic extracts (de Savigny et al., 1979; 
Kaushal et al., 1984). In nematodes, most of the information on Hsp90 comes 
from studies on C. elegans. The C. elegans genome contains a single hsp90 gene 
(daf-21) located on chromosome V, which is 74% and 76% identical to human 
Hsp90α and Hsp90β, respectively (Birnby et al., 2000). In addition, Hsp90 also 
has been characterised in Trichinella spiralis (Martinez et al., 2001; Martinez et 
al., 2002) and cloned from Haemonchus contortus (Gillan et al., 2009).  
 As described in Chapter 3, GA inhibits Hsp90 function in most eukaryotes 
with the exception of C. elegans and some other nematodes. However, the 
mechanism which confers resistance to GA on C. elegans Hsp90 is not 
understood.  In most organisms, GA interferes with the folding, maturation, 
localisation or degradation of certain Hsp90 client proteins and co-chaperones. 
Hsp90 requires a series of co-chaperones to form a complex required for its 
function. For example, the Hsp90-dependant activation of kinases requires cell 
cycle division protein 37 (Cdc37) (Vaughan et al., 2008). In that study, they 
showed that phosphorylation and dephosporylation of Cdc37 is necessary for the 
kinase client protein to bind to Hsp90. Most Hsp90 co-chaperones or client 
proteins have been characterised from human or yeast. However, a recent 
bioinformatic analysis revealed that the C. elegans genome contained most of 
the well characterised co-chaperones with the exception of cyclophilin-40 
(Johnson & Brown, 2009). Cyclophilin-40 is a member the peptidyl-prolyl cis-
Chapter 4  129 
trans isomerase family and was shown to interact with steroid receptors such as 
the glucocorticoid receptor and androgen receptor (Riggs et al., 2004).  
The role of post-translational modifications in regulating Hsp90 functions 
remains unclear. As reviewed previously, post-translational modifications are 
required for some Hsp90 chaperone functions (Scroggins & Neckers, 2007),. For 
example, dephosphorylation and re-phosphorylation of Hsp90 regulated the 
activity of heme-regulated inhibitor kinase, an Hsp90 client protein, (Szyszka et 
al., 1989) suggesting that Hsp90 phosphorylation is required for its function. In 
human Hsp90α, acetylation at lysine K294 was shown to reduce Hsp90 activity 
and chaperone function (Scroggins et al., 2007). K294 resides in the M-terminal 
domain of human Hsp90α and acetylation of K294 significantly impacts the 
interaction of Hsp90 with a diverse set of client proteins. These results suggest 
that acetylation of Hsp90 plays an important role in regulating chaperone 
function. 
The aim of this chapter was to further characterise B. pahangi Hsp90. 
Experiments were carried out to examine the expression profile of Hsp90 in 
different life-cycle stages, to further characterise the binding of B. pahangi 
Hsp90 to GA, to identify B. pahangi Hsp90-associated proteins and to investigate 
the effect of Hsp90 post-translational modifications on GA binding.  
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4.2 Results 
4.2.1 Hsp90 is expressed in all life-cycles of B. pahangi 
Three different stages of B. pahangi were available for analysis. Initial 
experiments focused on the expression of Hsp90 in adult, L3 and Mf by Western 
blotting using the B. pahangi anti-Hsp90 antibody. Anti-actin was used as a 
loading control for all the experiments. All worm lysates were prepared by 
grinding in liquid nitrogen as described in Materials and Methods (Section 2.1.3). 
The protein concentration for each lysate was assayed using the Bio-Rad Protein 
Assay. Equal amount of proteins were analysed by SDS-PAGE and Western 
blotting. Hsp90 is expressed in all three life cycle stages (Figure 4.1b) and 
reacted well with the B. pahangi anti-Hsp90 antibody. The autoradiograph was 
then scanned to quantify the band densities using FlourChemTM IS-5500 software. 
Figure 4.1c shows the mean ratio of Hsp90 to actin ± SD in each life-cycle stage 
in three separate experiments. The highest relative level of Hsp90 expression 
was seen in the Mf, followed by the adult worm with the lowest level in L3. 
However there was no statistically significant difference between the three 
groups (p>0.05).  
Next the extracts of the three life-cycle stages were used in GA pull-down 
assays to compare the ability of Hsp90 to bind to GA beads. Surprisingly, only 
Hsp90 from adult worms bound to the beads (Figure 4.2).  Initially, the failure of 
L3 and Mf extract to bind to GA beads was thought to be due to degradation of 
the beads. A new batch of GA beads was subsequently derivatised and prepared. 
Despite the new batch of GA beads, both L3 and Mf stages failed to bind to GA. 
These experiments were repeated again using fresh worm lysates but the same 
results were obtained.  
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Figure 4.1: Hsp90 is expressed in different stages of B. pahangi  
 
a) Coomassie Blue stained gel of equal amount of B. pahangi lysate from different life-cycle 
stages. Adult (Lane 1), L3 (Lane 2) and Mf (Lane 3).  
b) Immuno-blot of the three life-cycle stages. Hsp90 is expressed in different life-cycle stages 
and reacted with B. pahangi anti-Hsp90 antibody.  Adult (Lane 1), L3 (Lane 2) and Mf (Lane 3). 
Proteins were transferred to NCP using standard methods, then blocked o/n in 5% dried milk 
in PBS/0.5% Tween 20 and then the blot was probed with 1:5000 dilution of the B. pahangi 
anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. For actin, the blot was probed with 1:1000 dilution of anti-actin and bound 
antibody was detected using a 1:10,000 dilution of anti-mouse IgG.  The blot was developed 
using the Pierce Super Signal West Pico chemiluminescence kit. 
c) The graph shows Hsp90 expression levels in three different life-cycle stages of B. pahangi 
relative to actin as quantified by FlourChemTM IS-5500 software. The results represent the 
mean ±  standard deviation of Hsp90/actin ratio from three different experiments. 
Adult 2.10 ± 1.04, L3 0.967 ± 0.33, Mf 2.59 ± 1.32 
Adult vs L3,  p = 0.1641 
Adult vs Mf, p = 0.1353 
L3 vs Mf, p = 0.1548 
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Figure 4.2: Hsp90 from B. pahangi L3 and Mf did not bind to GA in pull-down assays.  
 
Western blotting analysis of B. pahangi Hsp90 pull-down assay. Adult (Lane 1), L3 (Lane 2) 
and Mf (Lane 3). For pull-down assays, 300 µg of protein extracts were incubated with 50 µl 
of GA beads for 2.5h at 4oC on a rocker. The beads were washed extensively in TNES and 
bound proteins were eluted by boiling in SDS-PAGE sample cocktail. Bound proteins were 
analysed by SDS-PAGE and immuno-blotting as described previously. 
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4.2.2 B. pahangi Hsp90 is constitutively expressed and not 
strongly inducible by heat shock or geldanamycin 
As a heat shock protein, Hsp90 responds to stress conditions such as heat 
and chemicals. In many cellular systems exposure to Hsp90 inhibitors induces a 
heat shock response.  Here I investigated whether Hsp90 levels were up-
regulated after exposure to heat shock or to GA. B. pahangi adult worms were 
used in this analysis. For heat shock treatments, 10 adult worms were heat 
shocked at 41oC for 60 min and allowed to recover for 2 h at 37oC. In addition, 
one group containing 10 adult worms were incubated at 37oC for 3 h as a control. 
All worms were solubilised in SDS-PAGE sample cocktail and levels of Hsp90 were 
then analysed by SDS-PAGE and Western blotting. 
 In other experiments, 10 adult worms were incubated in 1.0 µM GA for 24 
h as described in Materials and Methods (Section 2.2.2), then removed from the 
drug and directly solubilised in SDS-PAGE sample cocktail. Controls included 
worms incubated with carrier DMSO or in medium alone. Figure 4.3 shows the 
autoradiograph of B. pahangi Hsp90 expression levels after heat shock or 
exposure to GA with actin used as a loading control. The autoradiograph shows 
that no significant increase in the level of Hsp90 was observed in adult B. 
pahangi exposed to elevated temperatures (Lane 5) or treated with GA (Lane 3) 
compared to control groups (Lane 1, 2 and 4). The bands on the autoradiograph 
were scanned and band densities were obtained using FlourChemTM IS-5500 
software. Statistical significance between groups was calculated based on the 
density values as quantified by the software. There was no significant difference 
in the expression level of Hsp90 in any treatment group compared to the 
relevant control group (p>0.05).  
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                (a) (b) 
 
Figure 4.3: Hsp90 expression levels of B. pahangi are not significantly induced by heat 
shock or GA treatment.  
 
a) Coomassie blue stained gel of worm extracts. Adult B. pahangi from each group were 
analysed on a 10% SDS-PAGE gel. Equal amounts of protein were analysed (as assessed by 
Coomasie blue staining) of control group without GA (Lane 1), carrier DMSO (Lane 2), 
treated with GA at 1.0 µM for 24h (Lane 3), control group at 37oC (Lane 4) and heat shocked 
at 41oC (Lane 5).   
b) B. pahangi Hsp90 expression is not affected by heat shock or GA treatment. Control 
group without GA (Lane 1), carrier DMSO (Lane 2), treated with GA at 1.0 µM for 24h (Lane 
3), control group at 37oC (Lane 4) and heat shocked at 41oC (Lane 5).  All worms were 
solubilised directly into SDS-PAGE sample cocktail and analysed on 10% SDS-PAGE gels 
followed by Western blotting. Proteins were transferred to NCP using standard methods, 
blocked o/n in 5% dried milk in PBS/0.5% Tween 20 and then the blot probed with 1:5000 
dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. For loading control, anti-actin 
antibody was used at 1:1000 dilution and bound protein was detected using anti-mouse IgG 
at 1:10,000 dilution. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit and Hsp90 levels were assessed relative to actin, as described 
previously (data not shown).                 
GA vs Control, p = 0.6576 
DMSO vs Control, p = 0.1618 
37oC vs 41oC, p = 0.2123 
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4.2.3 How much B. pahangi Hsp90 binds to GA beads? 
Hsp90 is an abundant protein in cells and it can constitute up to 1-2% of 
the total cellular protein under normal conditions (Welch & Feramisco, 1982). In 
these experiments, the proportion of B. pahangi Hsp90 that bound to GA was 
investigated by carrying out a series of pull-down assays. The worm lysate was 
incubated with GA beads and the non-bound supernatant was retained for the 
next pull-down. This was repeated five times and the bound proteins were 
analysed by SDS-PAGE and Western blotting. Figure 4.4a shows a representative 
autoradiograph of a series of pull-down assays. It can be seen that most of the 
Hsp90 available to bind to GA beads was present in the first pull-down (Figure 
4.4a, Lane 2) with progressively diminishing amounts in subsequent pull-downs. 
In the fifth pull-down, no band was observed (Lane 6). The autoradiograph was 
scanned to quantify the band densities using FlourChemTM IS-5500 software. The 
percentage of Hsp90 binding in each pull-down was calculated relative to the 
amount of Hsp90 in the starting extract (Figure 4.4a, Lane 1).   
Figure 4.4b shows a graph of the mean percentage of B. pahangi Hsp90 
bound to GA beads after a series of five pull-down assays calculated from three 
different experiments. For the first pull-down, approximately 2.88% of the input 
Hsp90 bound to GA (2.88 ± 0.6025). For the second pull-down approximately 
2.10% Hsp90 bound to GA (2.10 ± 0.6401). For the third and fourth pull-downs, 
approximately 0.93% and 0.39% respectively bound to GA (0.93 ± 0.1305 and 0.39 
± 0.0901), while in the fifth pull-down no signal was observed. Based on these 
results, approximately 6.31% of the total cellular Hsp90 bound to GA beads in 
solid pull down assays.   
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Figure 4.4: Estimating the proportion of B. pahangi Hsp90 bound to GA beads 
 
a) Autoradiograph showing the binding of B. pahangi Hsp90 to GA beads in a series of pull-
down assays. A strong signal is obtained with B. pahangi input (Lane 1) and in the first pull-
down (Lane 2). Progressively less Hsp90 is present in the second pull-down (Lane 3), the third 
pull-down (Lane 4), fourth pull-down (Lane 5) with the fifth pull-down (Lane 6) being negative. 
B. pahangi input was analysed at 1:150 dilution.   
300 µg of protein extract was incubated with 50 µl of GA beads for 2.5h at 4oC on a rocker. 
Beads were washed extensively in TNES and bound proteins were eluted by boiling in SDS-
PAGE sample cocktail. The supernatant for each pull-down was retained and kept for another 
round of pull-down. These steps were repeated five times. Then, bound proteins for each pull-
down were analysed by SDS-PAGE and immuno-blotting. Proteins were transferred to NCP 
using standard methods, blocked o/n in 5% dried milk in PBS/0.5% Tween 20 and then the blot 
probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was 
detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was 
developed using the Pierce Super Signal West Pico chemiluminescence kit.  
b) Graph shows the proportion of Hsp90 binding to GA beads in pull-down assays. Results 
presented the mean ± standard deviation of Hsp90 bound to GA beads from three different 
experiments.  
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4.2.4 Hsp90 is secreted by adult B. pahangi 
Previous experiments analysing the ES products of adult B. malayi showed 
that Hsp90 is secreted (Kumari et al., 1994). In this section, the ES products of 
Mf and adult B. pahangi were analysed. Mf and adult worms were incubated in 
RPMI-1640 medium and ES products were collected and concentrated as 
described in Materials and Methods (Section 2.2.4). Figure 4.5 shows the analysis 
of ES products from both life-cycle stages. The gel shown in Figure 4.5a was 
stained with Coomassie blue but this staining method did not detect any bands in 
the ES products for either stage. The ES products were then analysed using the 
more sensitive silver staining, as shown in Figure 4.5b. In Lane 1 (adult stage) 
there were a few bands visible in the ES products but no staining was seen with 
Mf (Lane 2). In order to validate this observation, concentrated ES from both 
stages was analysed by SDS-PAGE and Western blotting using the B. pahangi anti-
Hsp90 antibody. The autoradiograph in Figure 4.5c shows the analysis of ES 
products detected using B. pahangi anti-Hsp90 antibody. Hsp90 was shown to be 
secreted in ES products of adults (Lane 1) but not Mf (Lane 2).  
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Figure 4.5: Analysis of ES products of adult and Mf stages of B. pahangi 
 
a) Coomassie blue stained gel of ES products from Mf and adult B. pahangi. Mr represents 
the molecular weight marker, adult (Lane 1) and Mf (Lane 2).  
b) Silver stained gel of ES products from Mf and adult B. pahangi. Mr represents the 
molecular weight marker, adult (Lane 1) and Mf (Lane 2).  
c) Autoradiograph of ES products as detected using B. pahangi anti-Hsp90 antibody. Adult 
stage (Lane 1) and Mf (Lane 2). ES products of both stages were concentrated and 
solubilised in SDS-PAGE sample cocktail by boiling for 3 min followed by centrifugation at 
13200 rpm for 3 min and analysed by SDS-PAGE and Western blotting. Proteins were 
transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% 
Tween 20 and then the blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 
antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit.  
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4.2.5 Identification of B. pahangi Hsp90-associated proteins 
As reviewed by Jackson et al (2004) and Wegele et al (2004), Hsp90 plays 
a role as a central component of the assembly and disassembly machine and as 
such, associates with several groups of proteins. In this section, attempts were 
made to identify B. pahangi-associated proteins by proteomic analysis or using a 
modified GA-biotin binding assay (Neef et al., 2010).   
4.2.5.1 Modified GA-biotin binding assay 
This assay relies upon the binding of biotin-labelled GA to Hsp90 protein 
complexes. The complexes are then isolated using Neutravidin-agarose beads.  
B. pahangi lysate was incubated in the present of GA-biotin, while the control 
sample was incubated without GA-biotin. The bound proteins were captured by 
incubating with Neutravidin-agarose beads and analysed as described previously 
in Materials and Methods (Section 2.2.5.1). 
Figure 4.6a shows a representative Coomassie blue gel of B. pahangi 
lysate incubated with GA-biotin or not, followed by Neutravidin capture. It can 
clearly be seen from the gels, that in the presence of GA-biotin, a number of 
proteins were present in the eluate of the Neutravidin-agarose beads (Lane 1). 
However, careful examination of Lane 2 (without GA-biotin) shows that most of 
the bands were also present, albeit at a lower level, suggesting that binding is 
mostly non-specific. Attempts were made to overcome this problem by pre-
incubating B. pahangi lysate with Neutravidin-agarose beads in order to 
eliminate any proteins that might bind non-specifically to the beads. Following 
the pre-incubation with Neutravidin-agarose beads, the supernatant was 
incubated with GA–biotin and processed as described previously. Figure 4.6b 
Chapter 4  143 
shows the pull-down assay after pre-incubation with Neutravidin-agarose beads. 
Lane 1 shows the B. pahangi proteins bound non-specifically to Neutravidin-
agarose beads. The supernatant from this incubation was then mixed with GA-
biotin and processed as described previously. Lane 2 shows that a number of 
proteins were present in the eluate of the Neutravidin-agarose beads. However, 
many of the bands were also observed in the control lane (Lane 3). Based on 
these results, this approach was not used further.        
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                (a) (b) 
 
Figure 4.6: GA-biotin binding assay  
 
a) Coomassie blue stained gel showing the proteins bound to GA-biotin as analysed by 
SDS-PAGE.  Bound protein captured by Neutravidin-agarose beads incubated with GA-
biotin (Lane 1) or without GA-biotin (Lane 2). 1.0 mg B. pahangi lysate was incubated with 
100 µl of GA-biotin for 15 h at 4oC. The bound proteins were captured by incubating the 
mixture with Neutravidin-agarose beads. Bound protein were eluted in 100 µl SDS-PAGE 
sample cocktail and 20 µl of sample was loaded onto a 10% gel for the analysis.  Control 
(Lane 2) was incubated without GA-biotin and analysed exactly as for Lane 1.  
b) Coomassie blue stained gel showing the proteins bound to GA-biotin. B. pahangi lysate 
was pre-incubated with Neutravidin-agarose beads (Lane 1), the remaining supernatant was 
then incubated with GA-biotin followed by Neutravidin-agarose beads (Lane 2) or without 
GA-biotin (Lane 3) followed by Neutravidin-agarose beads.       
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4.2.5.2 Proteomic analysis of B. pahangi Hsp90-associated proteins 
Hsp90 exists within the cell in complexes with co-chaperones and client 
proteins.  After exposure to GA, Hsp90 undergoes a conformational change with 
the result that client proteins are released from the complexes and subject to 
degradation. Thus, it may be possible to identify some Hsp90-associated proteins 
by their disappearance following GA treatment. B. pahangi adult worms were 
incubated in RPMI-1640 medium containing 1.0 µM GA or DSMSO alone for 24 h 
and worm lysates were prepared as described in Materials and Methods (Section 
2.2.5.1). Equal amounts of protein (50 µg) were labelled with Cy3 for GA-treated 
group or Cy5 for the control group and the samples mixed and subjected to IF 
and SDS-PAGE as described in Materials and Methods (Section 2.2.5.3). After SDS-
PAGE, the gel was scanned using a Typhoon 9400 scanner. The separate gel 
images of the treated group (with GA) and the control group (non-treated) were 
compared using the Differential In-Gel Analysis (DIA) software module of the 
DeCyder batch processor (Amersham Bio-Sciences, UK). Figure 4.6a shows the 
2D-gel image of the treated group with GA at 1.0 µM and Figure 4.7b shows the 
2D-gel image of control group. Using the DeCyder batch processor, 
approximately 2113 spots were detected, of which 96.2% showed similarity in 
the protein abundance for each sample. Approximately 3.1% of proteins were 
shown to be up-regulated in the treated group compared to the control group, 
while approximately 0.7% of the proteins were down-regulated in the treated 
group compared to the control group. Figure 4.7c shows the spots detected using 
DIA software. The spots in yellow represent those proteins that differed in 
abundance as analysed using the software. See Table 4.1 for a summary of the 
analysis.  
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Figure 4.7: Proteomic analysis of B. pahangi adult extract following GA treatment or control 
worms.  
 
a) Scanned image of a 2D-gel of B. pahangi adult worms treated with GA using the Typhoon 
9400 Scanner. 60 adult worms were cultured in RPMI-1640 medium containing a final 
concentration of GA at 1.0 µM at 37oC in an atmosphere of 5% CO2 in air for 24 h. Equal 
amounts of protein (50 µg) were labelled with Cy3 for GA-treated and subjected to IF and SDS-
PAGE as described in Materials and Methods (Section 2.2.5.3).   
b) Scanned image of a 2D-gel of the control group using the Typhoon 9400 Scanner. 60 adult 
worms were cultured in RPMI-1640 medium containing an equivalent volume of DMSO at 37oC 
in an atmosphere of 5% CO2 in air for 24 h. Equal amounts of protein (50 µg) were labelled with 
Cy5 for control and subjected to IF and SDS-PAGE as described in Materials and Methods 
(Section 2.2.5.3).  
c) Protein spots detected by the DIA software. The red circles represent the spots of equal 
abundance in both samples, while the yellow circles represent the spot that were differentially 
expressed in the two samples, as detected by the DIA software.  
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Table 4.1: Summary of spot statistics as analysed by DIA Software 
 
 Number of spots Percentage (%) 
Increased 61 3.1 
Similar 1911 96.2 
Decreased 14 0.7 
Total 2113 100 
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Unfortunately it was not possible to identify the up-regulated and down-
regulated protein spots because the spot picking equipment required was out of 
order. In an attempt to analyse the differences, the experiment was repeated 
using a new fresh worm lysate, prepared exactly as described previously. 
However, in this experiment, the experimental and the control group were 
analysed separately. The IPG strip samples of the treated group and the control 
group were transferred onto different gels. The gels were stained by Coomassie 
blue, destained and then scanned using the Typhoon Trio Variable Imager. Any 
differences were spotted manually using the Ettan Spot handling workstation 
(Amersham Bio-Sciences, UK).  
Figure 4.8a and 4.8b show the image of the GA-treated group and the 
non-treated group as stained by Coomassie blue. Protein spots that are present 
on the control gel but absent in the GA-treated group are considered to be   
down-regulated proteins, while protein spots that are absent in the control 
group but present in GA-treated group are considered to be up-regulated 
proteins. There were only a few spots in the control group that were absent in 
the GA-treated group (black circles). In addition, there were two clear protein 
spots that are present in the GA-treated group compared to the control group 
(Figure 4.8c, blue circles). Overall, 12 spots were identified of which seven were 
differently expressed (see Figure 4.8c). Spots of interest were carefully excised 
and subjected to in-gel trypsin digest following which the dried digested samples 
were subjected to analysis by mass spectrometry. All peptide samples were 
separated on liquid chromatography-electrospray (LC) system before analysing 
by ionization/multi-stage mass spectrometry (ESI-MS) (see Appendix 6). Table 
4.2 shows the results of the protein identification of 2D-gel spots in a 
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comparative screen between GA-treated and control worms. These proteins 
belong to several groups most of which have structural or chaperone function.      
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Figure 4.8: 2D-gel image of B. pahangi protein lysate as analysed by 2D SDS-PAGE. 
  
a) Image of 2D-gel scanned using Typhoon Scanner represents the GA-treated group. 60 adult 
worms were cultured in RPMI-1640 medium containing a final concentration of GA at 1.0 µM at 
37oC in an atmosphere of 5% CO2 in air for 24 h. Equal amounts of protein (50 µg) were 
prepared as described previously and subjected to IF and SDS-PAGE as described in 
Materials and Methods (Section 2.2.5.3). Gel was stained with Coomassie blue.    
b) Image of 2D-gel scanned using Typhoon Trio Variable Imager representing the untreated 
control group. 60 adult worms were cultured in RPMI-1640 medium containing an equivalent 
volume of DMSO at 37oC in an atmosphere of 5% CO2 in air for 24 h.  Equal amounts of protein 
(50 µg) were prepared as described previously and subjected to IF and SDS-PAGE as 
described in Materials and Methods (Section 2.2.5.3). Gel was stained with Coomassie blue.     
c) 2D-image of gel as analysed by Coomassie blue staining showing the spot of interest for 
the analysis. 12 spots were excised. The black circles represent the spots that decreased in 
abundance in the GA group. The red circles represent the spots which were similar in 
abundance in both groups and the blue circles represent the spots which were increased in 
abundance after exposure to 1.0 µM GA.  
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Table 4.2: Identification of 2D-gel spots differentially expressed in a comparative screen 
between B. pahangi GA-treated group vs control group.  
 
Sample ID* Protein hit Hit score Function 
1a Tropomyosin 1233 Structural 
1b Myosin regulatory light chain 1 469 Structural 
1c Actin-depolymerising factor 1 700 Structural 
1d Actin-depolymerising factor 1 757 Structural 
1e DJ-1 family protein 817 Unknown 
2a Small heat shock protein 194 Chaperone 
2b Alkali myosin light chain 601 Structural 
2c Thioredoxin 219 Antioxidant 
2d Small heat shock protein 814 Chaperone 
2e Tropomyosin 1174 Structural 
3a Myosin regulatory light chain 1 613 Structural 
3b Tropomyosin 701 Structural 
    
* 1 – down-regulated in GA vs control group, 2 – similar in both groups, 3 – up-regulated in 
GA vs control group. 
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4.2.6 Recombinant human Hsp90α binds to GA beads 
Post-translational modifications such as phosphorylation, acetylation, 
nitrosylation and ubiquitinylation have been shown to regulate the chaperone 
function of Hsp90. In order to investigate the possible effect of post-
translational modifications on Hsp90 binding to GA, the binding of recombinant 
human Hsp90α (rHsp90α) was compared with native human Hsp90. Human Hsp90 
was used in these experiments because recombinant B. pahangi Hsp90 was not 
available for analysis. Native Hsp90 was isolated from SkBr3 cells. The rHsp90α 
(StressMarq, UK) was expressed in E. coli and therefore does not bear any post-
translational modification. 8 µg of SkBr3 was analysed by SDS-PAGE. For 
comparison 2 µg of rHsp90 was analysed (Figure 4.9a). An abundant band at 
approximately 90 kDa was detected for rHsp90α (Lane 1) but only a faint band 
for the SkBr3 lysate was detected (Lane 2). Both samples were then tested 
against B. pahangi anti-Hsp90 antibody at 1:5000 dilution or AC88 monoclonal 
anti-Hsp90 antibody at 1:1000 dilution. Figure 4.9b shows that the B. pahangi 
anti-Hsp90 antibody failed to react with rHsp90α (Lane 1) or SkBr3 lysate (Lane 
2). However, the AC88 monoclonal antibody is able to detect Hsp90 in both 
samples (data not shown). Analysis of pull-down assays showed that Hsp90 from 
both sources bound to GA beads (Figure 4.9c), which suggests that the presence 
or absence of post-translational modifications did not affect the ability of human 
Hsp90 to bind to GA. Blocking assays were then used to show the specificity of 
the binding by pre-incubation in soluble GA at 1.0 µM or 2.0 µM GA. Figure 4.9d 
and Figure 4.9e show that the binding of rHsp90α and SkBr3 Hsp90 is blocked by 
soluble GA, with 1.0 µM GA being sufficient to completely block Hsp90 binding to 
GA beads for both extracts.  
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Figure 4.9: Analysis of recombinant human Hsp90α and SkBr3 extract 
 
a) Coomassie blue stained gel of rHsp90α and SkBr3 extract. 2 µg of rHsp90α (Lane 1) and 8 
µg of SkBr3 lsyate (Lane 2) were analysed. Mr represents the molecular weight marker.   
b) Autoradiograph of rHsp90α and SkBr3 extract probed with B. pahangi anti-Hsp90 antibody. 
2 µg of rHsp90α (Lane 1) and 8 µg of SkBr3 lsyate (Lane 2) were analysed by SDS-PAGE and 
Western blotting. Proteins were transferred to NCP using standard methods, blocked o/n in 
5% dried milk in PBS/0.5% Tween 20 and then the blot probed with 1:5000 dilution of the B. 
pahangi anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-
rabbit IgG conjugated to HRP. The blot was developed using the Pierce Super Signal West 
Pico chemiluminescence kit.                      
c) Pull-down analysis of rHsp90α and SkBr3 extract with GA beads or control beads. rHsp90α 
with GA beads (Lane 1), rHsp90α with control beads (Lane 2), SkBr3 laysate with GA beads 
(Lane 3) and SkBr3 lysate with control beads (Lane 4). 5 µg of rHsp90α or 500 µg of SkBr3 
extract were incubated with 50 µl of GA beads for 2.5h at 4oC on rocker. Beads were washed 
extensively in TNES and bound proteins were eluted by boiling in SDS-PAGE sample cocktail. 
Then, bound proteins were analysed by SDS-PAGE and immuno-blotting. Proteins were 
transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% Tween 
20 and then the blot probed with 1:1000 dilution of the AC88 anti-Hsp90 monoclonal antibody. 
Bound antibody was detected using a 1:10,000 dilution of anti-mouse IgG. The blot was 
developed using the Pierce Super Signal West Pico chemiluminescence kit.  
d)  Blocking assays of rHsp90α with soluble GA at 1.0 µM or 2.0 µM GA. rHsp90α without 
soluble GA (Lane 1), 1.0 µM GA (Lane 2), 2.0 µM GA (Lane 3), DMSO (Lane 4) and control beads 
(Lane 5). 5 µg of rHsp90α was pre-incubated with soluble GA at different concentration for 1 h 
at room temperature and subjected to pull-down assay. Bound protein was analysed by SDS-
PAGE and Western blotting.  
e) Blocking assays of SkBr3 extract with soluble GA at 1.0 µM or 2.0 µM GA. SkBr3 extract 
without soluble GA (Lane 1), 1.0 µM GA (Lane 2), 2.0 µM GA (Lane 3), DMSO (Lane 4) and 
control beads (Lane 5). 500 µg of SkBr3 extract was pre-incubated with soluble GA for 1 h at 
room temperature and processed exactly as rHsp90α. 
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4.2.7 Competition assays with B. pahangi Hsp90 
4.2.7.1 Competition assay with soluble GA 
To further characterise the binding of B. pahangi Hsp90 to GA, I examined 
the ability of soluble GA to block binding to solid phase GA. The soluble extract 
of B. pahangi worms was pre-incubated with varying concentrations of GA from 
25 nM to 1000 nM for 60 min at room temperature. Pull-downs were then carried 
out as described previously, analysed by immuno-blotting and quantified by 
scanning of the subsequent autoradiograph. The autoradiograph in Figure 4.10a 
demonstrates that soluble GA blocks the binding of B. pahangi Hsp90 to GA-
derivatised beads. At 1000 nM free GA (Lane 6), the binding of B. pahangi Hsp90 
to GA beads is completely blocked. Overnight exposure of the blot failed to show 
any band (result not shown). The autoradiograph was then scanned and band 
densities were obtained using FlourChemTM IS-5500 software.  Based on these 
values, a graph was plotted and analysed. Figure 4.10b shows the competition 
assay of B. pahangi Hsp90 binding to GA pre-incubated with free GA. The IC50 
value, which represents the concentration of free GA that block the binding of 
50% of Hsp90 to GA beads, is 100-200 nM GA.  
 
 
 
 
 
 
Chapter 4  158 
 
 
 
Figure 4.10: Competition for Hsp90 binding to GA beads with soluble GA. 
 
a) The autoradiograph shows an experiment in which B. pahangi extracts were pre-incubated 
with increasing concentrations of soluble GA. The GA pull-down assays were performed as 
described previously either using GA beads (Lane 1), pre-incubated with soluble GA at 25 nM 
(Lane 2), 50 nM (Lane 3), 100 nM (Lane 4), 200 nM (Lane 5), 1000 nM Lane 6), DMSO alone 
(Lane 7) or control beads (Lane 8). Bound proteins were analysed by SDS-PAGE and Western 
blotting. Proteins were transferred to NCP using standard methods, blocked o/n in 5% dried 
milk in PBS/0.5% Tween 20 and then the blot probed with 1:5000 dilution of the B. pahangi 
anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit. The figure shown is representative of three separate experiments.  
b) Graph shows the binding of B. pahangi Hsp90 to GA beads is competed by soluble GA. At 
1000 nM, GA completely blocks the binding of Hsp90 to GA beads. The estimated IC50 value is 
between 100 nM to 200 nM GA. Results presented are the mean ± standard deviation of three 
different experiments. Binding to GA beads in the absence of GA was set at 100%. 
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4.2.7.2 The ability of Hsp90 to bind to GA beads is altered by novobiocin  
GA and novobiocin do not share the same binding site in Hsp90. However, 
studies with mammalian Hsp90 have shown that novobiocin can affect the ability 
of Hsp90 to bind to GA. GA binds to the N-terminal domain of Hsp90 while 
novobiocin binds to the C-terminal domain. In this experiment, I tested whether 
novobiocin can affect the binding of B. pahangi Hsp90 to GA. B. pahangi lysates 
were pre-incubated with different concentration of novobiocin (from 2.5-20 mM) 
prior to addition of GA beads (as described in Materials and Methods)(Section 
2.2.7.1). The results of a representative experiment are shown in Figure 4.11a. 
It can be seen that the amount of Hsp90 bound to GA decreased as the 
concentration of soluble novobiocin increased (Lane 1 to Lane 5).  At 20 mM 
soluble novobiocin (Lane 5), binding was completely inhibited and no signal was 
obtained even though the blot was exposed overnight (result not shown). Bands 
on the autoradiograph were scanned and band densities were obtained using 
FlourChemTM IS-5500 software. Figure 4.11b shows that 10 mM soluble novobiocin 
was sufficient to inhibit approximately 90% of the binding with an IC50 value of 
approximately 5 mM novobiocin. The IC50 value here represents the 
concentration of soluble novobiocin able to inhibit 50% of Hsp90 binding to GA 
beads. The ability of free soluble novobiocin to compete with GA beads to bind 
Hsp90 suggested there is some kind of interaction between the N-terminal 
domain and the C-terminal domain which affects the binding of Hsp90 to GA.        
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Figure 4.11: Binding of B. pahangi Hsp90 to GA beads is altered by excess novobiocin. 
 
a) The autoradiograph shows that soluble novobiocin alters the ability of Hsp90 to bind to GA 
beads. B. pahangi extract incubated with GA beads without soluble novobiocin (Lane 1), with 
2.5 mM (Lane 2), 5.0 mM  (Lane 3), 10.0 mM (Lane 4), 20.0 mM (Lane 5) novobiocin or with 
control beads (Lane 6). Lysates were prepared in liquid Nitrogen with a pestle and mortar. 500 
µg of lysate in a total volume of 300 µl was pre-incubated with soluble novobiocin (2.5 mM, 5.0 
mM, 10.0 mM and 20.0 mM) for 1h at room temperature and then incubated with GA beads or 
beads alone. Bound proteins were analysed by SDS-PAGE and Western blotting. Proteins 
were transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% 
Tween 20 and then the blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. 
Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. 
The blot was developed using the Pierce Super Signal West Pico chemiluminescence kit. 
Exposure 30 sec. 
  b) Graph shows that the binding of B. pahangi Hsp90 is competed by soluble novobiocin. 20 
mM novobiocin completely blocks the binding of Hsp90 to GA beads. IC50 value is 
approximately 5.0 mM. Results presented are the mean ± standard deviation from three 
different experiments. Binding to GA beads in the absence of novobiocin was set at 100%. 
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4.2.7.3 ATP affects the binding of B. pahangi Hsp90 to GA beads 
In mammalian and yeast Hsp90, GA and ATP were shown to bind to the 
same site in the N-terminal domain of Hsp90. The binding of ATP to Hsp90 
followed by ATP hydrolysis is essential for the activity of Hsp90 as reviewed in 
Chapter 1. In this section the ability of ATP to affect the binding of Hsp90 to GA 
beads was tested by pre-incubation of B. pahangi lysates with ATP at various 
concentrations (5.0 mM, 10.0 mM, 15.0 mM and 20.0 mM). Pre-incubation of 
worm lysate with ATP affected the ability of Hsp90 to bind to GA beads. Figure 
4.12a shows an autoradiograph of a typical experiment while Figure 4.12b shows 
that approximately 15.0 mM ATP was sufficient to block 50% of Hsp90 binding to 
GA beads. However, the highest concentration used in the experiments (20.0 mM 
ATP) was not able to completely block the binding of Hsp90 to GA beads. The 
IC50 value here represents the concentration of soluble ATP that inhibits 50% of 
Hsp90 binding to GA beads. 
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Figure 4.12: ATP alters the ability of B. pahangi Hsp90 to bind to GA beads 
 
a) The autoradiograph shows an experiment in which B. pahangi lysate was pre-incubated 
with increasing concentrations of soluble ATP. The solid GA pull-down assays were 
performed as described previously either using GA beads (Lane 1), pre-incubated with soluble 
ATP at 5.0 mM (Lane 2), 10.0 mM (Lane 3), 15.0 mM (Lane 4), 20.0 mM (Lane 5) or control beads 
(Lane 6). Bound proteins were analysed by SDS-PAGE and Western blotting. Proteins were 
transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% Tween 
20 and then the blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound 
antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot 
was developed using the Pierce Super Signal West Pico chemiluminescence kit.  The figure 
shown is representative of three separate experiments. 
b) Graph shows the binding of B. pahangi Hsp90 to GA beads is altered by soluble ATP. The 
estimated IC50 value is 15.0 mM. Results presented are the mean ± standard deviation from 
three different experiments. Binding to GA beads in the absence of ATP was set at 100%. 
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4.2.7.4 The binding of B. pahangi Hsp90 to ATP beads is competed by free 
GA 
In further experiments, I investigated whether pre-incubation of B. 
pahangi lysates with soluble GA could inhibit the binding of B. pahangi Hsp90 to 
bind ATP using γ-phosphate immobilised ATP. B. pahangi lysates were incubated 
with soluble GA at different concentrations prior to incubation with ATP beads. 
Then the bound proteins were analysed by SDS-PAGE and Western blotting (as 
described previously). Figure 4.13a shows that B. pahangi Hsp90 bound to ATP 
beads and that binding was competed by free GA. The lowest concentration of 
GA used was 0.25 µM and the highest was 2.0 µM. However, 2.0 µM GA was not 
sufficient to completely block the binding of Hsp90. Then, the autoradiograph 
was scanned and band densities were obtained using FlourChemTM IS-5500 
software. Figure 4.13b shows that approximately 1.0 µM GA was sufficient to 
block about 50% of the Hsp90 binding to ATP beads. The IC50 represents the value 
of free GA that inhibits 50% of the Hsp90 binding to ATP beads. 
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Figure 4.13: Binding of B. pahangi Hsp90 to ATP beads is competed by soluble GA. 
 
a) Autoradiograph showing the results of a typical ATP-binding assay. B. pahangi lysates 
were prepared in liquid Nitrogen with a pestle and mortar. 500 µg of lysate in a total volume of 
500 µl was pre-incubated with soluble GA at 0.25 µM (Lane 2), 0.5 µM (Lane 3), 1.0 µM (Lane 4), 
2.0 µM (Lane 5) or with control beads (Lane 6) for 60 min at room temperature and then 
incubated with ATP beads or with beads alone. Bound proteins were analysed by SDS-PAGE 
and Western blotting. Proteins were transferred to NCP using standard methods, blocked o/n 
in 5% dried milk in PBS/0.5% Tween 20 and then the blot probed with 1:5000 dilution of the B. 
pahangi anti-Hsp90 Ab. Bound Ab was detected using a 1:10,000 dilution of anti-rabbit IgG 
conjugated to HRP. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit.                      
b) Graph showing that the binding of B. pahangi Hsp90 to ATP is competed by soluble GA. 1.0 
µM GA is sufficient to block 50% of Hsp90 binding to ATP beads. Data presented are the mean 
± standard deviation from three separate experiments. Binding to ATP beads in the absence of 
GA was set at 100%. 
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4.2.8 Analysis of Hsp90 in B. pahangi and C. elegans 
In Chapter 3, the ability of B. pahangi Hsp90 to bind GA was shown to be 
shared by some clade III parasitic species and by Trichinella spiralis (clade I) but 
not with parasitic species from other clades or with free-living nematodes. In 
most eukaryotes, the sequence of Hsp90 proteins is highly conserved. The most 
obvious explanation for the surprising lack of GA binding by Hsp90 from some 
worms would be an alteration in the N-terminal domain of the chaperone. In 
order to investigate the differences between B. pahangi and C. elegans Hsp90 
sequence, an alignment of the predicted amino acid sequence of B. pahangi and 
C. elegans was compared (Figure 4.14). This confirmed the high degree of 
conservation within the whole sequence (Figure 4.14). C. elegans Hsp90 is 84% 
identical (91% similar) to B. pahangi Hsp90. The N-terminal domain shows a 
minimal number of substitutions (see Figure 4.14). The sequence of C. elegans 
Hsp90 is shorter than B. pahangi Hsp90, because the charged region contains 
fewer amino acids.      
Despite the high degree of similarity between C. elegans Hsp90 and B. 
pahangi Hsp90, C. elegans Hsp90 failed to bind GA in solid phase pull-down 
assays (see Chapter 3). In order to further investigate these contrasting results, 
Hsp90 expression levels were compared in both species. Worm lysates were 
prepared as described previously. For this analysis, only adult stages of both 
nematodes were used. The protein concentration of each lysate was estimated 
using the Bio-Rad protein assay and equal amounts of protein were loaded onto 
10% SDS-PAGE gels and blotted (see Figure 4.15a).  
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B. pahangi     1 MSEEMNGETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR 
C. elegans     1 --MSENAETFAFQAEIAQLMSLIINTFYSNKEIYLRELISNASDALDKIR 
                                                               
B. pahangi    51 YQALTEPAELETGKELYIKITPNKADKTLTIMDTGIGMTKADLVNNLGTI 
C. elegans    49 YQALTEPSELDTGKELFIKITPNKEEKTLTIMDTGIGMTKADLVNNLGTI 
                  
B. pahangi   101 AKSGTKAFMEALQAGADISMIGQFGVGFYSAFLVADKVVVASKHNDDDCY 
C. elegans    99 AKSGTKAFMEALQAGADISMIGQFGVGFYSAFLVADKVVVTSKNNDDDSY 
                  
B. pahangi   151 QWESSAGGSFIIRQVNDPELTRGTKITLYIKEDQTDYLEERRIKEIVKKH 
C. elegans   149 QWESSAGGSFVVRPFNDPEVTRGTKIVMHIKEDQIDFLEERKIKEIVKKH 
                  
B. pahangi   201 SQFIGYPIKLTVEKERDKEVSDDEAEEEKKDEDKEKKEGEIEDVGEDEEE 
C. elegans   199 SQFIGYPIKLVVEKEREKEVEDEEAVEAK---DEEKKEGEVENVADDADK 
                  
B. pahangi   251 DKKDKDKKKKKIKEKYHEDEELNKTKPIWTRNPDDISNEEYAEFYKSLSN 
C. elegans   246 ------KKTKKIKEKYFEDEELNKTKPIWTRNPDDISNEEYAEFYKSLSN 
                  
B. pahangi   301 DWEDHLAVKHFSVEGQLEFRALLFVPQRAPFDLFENKKTKNAIKLYVRRV 
C. elegans   290 DWEDHLAVKHFSVEGQLEFRALLFVPQRAPFDLFENKKSKNSIKLYVRRV 
                  
B. pahangi   351 FIMENCDELMPEYLNFIKGVVDSEDLPLNISREMLQQSKILKVIRKNLVK 
C. elegans   340 FIMENCEELMPEYLNFIKGVVDSEDLPLNISREMLQQSKILKVIRKNLVK 
                  
B. pahangi   401 KCLELFDEIAEDKDNFKKFYEQFSKNIKLGIHEDSTNRKKLSEFLRFYTS 
C. elegans   390 KCMELIDEVAEDKDNFKKFYEQFGKNLKLGIHEDSTNRKKLSDFLRYSTS 
                  
B. pahangi   451 ASSEEMTSLKDYVSRMKENQKQIYFITGESREAVASSAFVERVKRRGFEV 
C. elegans   440 AG-DEPTSLKEYVSRMKENQTQIYYITGESKDVVAASAFVERVKSRGFEV 
                  
B. pahangi   501 IYMTDPIDEYCVQQLKEYDGKKLVSVTKEGLELPESEEEKKKFEEDKVKF 
C. elegans   489 LYMCDPIDEYCVQQLKEYDGKKLVSVTKEGLELPETEEEKKKFEEDKVAY 
                  
B. pahangi   551 ENLCKVMKDILEKKVEKVAVSNRLVSSPCCIVTSEYGWSANMERIMKAQA 
C. elegans   539 ENLCKVIKDILEKKVEKVGVSNRLVSSPCCIVTSEYGWSANMERIMKAQA 
                  
B. pahangi   601 LRDSSTMGYMAAKKHLEINPDHSVIKALRERVEADKNDKTVKDLVVLLFE 
C. elegans   589 LRDSSTMGYMAAKKHLEINPDHAIMKTLRDRVEVDKNDKTVKDLVVLLFE 
                  
B. pahangi   651 TALLSSGFSLEDPQLHASRIYRMIKLGLDITEDEEEEAIASVSGEKDECV 
C. elegans   639 TALLASGFSLEEPQSHASRIYRMIKLGLDIGDDEIEDSAVPSS---CTAE 
                  
B. pahangi   701 PNLVGAEEDASRMEEVD 
C. elegans   686 AKIEGAEEDASRMEEVD 
 
 
Figure 4.14: Hsp90 is conserved in B. pahangi and C. elegans. 
 
Figure shows an alignment of the predicted amino acid sequences of B. pahangi (Bp, 
accession number AJ005784) and C. elegans (Ce, accession number Z75530) Hsp90s by 
Clustal-W. Identical amino acids are in red with yellow-shaded box. Green shading 
represent amino acids that are similar. Bold letters represent amino acids that differ in both 
sequences. The highly conserved N-terminal domain is indicated by the dashed box.  
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Figure 4.15b shows the autoradiograph for Hsp90 expression in B. pahangi 
and C. elegans with actin as a loading control. A band of ~83 kDa was detected 
in both species by Western blot using an antibody raised to recombinant B. 
pahangi Hsp90. The autoradiograph was then scanned and band densities were 
obtained using FlourChemTM IS-5500 software. This analysis showed that Hsp90 is 
expressed at a relatively higher level in B. pahangi compared to C. elegans 
Hsp90 (p<0.05). 
Previous results showed that soluble GA competes with ATP beads to bind 
to Hsp90. In C. elegans, Hsp90 failed to bind GA but retained its ability to bind 
ATP (David et al., 2003). To address this issue, I compared the ability of B. 
pahangi and C. elegans Hsp90 to bind ATP using γ-phosphate immobilised ATP as 
previously described (Grenert et al., 1997; Soti et al., 2003). Worm lysates were 
incubated with ATP beads for 60 min at room temperature. The resin was then 
pelleted and washed with buffer and analysed by SDS-PAGE and Western 
blotting. Figure 4.16 shows that both B. pahangi and C. elegans Hsp90 bind to 
ATP beads. The results presented are based on three independent experiments.  
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Figure 4.15: Hsp90 is more highly expressed in B. pahangi than in C. elegans. 
 
a) Coomassie blue stained gel of B. pahangi (Lane 1) and C. elegans (Lane 2) adult worm 
extracts. Mr presents the molecular weight marker. 
b) Hsp90 expression levels of B. pahangi (Lane 1) and C. elegans (Lane 2) with actin as a 
loading control. Equal amount of proteins were analysed by SDS-PAGE and Western 
blotting. Proteins were transferred to NCP using standard methods, blocked overnight in 5% 
dried milk in PBS/0.5% Tween 20 and then the blot probed with 1:5000 dilution of the B. 
pahangi anti-Hsp90 antibody. Bound antibody was detected using a 1:10,000 dilution of anti-
rabbit IgG. The blot was developed using the Pierce Super Signal West Pico 
chemiluminescence kit.           
c) The graph shows the expression levels of Hsp90 for B. pahangi and C. elegans as 
detected using the B. pahangi anti-Hsp90 antibody. The autoradiograph was scanned for 
densities using FlourChemTM IS-5500 software. Hsp90 expression is significantly higher in B. 
pahangi compared to C. elegans. The data represent the mean ratio of Hsp90/actin ± 
standard deviation from three different experiments.  
B. pahangi 2.2138 ± 0.9138 
B. pahangi Hsp90 vs C. elegans Hsp90   * p = 0.0010 
C. elegans 0.7155 ± 0.1033 
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Figure 4.16: B. pahangi and C. elegans Hsp90 bind to ATP beads. 
 
Autoradiograph shows the comparison of B. pahangi (Lane 1) and C. elegans (Lane 2) 
Hsp90 binding to ATP beads. 500 µg of worm lysates were incubated with 100 µl of ATP 
beads for 60 min at room temperature, pelleted and washed with buffer and bound proteins 
were analysed by 10% SDS-PAGE and Western blotting which was blotted and probed with 
1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was detected using a 
1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed using the 
Pierce Super Signal West Pico chemiluminescence kit. 
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4.3 Discussion 
The development of a compound with macrofilaricidal activity has long 
been a goal of the World Health Organisation (WHO). Current treatment of 
filariasis is largely dependent on treatment with drugs, such as 
diethylcarbamazine or ivermectin, which kill the Mf but not the adult worm. The 
only novel chemotherapeutic target currently under development for the filarial 
nematodes is the Wolbachia endosymbiont (Hoerauf, 2008; Supali et al., 2008). 
Wolbachia are present in most of the human filariae and were shown to be 
important for worm fertility and survival (Debrah et al., 2007; Hoerauf et al., 
2008). Previously, Hsp90 was identified as a possible target in B. pahangi 
(Devaney et al., 2005). Inhibition of B. pahangi Hsp90 by GA not only kills the Mf 
but also kills the adult worm. Thus Hsp90 might be a useful target for lymphatic 
filariasis. The aim of this Chapter was to further characterise B. pahangi Hsp90.   
Results in this Chapter show that Hsp90 is expressed in all B. pahangi life 
cycle stages analysed, at a similar level. However, in the pull-down assay, only 
adult stage Hsp90 was observed to bind to GA, not Hsp90 from the L3 and Mf. 
The inability to detect Hsp90 binding to GA beads could perhaps reflect a lack of 
sensitivity of the assay, or alternatively may suggest that Hsp90 from Mf and L3 
is processed in such way that it fails to bind to GA. Nothing is currently known 
about co-chaperones in B. pahangi and whether they may be required for Hsp90 
to bind to GA. These data were surprising as GA kills Mf, suggesting that it can 
bind to Mf Hsp90.  
 In many eukaryotes, Hsp90 is induced after heat shock or following 
exposure to stress. However, in this Chapter, Hsp90 expression was not strongly 
induced by heat shock or GA treatment in B. pahangi. These results correlate 
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well with previous studies on  B. pahangi hsp90 by (Thompson et al., 2001) 
where it was shown that hsp90 mRNA levels were minimally induced following 2 
h of heat shock (1.2–1.5 fold). In contrast, studies in C. elegans using in situ 
hybridisation showed that under stress conditions, daf-21 mRNA was expressed 
all over the body of C. elegans while under normal conditions, daf-21 is localised 
to the germline of adult C. elegans (Inoue et al., 2003). This suggested that daf-
21 mRNA was up-regulated by heat shock. The difference between the results of 
that study using in situ hybridisation and the results presented here may relate 
to the different methods used.    
Hsp90 was detected in the ES products of adult B. pahangi but not in the 
ES products of Mf. ES products contain molecules shed from the parasite 
surface as well as those secreted from the pharyngeal glands, excretory system 
etc. These results suggest that the secreted Hsp90 might be stage specific but 
the reason why Hsp90 is secreted in adult ES products of Brugia remains 
unknown. The first discovery of extra-cellular Hsp90 was reported by Ullrich et 
al (1986) in mouse tumour cells. Hsp90 has been identified at the cell surface 
of other cancer cells where it was shown to be involved in cell motility, 
invasion and metastasis (Eustace et al., 2004; Sidera et al., 2004). Adult 
filarial worms secrete many bio-active molecules (Hewitson et al., 2008), and 
it is possible that Hsp90 may be required for the activity of some of these.  
Attempts were made to identify Hsp90 client proteins/co-chaperones using 
two different methods. The first method, using a modified GA-biotin binding 
assay, did not identify any potential Hsp90-associated proteins due to the non-
specific binding observed in the assay. Attempts were made to overcome this 
problem but were not successful in increasing the specificity of binding. 
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However, the original studies by (Neef et al., 2010), showed that this technique 
was able to detect and identify heat shock factor 1A (HSF1A)-associated proteins 
from human and yeast using HSF1A-biotin beads.    
The second method used a proteomic analysis. Following exposure to GA, 
Hsp90 complexes undergo a conformational change and as a result the client 
proteins are released from the complexes and subject to degradation. The 
rationale of this method was that client proteins would therefore be degraded 
following exposure of worms to GA. Thus it might be possible to identify 
proteomic differences between GA-treated and control worms. In the DIGE 
analysis, a total of 75 proteins (3.8%) were observed to differ in expression level 
between the groups. Of these, only 14 (0.7%) showed a reduction in expression 
following GA treatment but unfortunately it was not possible to identify these 
because of equipment failure. Without knowing the identity of any of these 
differentially expressed proteins, it is difficult to draw any conclusion from this 
experiment. It was, however, surprising that so few proteins showed a reduced 
expression following exposure of adult B. pahangi to GA.  The second analysis 
was carried out using a much less sensitive technique and, not surprisingly, few 
differences were observed. Of the five proteins down-regulated following GA 
treatment, most were structural proteins. Of these tropomyosin and myosin 
regulatory light-chain 1, appeared in both the up-regulated and down-regulated 
list. The reason for this are not clear but it may be that proteolytic fragments of 
tropomyosin were detected in the GA-treated group. Because of lack of 
sensitivity of this method, only a single experiment was carried out.  
A study by (Tsaytler et al., 2009) using complementary proteomic 
approaches also identified several Hsp90 protein partners with structural 
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functions e.g. myosin-9, Filamin A, actin etc. In C. elegans, tropomyosin in the 
muscle wall was suggested to be essential as it is required for the late 
development of C. elegans (Kagawa et al., 2007). Until recently, UNC-45, a 
muscle-specific protein, was one of the few targets of Hsp90 which had been 
experimentally validated in C. elegans (Barral et al., 2002). According to Barral 
et al (2002), a direct interaction between UNC-45 and Hsp90 occurs as UNC-45 
contains a tetratricopeptide repeat domain that binds to the C-terminal of 
Hsp90. However, further investigations are needed for an improved 
understanding of the role of Hsp90 in the regulation of the cytoskeleton and 
contractile activity. Furthermore, different methods need to be adopted to 
identify Hsp90-client proteins in B. pahangi.  
A recent study identified Hsp90 interacting proteins in bacteria 
(Shewanella oneidensis, Shewanella frigidimarina and Psychrobacter frigidicola) 
that live at different temperatures, using immunoprecipitation followed by a 
proteomic approach (Garcia-Descalzo et al., 2010). Many of the proteins 
identified were involved in energy metabolism such as isocitrate lyase, succinyl-
CoA synthetase, alcohol dehydrogenase etc. It was hypothesised that Hsp90 and 
its interacting proteins may play a role in adaptation to cold environments. 
Echeverria et al (2010) also identified Hsp90/p23 client proteins in Toxoplasma 
gondii using a similar co-immunoprecipitation approach. These had multiple 
functions such as glycolysis, ATP production, protein synthesis, chaperones and 
foldases, kinases and phosphatases. These studies help explain why Hsp90 is 
essential in most organisms and suggest that the application of an 
immunoprecipitation approach to B. pahangi might yield more data. 
Chapter 4   179 
In this Chapter, the binding of B. pahangi Hsp90 to GA was further 
explored. One area of interest was to investigate the amount of Hsp90 that was 
available for GA binding. Results in this Chapter show that only a small amount 
of Hsp90 binds to GA, approximately 6.31% of the cellular Hsp90. It is possible 
that the amount of GA bound to beads is a limiting factor in these experiments. 
However, this seems unlikely as by the fifth pull-down no binding was observed. 
Alternatively the low amount of Hsp90 bound to GA beads may reflect steric 
hindrance between bead-bound GA and soluble Hsp90, or alternatively it may be 
an accurate reflection of the amount of Hsp90 that can bind GA. If correct, the 
results suggest that it might be necessary to inhibit only a small percentage of 
total Hsp90 to kill the worm. 
The B. pahangi lysate was also subjected to competition assays with GA, 
ATP and novobiocin. Free soluble GA was shown to inhibit the binding of B. 
pahangi Hsp90 to GA beads in a dose-dependent manner. On the other hand, in 
the ATP binding assay, soluble GA was also shown to compete for binding of 
Hsp90 to ATP beads which suggests that ATP and GA share the same binding site 
in B. pahangi Hsp90. These results are consistent with the findings of Grenert et 
al (1997) where they showed that 100-200 nM GA is enough to block 50% of 
chicken Hsp90 binding to GA beads. Since the amount of GA derivatised to resin 
is not known and may vary from batch to batch, these values reflect relative IC50 
values.  
  Novobiocin, a coumarin type antibiotic inhibits Hsp90 functions in a very 
different manner to GA and radicicol. Novobiocin was shown to bind to the C-
terminal domain of Hsp90, a different binding site from GA. Several point 
mutations in the N-terminus of chicken Hsp90 did not affect novobiocin binding 
Chapter 4   180 
and the N-terminus failed to bind novobiocin-beads (Marcu et al., 2000a). Many 
previous studies have shown that novobiocin affects the interaction of Hsp90 
with its client proteins (Marcu et al., 2000a; Katschinski et al., 2002; Haendeler 
et al., 2003; Yun et al., 2004; Allan et al., 2006). The binding of B. pahangi 
Hsp90 to GA beads was shown to be competed by excess novobiocin. It is 
noteworthy that the concentration of novobiocin required to inhibit binding of B. 
pahangi Hsp90 to GA beads is very high, in the millimolar range. However, this 
reflects the concentration of novobiocin required to inhibit Hsp90 binding in 
mammalian cells (Marcu et al., 2000a) and in B. pahangi where novobiocin at 
concentrations of 200-500 µM kills adult worms (Devaney, unpublished).  It has 
been proposed that the N-terminal and C-terminal domain of Hsp90 interact 
(Yun et al., 2004). Other studies have demonstrated that novobiocin binding may 
alter the conformation of the Hsp90 C-terminal domain leading to the 
dissociation of TPR containing co-chaperones (Marcu et al., 2000a; Marcu et al., 
2000b; Soti et al., 2003; Wayne & Bolon, 2007). Taken together these results 
support the hypothesis that an interaction occurs between domains in Hsp90 
which is essential for the chaperoning functions.  
One area that remains to be resolved is the lack of binding of C. elegans 
Hsp90 to GA compared to Brugia. A possible explanation is that B. pahangi and 
C. elegans bear different post-translational modifications that affect GA binding. 
It was not possible to directly compare recombinant worm Hsp90 with native 
protein, so a comparison was made between recombinant human Hsp90α with 
native Hsp90 isolated from SkBr3 cells. Hsp90 is extensively modified and these 
modifications are known to impact the Hsp90 chaperone machinery. As reviewed 
previously phosphorylation, acetylation and other modifications of Hsp90 are 
important elements in regulating the Hsp90 chaperone function (Scroggins & 
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Neckers, 2007). A recent study of Plasmodium falcifarum Hsp90 showed that 
exposure of infected red blood cells to the histone deacetylase inhibitor, 
Trichostatin A, had a synergetic effect with GA and inhibited malaria growth 
(Pallavi et al., 2010). These studies suggest that the degree of acetylation of 
Hsp90 may affect its ability to bind to GA. However, in this Chapter it was shown 
that both rHsp90α and native Hsp90 bound to GA, suggesting that post-
translational modifications of human Hsp90 are not essential for Hsp90 to bind to 
GA but might be required for other Hsp90 chaperone functions. Thus, while it 
was not possible to exclude differences in post-translational modifications being 
important in GA binding, there was no evidence to support it.  
The final result in this Chapter showed that C. elegans and B. pahangi 
Hsp90 bind ATP similarly even though Hsp90 is expressed at a relatively higher 
level in B. pahangi than in C. elegans. However, the analysis of Hsp90 expression 
level was based on the use of an antibody raised to B. pahangi Hsp90, which may 
have a higher affinity for B. pahangi Hsp90 than for C. elegans Hsp90. However, 
the C-terminal domain to which the antibody was raised is very similar between 
B. pahangi and C. elegans as shown in Figure 4.14. The ATP binding assay for 
both nematodes validates previous reports by David et al (2003), where they 
showed that C. elegans Hsp90 binds to ATP but not to GA. C. elegans Hsp90 and 
B. pahangi Hsp90 are highly conserved (91.4% similar and 84.1% identical) with 
only minor substitution amino acids in the N-terminal domain. However, these 
substitutions are unlikely to contribute to conformational differences between 
B. pahangi and C. elegans that affect GA binding (Devaney et al., 2005). 
Additionally, the charged region of B. pahangi Hsp90 is longer than C. elegans 
Hsp90. A study in yeast showed that the charged region plays an important role 
in regulating the chaperone function of Hsp90 (Scheibel et al., 1999). In future 
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studies it may be of interest to examine the role of the charged region in B. 
pahangi Hsp90 in more detail.  
In conclusion, the mystery of why C. elegans Hsp90 fails to bind GA remains 
unsolved. From other studies in this laboratory, there are clear differences in 
the function of Hsp90 in the two nematodes e.g. B. pahangi Hsp90 was unable to 
rescue a C. elegans daf-21 mutant, although  the protein was successfully 
expressed (Gillan et al., 2009). Thus despite a high degree of sequence 
similarity, Hsp90 appears to be functionally diverse in nematodes. These studies 
differ from results in yeast, where Hsp90 from human or Trypanosoma cruzi can 
complement a yeast hsp90 mutant (Palmer et al., 1995) as can C. elegans hsp90 
and human hsp90β (Piper et al., 2003) despite significantly lower levels of 
identity (60.5% and 60.3%, respectively). According to Gillan et al (2009) the 
overall degree of sequence similarity may not be a good measure of Hsp90 
function. Given the interaction between the different domains of Hsp90, it may 
be important to look outside the N-terminal domain and also to attempt to 
identify client proteins/co-chaperones which may differ significantly between 
these two nematodes.     
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5 Hsp90 and drug resistance 
5.1 Introduction 
To date, there are no data on the possible involvement of Hsp90 in drug 
resistance in nematodes. In this chapter, I investigated the hypothesis that 
Hsp90 may have a role in drug resistance in nematodes using anthelmintic 
resistant and susceptible worms. As reviewed in the Introduction, Hsp90 was 
shown to be involved in drug resistance in tumour cells and fungi. In fungi, the 
emergence of azole resistance was suggested to be associated with Erg11 (an 
enzyme in the cytochrome P450 family which is involved in the biosynthesis of 
ergosterol) and calcineurin. Calcineurin belongs to the protein phosphatase 
family and was identified as an Hsp90 client protein, involved in regulating 
numerous responses to membrane stress (Cowen & Lindquist 2005; Cowen et al., 
2006; Singh et al., 2009). In contrast, in some tumour cells, P-gp was suggested 
to be involved in the drug resistance mediated by Hsp90β (Betram et al., 1996). 
Thus the question arises: could Hsp90 have a role in anthelmintic resistance in 
nematodes?  
Gastrointestinal nematode infections can cause great losses in revenue due 
to decreased livestock production and animal death. Additional losses are 
suffered due to sub-clinical effects of parasite infection. It is estimated that the 
cost of controlling gastrointestinal nematode infection is between US$220 to 500 
million in Australia (Emery & Wagland, 1991; McLeod, 1995). In the UK itself, the 
cost of treatment and losses for the sheep industry reach around £84 million 
annually (Nieuwhof & Bishop, 2005). The most common method to control 
gastrointestinal nematode infection is by anthelmintic treatment. However, 
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inconsistent treatment, excessive use and overdose of drugs have caused a new 
problem to arise, drug resistance.  
Anthelmintics are separated into several classes based on their chemical 
structure and mode of action. To date, three groups of anthelmintic are widely 
used, namely the benzimidazoles, imidazothiazoles and macrocylic lactones. The 
most widely used and available anthelmintics belong to the benzimidazole 
group. Benzimidazoles were introduced to the market in 1961 beginning with 
thiabendazole followed by albendazole and fenbendazole. Anthelmintics of the 
imidazothiazole-tetrahydropyridimine group were introduced to the market in 
1968. The most widely used are levamisole, pyrantel and morantel. Levamisole 
is a nicotinic receptor agonist (Aceves et al., 1970; Aubry et al., 1970) with a 
selective action on nematode receptors. The third group of anthelmintics are 
the macrocyclic lactones such as ivermectin, moxidectin and abemectin. 
Macrocyclic lactones were introduced in the early 1980s and since then have 
become effective anthelmintics for combating gastrointestinal nematode 
infections.  
Anthelmintic resistance is a major problem that threatens the livestock 
industry throughout the world, especially in countries with hot and humid 
climates. Such climates provide ideal conditions for the development of free-
living stages of nematode parasites on pasture. Several recent investigations 
have demonstrated a progressive spread of anthelmintic resistance, mainly in 
nematode populations of sheep (Sargison et al., 2005). This problem became 
worse when the first multiple drug resistance cases were reported in H. 
contortus from South Africa (Van Wyk et al., 1999), Malaysia (Chandrawathani et 
al., 2003) and the United States (Mortensen et al., 2003). Anthelmintic 
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resistance is present in a population when there is a greater frequency of 
individuals within a population which are able to tolerate an anthelmintic 
compared to a normal population (Prichard et al., 1980). Several reviews on 
possible mechanisms of anthelmintic resistance have been published over the 
last few years (Kaplan, 2004; Jabbar et al., 2006). Since anthelmintics kill the 
majority of susceptible nematodes, the next generation will consist largely of 
offspring of the resistant nematodes (Le Jambre, 1985). If the character that 
provides resistance is controlled by a single major gene, then the resistant 
population will build up very rapidly (Le Jambre, 1985) and this trait is 
inheritable. 
In the work described in this Chapter, Hsp90 levels were compared in 
anthelmintics susceptible and resistant worms. The first group studied were field 
isolates of the Trichostrongylid species, Teladosargia circumcincta. 
Trichostrongylid nematodes are highly prevalent in grazing animals and have 
developed resistance to anthelmintics. Two UK isolates were compared; Tci5 is 
resistant to all classes of broad spectrum anthelmintics (Bartley et al., 2005), 
while Tci2 is susceptible to all of these drugs.  
The second group of nematodes compared were Caenorhabditis elegans 
strains that were derived from mutagenesis screens. In these studies, C. elegans 
is exposed to a mutagen and worms are selected by their ability to grow on drug 
(Driscoll et al., 1989, Dent et al., 2000). The strains used were C. elegans 
CB3474 and DA1316. C. elegans CB3474 is resistant to benzimidazole compounds 
via mutations in the ben-1 gene which encode β-tubulin isotype 1 (Driscoll et al., 
1989). C. elegans DA1316 is an ivermectin-resistant strain which contains 
mutations in avr-14, avr-15 and glc-1, each of which encode glutamate-gated 
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chloride channel (GluCl) sub-units and exhibits high level resistance to 
ivermectin (Dent et al., 2000).  
Finally, a third group of C. elegans were studied; these were wild-type N2 
worms which had been continually grown on increasing levels of ivermectin and 
selected for their ability to survive and reproduce on drug (James & Davey, 
2009). These worms were continuously passaged on increasing concentration of 
ivermectin. IVM-6 worms were resistant to ivermectin at 6 ng/ml, while IVM-10 
worms were resistant to 10 ng/ml. Both strains also showed cross-resistance to 
moxidectin and to other anthelmintics such as levamisole and pyrantel. 
The first aim of the studies described in this Chapter was to determine 
whether Hsp90 expression levels were altered in anthelmintic resistant 
nematodes. Secondly, experiments were undertaken using the RNAi approach to 
knock-down hsp90 levels in C. elegans ivermectin-resistant worms, to determine 
whether Hsp90 is involved in resistance in these worms.  
 
 
 
 
 
 
 
 
Chapter 5    188
5.2 Results 
5.2.1 Hsp90 expression levels in drug resistant nematodes are 
not significantly different compared to susceptible 
nematodes 
5.2.1.1 T. circumcincta isolates – resistance acquired by natural selection 
in the field 
The two T. circumcincta isolates used in this study were obtained from 
the Moredun Research Institute, Edinburgh, UK. T. circumcincta extract was 
prepared as described previously in Materials and Methods (Section 2.1.3) and 
equal amounts of protein extracts (2-4 µg) were analysed by SDS-PAGE and 
Western blotting. Figure 5.1a shows a Coomassie blue stained gel, while the 
corresponding autoradiograph is shown in Figure 5.1b. In this experiment B. 
pahangi extract was used as a control for the antibody and actin was used as a 
loading control. The autoradiograph shows that there was no difference in Hsp90 
expression levels in the T. circumcincta Tci5 isolate (Lane 2) compared to the T. 
circumcincta Tci2 isolate (Lane 3). The autoradiograph was scanned and band 
densities were quantified using using FluorChemTM IS-5500 software. Based on the 
Hsp90/actin ratio a graph was plotted. The expression level of Hsp90 in the T. 
circumcincta Tci5 isolate was similar to the Tci2 isolate (Tci5 0.9586 ± 0.0461, 
Tci2 0.7542 ± 0.0318)(p>0.05).          
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Figure 5.1: Analysis of Hsp90 expression levels in anthelmintic susceptible and resistant T. 
circumcincta   
 
a) Coomassie blue staining of approximately equal amounts of protein. Mr represents 
molecular marker, B. pahangi (Lane 1), T. circumcincta Tci5 isolate (Lane 2) and T. 
circumcincta isolate Tci2 (Lane 3).  
b) Equal amounts of soluble extract of B. pahangi (Lane 1), T. circumcincta Tci5 (Lane 2) and 
Tci2 (Lane 3) were analysed by Western blotting using the B. pahangi anti-Hsp90 antibody at 
1:5000 dilution followed by 1:10,000 dilution of HRP-labelled anti-rabbit IgG (Sigma). Bound 
antibody was detected by chemiluminescence using Super Signal ® West Pico Kit. Anti-actin 
was used as the loading control and B. pahangi extract was used as a positive control. 
c) Graph shows the Hsp90 expression levels in T. circumcincta resistant and susceptible 
isolates. Hsp90 expression was higher in the T. circumcincta Tci5 isolate compared to the T. 
circumcincta Tci2 isolate but the difference was not significant between the two isolates 
(p>0.05).  Graph presented here shows the mean ± standard deviation of three different 
experiments. 
T. circumcincta Hsp90 Tci5 vs Tci2, p = 0.0809    
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5.2.1.2 C. elegans resistant strains – resistance acquired by mutagenesis 
C. elegans CB3474 is a strain which shows resistance to benzimidazole 
compounds via a mutation in the ben-1 gene (Driscoll et al., 1989). C. elegans 
DA1316 is a strain which contains mutations in three separate genes, all of which 
are required for high level resistance to ivermectin (Dent et al., 2000). Both 
strains were selected in mutagenesis screens. Levels of Hsp90 were compared in 
these mutant worms and in wild-type N2 worms by Western blotting. Figure 5.2a 
shows a Coomassie blue stained gel of the soluble extracts, with the 
corresponding autoradiograph shown in Figure 5.2b. The autoradiograph was 
scanned and band densities were quantified using FluorChemTM IS-5500 
software. The graph in Figure 5.2c shows  Hsp90 expression levels in C. elegans 
N2, C. elegans CB3474 and C. elegans DA1316.The expression levels of Hsp90 in 
C. elegans N2 was similar compared to the mutant worms (N2 1.3181± 0.0361, 
CB3474 1.1471± 0.0412, DA1316 1.2853± 0.0685)(p>0.05).  
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Figure 5.2: Analysis of Hsp90 levels in C. elegans drug resistant strains 
 
a) Coomassie blue stained gel of soluble extracts of C. elegans N2 (Lane 1), C. elegans 
CB3474 (Lane 2) and C. elegans DA1316 (Lane 3). Mr represents the molecular weight marker. 
b) Autoradiograph of Hsp90 expression levels in susceptible and resistant C. elegans. 
Extracts were loaded exactly as in Panel a. C. elegans N2 (Lane 1), C. elegans CB3474 (Lane 2) 
and C. elegans DA1316 (Lane 3).  Actin was used as a loading control.  
c) The expression level of Hsp90 based on Hsp90/Actin ratio as quantified using FluorChemTM 
IS-5500 software. Graph presented here shows the mean ± standard deviation of three 
different experiments. 
C. elegans N2 vs C. elegans CB3474, p = 0.0809  
C. elegans N2 vs C. elegans DA1316, p = 0.6625  
C. elegans CB3474 vs C. elegans DA1316, p = 0.0809 
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5.2.1.3 C. elegans ivermectin-resistant strains – acquired by selection on 
drug 
In some cases, nematode tolerance to drug can be induced by continuous 
exposure to drug in the laboratory. In this case, wild-type N2 worms were 
adapted to culture with ivermectin at 6 ng/ml or 10 ng/ml. Hsp90 expression 
levels were compared in C. elegans N2, C. elegans IVM-6 and IVM-10 worms. 
Figure 5.3a shows a Coomassie blue stained gel of the extracts while Figure 5.3b 
shows the corresponding autoradiograph of Hsp90 expression levels in ivermectin 
resistant and susceptible worms. The autoradiograph was scanned and band 
density was quantified using FluorChemTM IS-5500 software and graph was plotted 
based on Hsp90/actin ratio. The graph in Figure 5.3a indicates that the expression 
level of Hsp90 in C. elegans N2 was similar compared to the IVM-6 and IVM-10 
worms (N2 2.3657±0.1774, IVM-6 1.9683± 0.4080 and IVM-10 1.9104± 
0.0668)(p>0.05).  
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Figure 5.3: Analysis of Hsp90 expression levels in C. elegans N2 and ivermectin resistant 
worms 
 
a) Coomassie blue stained gel of soluble extracts of adult stage of C. elegans N2, C. elegans 
IVM-6 and C. elegans IVM-10. 30 adult worms were directly solubilised in 30 µl SDS-PAGE 
sample cocktail by boiling for 3 min. 5 µl of sample extract was loaded onto the gel for the 
analysis.  
b) Autoradiograph of Hsp90 expression levels as detected using the B. pahangi anti-Hsp90 
antibody. C. elegans N2 (Lane 1), C. elegans IVM-6 (Lane 2) and C. elegans IVM-10 (Lane 3). B. 
pahangi anti-Hsp90 antibody was used at 1:5000 dilution followed by 1:10,000 dilution of HRP-
labelled anti-rabbit IgG (Sigma). Bound antibody was detected by chemiluminescence using 
Super Signal ® West Pico Kit. Actin was used as a loading control (Mr weight ~42 kDa). 
c) The expression level of Hsp90 based on the Hsp90/actin ratio as quantified using 
FluorChemTM IS-5500 software. Graph presented here shows the mean ± standard deviation of 
three different experiments.  
C. elegans N2 vs C. elegans IVM-6, p = 0.3827  
C. elegans N2 vs C. elegans IVM-10, p = 0.0809 
C. elegans IVM-16 vs C. elegans IVM-10, p =  0.6625 
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5.2.2 Optimising the conditions for hsp90(RNAi)  
C. elegans is a useful model for parasitic nematodes, because defining the 
function of genes of interest in parasitic species can be difficult due to the lack 
of appropriate knock-out approaches or suitable functional assays (Britton & 
Murray, 2006). In this section C. elegans wild-type worms were used in 
preliminary hsp90(RNAi) experiments to optimise RNAi conditions, prior to using 
this approach to investigate the possible role of Hsp90 in drug resistance.       
5.2.2.1 Investigating the effect of temperature and time of feeding on the 
efficiency of RNAi 
In the initial experiments, wild-type N2 worms were fed on a 300 bp 
hsp90(RNAi) construct described previously (Section 2.3.2.5). RNAi was 
conducted at different temperatures or for different time periods, as both 
variables can affect the intake of the construct and the efficiency of the RNAi. 
The aim of these experiments was to obtain a reduction in Hsp90 levels, while 
maintaining the viability of the worms. L4 of wild-type N2 were fed on the 300 
bp hsp90(RNAi) construct for 6 h, 12 h or 24 h at 20oC. 30 worms were then 
solubilised in 30 µl SDS-PAGE sample cocktail and analysed by Western blotting. 
Figure 5.4a shows the autoradiograph of Hsp90 expression levels after different 
feeding duration. At 6 h, there was a small but insignificant increase in Hsp90 
expression in RNAi treated worm compared to the control group (Lane 1 and 
Lane 2)(p>0.05). However, after 12 h of feeding there was a small reduction in 
Hsp90 expression level in RNAi treated worms compared to the control group 
(Lane 3 and Lane 4)(p>0.05), with a further reduction after 24 h of feeding (Lane 
5 and Lane 6)(p<0.05). In these experiments, Hsp90 levels were reduced by 
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approximately 42% after 24 h feeding on the hsp90(RNAi) construct. Thus 
subsequent RNAi experiments were carried out at 24 h.  
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Figure 5.4: Different RNAi feeding periods affect Hsp90 expression levels. 
 
a) Wild-type N2 L4 worms were fed on the hsp90(RNAi) construct for 6, 12 and 24 h. Control 
worms were fed on empty vector under identical conditions. 6 h-Control (Lane 1), hsp90(RNAi) 
(Lane 2), 12 h-Control (Lane 3), hsp90(RNAi)(Lane 4), 24 h-Control (Lane 5), hsp90(RNAi) (Lane 
6).  All experiments were carried out at 20oC. Equal volumes of extract (5 µl) were loaded onto 
a 10% gel and analysed by SDS-PAGE and Western blotting as described previously.  
b) Hsp90 expression levels following hsp90(RNAi) at 20oC after different feeding times. 
Results are expressed as ratio of Hsp90/actin in RNAi treated worms compared to controls.  
All values represent the mean ± standard deviation of three experiments. All percentages are 
expressed relative to the appropriate control, which was set to 100%.  
6 h-106.24% ± 8.87, 12 h-90.70% ± 22.55,  24 h-58.35% ± 2.47, 
Control vs 6 h feeding on the hsp90(RNAi) construct, p = 0.311 
Control vs 12 h feeding on the hsp90(RNAi) construct, p = 0.576 
*Control vs 24 h feeding on the hsp90(RNAi) construct, p = 0.001 
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In the next experiments, worms were fed on the 300 bp hsp90(RNAi) 
construct for 24 h at different incubation temperatures of 16oC, 20oC or 25oC. 
Temperature was shown to influence the effectiveness of RNAi in previous 
studies (Kamath et al., 2003). Figure 5.5a shows the autoradiograph of Hsp90 
expression levels of wild-type N2 after 24 h feeding on the 300 bp hsp90(RNAi) 
construct at 16oC, 20oC or 25oC. The autoradiograph was then scanned to 
quantify Hsp90 expression levels using FlourChemTM IS-5500. Figure 5.5b shows 
the graph of Hsp90 expression levels after feeding on the 300 bp hsp90(RNAi) 
construct for 24 h at different temperatures. Hsp90 expression levels were 
reduced at all temperatures tested. However, the greatest reduction was 
observed at 25oC (49.84% ± 3.82), followed by 20oC (40.48% ± 3.03) and 16oC 
(9.64% ± 7.30). The reduction in Hsp90 expression was significantly different 
from the controls at 20oC and 25oC (p<0.05) but not at 16oC.   
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Figure 5.5:  hsp90(RNAi) was more efficient at higher temperature.  
 
a) Autoradiograph of wild-type N2 Hsp90 expression levels after 24 h feeding on the 300 bp 
hsp90(RNAi) construct at different incubation temperatures. 16oC-Control (Lane 1), 300 bp 
hsp90(RNAi) (Lane 2), 20oC-Control (Lane 3), hsp90(RNAi) (Lane 4), 25oC-Control (Lane 5), 
hsp90(RNAi) (Lane 6).  30 worms were solubilised in 30 µl SDS-PAGE sample cocktail by 
boiling and equal volumes (5 µl) were loaded onto a 10% gel and analysed by Western 
blotting.   
b) Hsp90 levels after 24 h feeding on the 300 bp hsp90(RNAi) construct at different 
temperatures. Results are expressed as the ratio of Hsp90/actin RNAi treated worms 
compared to controls. All values represent the mean ± standard deviation of three 
experiments. All percentages are expressed relative to the appropriate control, which was set 
to 100%. 
16o C-90.35% ± 7.30, 20oC- 58.51% ± 3.03, 25oC-50.16% ± 3.82 
Control vs RNAi treated at 16oC, p = 0.168 
* Control vs RNAi treated at 20oC, p = 0.02 
*
 Control vs RNAi treated at 25oC, p = 0.02 
 
 
Chapter 5    203
       
 
(a) 
 
0
20
40
60
80
100
120
16 20 25
Temperatures 
Hs
p9
0 
ex
pr
es
si
o
n
 
le
v
el
s 
ba
se
d 
o
n
 
Hs
p9
0/
ac
tin
 
ra
tio
 
(%
)
Control hsp90(RNAi)
 
(b) 
 
   
* 
* 
Chapter 5    204
5.2.2.2 Feeding on the 300 bp hsp90(RNAi) construct affects the growth of 
wild-type N2 and produces a phenotype  
For the next hsp90(RNAi) experiment, L4 were fed at 20oC for 24 h on the 
300 bp hsp90(RNAi) construct. Three worms were then transferred onto 
triplicate fresh NGM plates spotted with OP50 and were left for 24 h to let the 
worm lay eggs. The next day, the numbers of eggs were scored. Figure 5.6 shows 
the fertility of wild-type N2 after feeding on empty vector or on the 300 bp 
hsp90(RNAi) construct. The Po wild-type N2 grown on the 300 bp hsp90(RNAi) 
plates had a smaller brood size (58 ± 27) compared to Po wild-type N2 grown on 
control plates (control group 223 ± 12)(p<0.05). These experiments confirmed 
that knock-down of Hsp90 affects the fertility of wild-type N2 worms.  
In addition, other phenotypes were observed in Po RNAi treated worms. 
Figure 5.7 shows the Po worms after 24 h feeding on control plates or on the 
hsp90(RNAi) construct. Control worms appeared normal (Figure 5.7a) while some 
hsp90(RNAi) worms developed a protruding vulva (Figure 5.7b) and a ‘bagging 
effect’ in which eggs hatched and the larvae were released in the body of the 
worm (Figure 5.7c). The F1 generation of control worms were normal (Figure 
5.8a), while a protruding vulva was observed in many hsp90(RNAi) worms (see 
Figure 5.8b). The F1 with protruding vulva were 100% sterile and showed reduced 
motility. A similar phenotype was previously reported in hsp90(RNAi) knock-out 
worms (Gillan et al., 2009) where they reported the wild-type N2 F1 generation 
were infertile.     
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Figure 5.6: Egg counts of wild-type N2 after feeding on the 300 bp hsp90(RNAi) construct. 
 
Fewer eggs were produced in wild-type N2 fed on the 300 bp hsp90(RNAi) construct 
compared to the control group fed on empty vector. N2 were fed on the hsp90(RNAi) 
construct for 24 h at 20oC and three worms were transferred onto new NGM plates seeded 
with OP50. Worms were left for a further 24 h at 20oC and the number of eggs produced was 
counted. 
N2-Control- 223 ± 12 
* N2-RNAi- 58 ± 27 
p = 0.0404 
     
 
 
 
 
 
 
* 
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Figure 5.7: hsp90(RNAi) phenotypes observed in wild-type N2 after 24 h feeding on the 300 bp 
construct. 
 
a) N2 Po after 24 h feeding on the empty vector. 
b) N2 Po after 24 h feeding on the hsp90(RNAi construct. Arrow shows the protruding vulva.   
c) Po of N2 fed on the hsp90(RNAi) construct showing a ‘bagging effect’. Arrow shows the 
larvae hatched within the body of parent worm.  
Worms were viewed on a Carl Zeiss, Stemin SV 6 microscope and images were captured using 
Canon Powershot G6 software. Final magnification x75.   
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Figure 5.8: hsp90(RNAi) phenotypes observed in wild-type N2 after 24 h feeding on the 300 bp 
construct. 
 
a) F1 of N2 fed on empty vector after 24 h, showing normal development. 
b) F1 of N2 fed on 300 bp hsp90(RNAi) construct. Arrow shows protruding vulva.   
Worms were viewed on a Carl Zeiss, Stemin SV 6 microscope and images captured using 
Canon Powershot G6 software. Final magnification x75.     
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5.2.2.3 A shorter hsp90(RNAi) construct reduced the Hsp90 expression 
levels in C. elegans N2  
The aim of the hsp90 knock-down experiments was to reduce the level of 
Hsp90 in an ivermectin resistant strain of C. elegans and to determine whether 
this reduction in Hsp90 level had any effect on sensitivity to drug. For these 
experiments it was important that the reduction in Hsp90 level did not affect 
worm viability. As can be seen in the previous section, the 300 bp hsp90(RNAi) 
construct produced a variety of detrimental phenotypes in N2 worms and 
therefore was not appropriate for use in these experiments. Based on these 
observations, the experiments were repeated using a smaller 75 bp hsp90(RNAi) 
construct. This construct was prepared by Dr. Victoria Gillan as described in 
Materials and Methods (Section 2.3.2.3). In initial experiments, C. elegans N2 
were fed on the 75 bp hsp90(RNAi) construct at different incubation 
temperatures (16oC, 20oC and 25o C) for 24 h. After 24 h, 30 worms were 
solubilised in 30 µl SDS-PAGE sample cocktail and analysed by Western blotting. 
Figure 5.9a shows the autoradiograph of Hsp90 expression in C. elegans N2 fed 
on the 75 bp hsp90(RNAi) construct compared to control empty vector or the 300 
bp hsp90(RNAi) construct at different feeding temperatures. Bands on the 
autoradiograph were scanned and the reduction in Hsp90 levels was estimated 
based on the Hsp90 to actin ratio. The reduction of Hsp90 levels was most 
pronounced in wild-type N2 fed on the longer construct at 20oC or 25oC (Figure 
5.9, Lane 6 and Lane 9). However, even using the shorter 75 bp hsp90(RNAi) 
construct a reduction in Hsp90 levels was observed at all temperatures (Figure 
5.9b). No phenotypes were observed in wild-type N2 fed on the 75 bp 
hsp90(RNAi) construct but the same phenotypes were observed with the 300 bp 
hsp90(RNAi) construct as described previously. This experiment was repeated 
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twice under identical conditions with similar results. For the subsequent 
experiments, the 75 bp hsp90(RNAi) construct was used.  
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Figure 5.9: A comparison of Hsp90 expression levels in C. elegans N2 fed on the 75 bp or 300 
bp hsp90(RNAi) constructs at different feeding temperatures. 
 
a) Autoradiograph of Hsp90 levels in C. elegans N2 fed on control empty vector, 75  bp or 300 bp  
hsp90(RNAi) constructs with actin as a loading control at different feeding temperatures (16oC, 
20oC and 25oC) for 24 h. Wild-type N2 fed on control empty vector (Lane 1, 4, 7), wild-type N2 fed 
on the 75 bp (Lane 2, 5 and 8) or the 300 bp RNAi construct (Lane 3, 6 and 9). An equal volume 
of extract was analysed on a 10% gel followed by Western blotting. Proteins were transferred to 
NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% Tween 20 and then the 
blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. Bound antibody was 
detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. The blot was developed 
using the Pierce Super Signal West Pico chemiluminescence kit.   
b) Graph shows the wild-type N2 Hsp90 expression levels after feeding on the control empty 
vector, 75 bp or 300 bp construct. The greatest reduction in Hsp90 levels was observed at 20oC 
or 25oC in worms fed on the 300 bp hsp90(RNAi) construct. Results represented the mean ± 
standard deviation from two different experiments.                     
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5.2.2.4 Reduction in Hsp90 levels in ivermectin-resistant worms 
In fungi and yeast, reducing Hsp90 levels increased the sensitivity of azole-
resistant strains to drug. In the experiments presented here, the sensitivity of C. 
elegans IVM-10 worms to ivermectin was investigated following hsp90(RNAi) in 
order to ask whether Hsp90 might have a role in ivermectin-resistance. Based on 
the hsp90(RNAi) results shown previously, the 75 bp hsp90(RNAi) construct was 
used in all experiments at a temperature of 20oC for 24 h feeding time. Hsp90 
levels in wild-type N2 and IVM-10 worms were analysed by solubilising 30 worms 
in 30 µl SDS-PAGE sample cocktail and analysing by Western blotting. Figure 
5.10a shows an autoradiograph of Hsp90 expression levels in wild-type N2 and 
IVM-10 worms after feeding on the 75 bp hsp90(RNAi) construct. Hsp90 levels in 
both strains were reduced following 24 h of RNAi (Lane 2 and Lane 4) compared 
to control worms (Lane 1 and 3). The Hsp90 reduction levels were estimated 
based on the density values using FlourChemTM IS-5500 software and a graph was 
plotted. Figure 5.10b shows that Hsp90 expresson levels were significantly 
reduced in wild-type N2 worms (21.64% ± 10.75) and in IVM-10 worms (29.72% ± 
7.17) following 24 h feeding on the 75 bp hsp90(RNAi) construct compared to 
empty vector control for both groups (p<0.05).  
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Figure 5.10: Hsp90 levels in wild-type N2 and IVM-10 resistant worms were reduced after 
feeding on the 75 bp hsp90(RNAi) construct 
 
a) Autoradiograph shows Hsp90 levels after 24 h of RNAi with actin as a loading control at 
20oC. Wild-type N2 fed on the empty vector construct (Lane 1), 75 bp construct (Lane 2), IVM-
10 worms fed on the empty construct (Lane 3) and 75 bp construct (Lane 4). 5 µl of each 
sample was loaded onto a 10% gel and analysed by SDS-PAGE and Western blotting. Proteins 
were transferred to NCP using standard methods, blocked o/n in 5% dried milk in PBS/0.5% 
Tween 20 and then the blot probed with 1:5000 dilution of the B. pahangi anti-Hsp90 antibody. 
Bound antibody was detected using a 1:10,000 dilution of anti-rabbit IgG conjugated to HRP. 
For the loading control, anti-actin antibody was used at 1:1000 dilution and bound protein was 
detected using anti-mouse IgG at 1:10,000. The blot was developed using the Pierce Super 
Signal West Pico chemiluminescence kit.      
b) Graph shows the Hsp90 expression levels after feeding on the 75 bp hsp90(RNAi) construct 
based on the integrated density value quantified using FlourChemTM Is-5500 software. Results 
presented the percentage of mean ± standard deviation of Hsp90/actin ratio from three 
different experiments. The Hsp90 levels of worms fed on the empty vector was set at 100%.    
C. elegans N2 reduction in Hsp90 level vs N2-Control = 21.64 % ± 10.75 
IVM-10 reduction in Hsp90 level vs IVM-10-Control = 29.72 %  ± 7.17 
*N2-Control vs N2-RNAi, p = 0.037 
*IVM-10-Control vs IVM-10-RNAi, p = 0.009 
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In addition, egg production by adult worms was also was analysed in these 
experiments. Three worms were placed onto each of three fresh NGM plates 
seeded with OP50 after feeding on the 75 bp hsp90(RNAi) construct or on empty 
vector for 24 h. Plates were incubated at 20oC for further 24 h. At this point 
worms were removed from the plates and the number of eggs counted. Figure 
5.11 shows the egg production by wild-type N2 and IVM-10 worms in a typical 
RNAi experiment. Wild-type N2 fed on the empty vector construct produced 245 
± 75 eggs over the 24 h period, compared to 160 ± 64 eggs by worms fed on the 
75 bp hsp90(RNAi) construct. IVM-10 worms fed on the empty construct 
produced 186 ± 68 eggs compared to 126 ± 43 by worms fed on the 75 bp 
hsp90(RNAi) construct. However, the difference is not significant (p>0.05). 
Further observation of the F1 generation feeding on the 75 bp hsp90(RNAi) 
construct showed that the F1 generation were fertile and appeared normal 
compared to the F1 generation feeding on the empty construct. This experiment 
indicated that the reduction in Hsp90 levels by feeding on the 75 bp hsp90(RNAi) 
construct did not significantly affect egg production or worm viability.   
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Figure 5.11: Egg production by wild-type N2 and IVM-10 worms fed on the 75 bp 
hsp90(RNAi) construct. 
 
No significant difference was observed in egg production in wild-type N2 and IVM-10 worms 
fed on the 75 bp hsp90(RNAi) construct compared to controls (p>0.05). Wild-type N2 or IVM-
10 worms were fed on the 75 bp hsp90(RNAi) construct for 24 h at 20oC. Three worms were 
then transferred onto each of three new NGM plates seeded with OP50. Worms were left for 
further 24 h at 20oC and the number of eggs counted. Results presented are the mean ± 
standard deviation of eggs produced by wild-type N2 or IVM-10 worms from three different 
experiments.  
N2-Control vs N2-RNAi, p = 0.1904 
IVM-10-Control vs IVM-10-RNAi, p = 0.3827 
N2-Control vs IVM-10-Control, p = 0.6625 
N2-RNAi vs IVM-10-RNAi, p = 0.6625 
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5.2.2.5 Reduction in Hsp90 levels alters the ivermectin-resistant 
phenotype 
Previous results showed that Hsp90 levels were reduced in wild-type N2 and 
IVM-10 resistant worms fed on the 75 bp hsp90(RNAi) construct for 24 h at 20oC. 
However, the RNAi conditions did not affect the growth or the fertility of the 
worms. The aim of this work was to ask whether a reduction in Hsp90 levels 
could alter the ivermectin-resistant phenotype of IVM-10 worms. To assess the 
sensitivity of the RNAi-treated worm to drug, wild-type N2 or IVM-10 worms were 
fed on the 75 bp hsp90(RNAi) construct at 20oC for 24 h. Then 5 worms were 
transferred to each of 6 wells of a 24-well microtitre plate containing ivermectin 
at different concentrations (0, 1, 5 and 10 ng/ml). OP50 was added to each well 
and the plates were incubated at 20oC. Worm motility was scored at 24 h and 
again at 48 h as described in Materials and Methods (Section 2.3.2.3). Figure 
5.12a shows the results of the motility assay at 24 h and in Figure 5.12b, the 48 
h results. At 24 h, motility of worms in all groups was similar at all 
concentrations of ivermectin. However by 48 h, wild-type N2 worms showed a 
reduced motility which was most apparent at 10 ng/ml ivermectin. In contrast, 
IVM-10 worms fed on empty vector maintained the tolerance to drug, while 
worms fed on the 75 bp hsp90(RNAi) construct behaved more like the wild-type 
N2 control i.e. their motility was compromised in the presence of ivermectin. 
This experiment was repeated three times with similar results. 
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Figure 5.12: A reduction in Hsp90 levels alters the sensitivity of IVM-10 ivermectin-resistant 
worm to drug. 
 
Wild-type N2 or IVM-10 resistant worms were fed on the 75 bp hsp90(RNAi) or on empty vector  
for 24 h at 20oC, followed by incubation in liquid culture containing ivermectin at different 
concentrations (0, 1, 5 and 10 ng/ml) at 20oC for 24 h or 48 h . After 24 h (Panel a) or 48 h 
(Panel b) the motility of the worms was scored. Graph presented here shows the mean ± 
standard deviation of three different experiments.  
Worm motility was scored based on the activity of the worms in liquid containing different 
concentrations of ivermectin at 24 h and 48 h. The scoring system for the motility assay is 
shown below.  
Activity Score 
Thrashing 
Slow 
Paralysed 
Dead 
3 
2 
1 
0 
  
   
30 worms for each concentration of drug were scored individually. The score then converted 
to a numerical value and expressed as a percentage of the maximum score (90 = 30 worms x 
3).  
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The data shown in Figure 5.12 is presented in more detail in Figure 5.13. At 
24 h there was little difference overall in the motility of wild-type N2 and IVM-10 
worms fed on the 75 bp hsp90(RNAi) construct. However, two groups showed a 
small but significant difference in motility between RNAi and empty vector 
controls (p<0.05)(Figure 5.13a). The first group was wild-type N2 incubated 
without ivermectin and the second was IVM-10 worms incubated in 10 ng/ml 
ivermectin. In both cases, there was a reduction in motility in RNAi-treated 
worms.  
At 48 h, wild-type N2 worms incubated in increasing concentrations of 
ivermectin showed a progressive reduction in motility, irrespective of RNAi 
treatment or not, except for those incubated in the highest concentration of 
ivermectin (10 ng/ml)(Figure 5.13b). In this group there was a significant 
difference between the motility of RNAi-treated worms compared to controls. 
No differences were observed in IVM-10 worms incubated without drug or with 
drug at 1 ng/ml, irrespective of RNAi treatment. However, at higher 
concentrations of ivermectin (5 and 10 ng/ml), a significant difference was 
observed between control and RNAi-treated IVM-10 worms. The motility of the 
RNAi group was significantly reduced compared to the control empty vector. 
These results indicate that reducing Hsp90 levels in IVM-10 resistant worms 
alters the sensitivity of the worms to high levels of ivermectin. 
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Figure 5.13: Motility assays of wild-type N2 and IVM-10 worms following hsp90(RNAi). 
 
Wild-type N2 or IVM-10 ivermectin resistant worms were fed on the 75 bp hsp90(RNAi) or on 
empty vector construct for 24 h at 20oC, followed by incubation in liquid culture containing 
ivermectin at different concentrations (0, 1, 5 and 10 ng/ml) at 20oC for 24 h or 48 h. The 
motility of the worms scored after 24 h or 48 h. Graph presented here shows the mean ± 
standard deviation of three different experiments.  
a)  24 h 
*N2-Control vs N2- RNAi at 0 ng/ml, p = 0.0087 
N2-Control vs N2-RNAi at 1 ng/ml, p = 0.0557 
N2-Control vs N2-RNAi at 5 ng/ml, p = 0.0714 
N2-Control vs N2-RNAi at 10 ng/ml, p = 0.5582  
IVM-10-Control vs IVM-10- RNAi at 0 ng/ml, p = 0.3155  
IVM-10-Control vs IVM-10-RNAi at 1 ng/ml, p = 0.5881 
IVM-10-Control vs IVM-10-RNAi at 5 ng/ml, p = 0.1387 
*IVM-10-Control vs IVM-10-RNAi at 10 ng/ml, p = 0.0451 
b) 48 h 
N2-Control vs N2-RNAi at 0 ng/ml, p = 0.2103 
N2-Control vs N2-RNAi at 1 ng/ml, p = 0.7475  
N2-Control vs N2-RNAi at 5 ng/ml, p = 0.3700 
*N2-Control vs N2-RNAi at 10 ng/ml, p = 0.0315 
IVM-10-Control vs IVM-10-RNAi at 0 ng/ml, p = 0.3674 
IVM-10-Control vs IVM-10-RNAi at 1 ng/ml, p = 0.8037 
*IVM-10-Control vs IVM-10-RNAi at 5 ng/ml, p = 0.0435 
*IVM-10-Control vs IVM-10-RNAi at 10 ng/ml, p = 0.046 
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5.3 Discussion  
Drug resistance is already a serious problem in nematode parasites of 
livestock and also is also a growing issue in human health e.g. in onchocerciasis 
(Boussinesq, 2008). While treatment still relies upon the use of anthelmintics, 
there is a need to understand the mechanisms of drug resistance. Recently, 
Hsp90 was suggested to mediate drug resistance in fungi (Cowen & Lindquist, 
2005; Singh et al., 2009). In this Chapter, the possible role of Hsp90 in mediating 
anthelmintic resistance was investigated by comparing Hsp90 levels in resistant 
and susceptible nematodes. Furthermore, in RNAi experiments, levels of Hsp90 
were reduced in order to determine whether a reduction in Hsp90 levels could 
alter the response of drug resistant worms to ivermectin.     
The most direct approach to study anthelmintic resistance is by the 
comparative analysis of resistant and susceptible parasites isolated directly from 
the field. The T. circumcincta isolate, Tci5 was characterised by Bartley et al 
(2005) and shown to be resistant to the three broad spectrum anthelmintic 
groups. In contrast, the Tci2 isolate is susceptible to all anthelmintic groups. The 
T. circumcincta Tci5 and Tci2 isolates were compared but no significant 
difference was observed in Hsp90 levels. Next Hsp90 levels were compared in 
two C. elegans strains where resistance was acquired by mutagenesis, namely C. 
elegans CB3464 and DA1316. The CB3464 strain is resistant to benzimidazole 
compounds, while the DA1316 strain shows a high level of resistant to ivermectin 
(Dent et al., 2000). Again, no difference in Hsp90 levels was observed between 
these worms and wild-type N2 controls. These assays were conducted in the 
absence of drug pressure. In future studies it would be interesting to compare 
Hsp90 levels in the presence of the relevant drug, to rule out the possibility that 
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drug exposure induces increased expression of Hsp90. Finally, Hsp90 levels were 
compared in ivermectin resistant C. elegans where resistance was acquired by 
continuous passage on plates containing drug. These worms were resistant to 
ivermectin at 6 ng/ml or 10 ng/ml. According to James & Davey (2009), IVM-6 
worms show a 4.5-fold difference and IVM-10 worms a 19-fold difference in IC50 
sensitivity to ivermectin compared to wild-type N2 worms. In that study they 
also showed that resistance might be associated with increased expression of 
drug pumps such as mrp-1 and pgp-1. These worms are not only resistant to 
ivermectin but also showed a cross-resistance to moxidectin, levamisole and 
pyrantel but not to albendazole (James & Davey, 2009). However, no difference 
was observed in Hsp90 levels between IVM-6, IVM-10 and wild-type N2 worms. 
C. elegans was shown to be a useful model to study parasitic nematodes 
(Blaxter, 1998; Gilleard, 2004).  Using RNAi to knock-down or to reduce the 
expression of certain genes can result in an observable phenotype. Results 
presented in this Chapter show that feeding C. elegans with E. coli expressing 
dsRNA (300 bp hsp90(RNAi) construct) reduced the Hsp90 levels by 
approximately 40% and produced a phenotype. The cessation of egg production 
and a protruding vulva was observed in P0 worms and in the progeny suggesting 
that Hsp90 is required during oogenesis or embryogenesis. The RNAi study by 
Piano et al (2000) shows that injection of C. elegans with hsp90 dsRNA results in 
an embryonic lethal phenotype in the progeny and the cessation of egg 
production in hermaphrodite worms. Gillan et al (2009) showed that the progeny 
of wild-type N2 fed on hsp90(RNAi) were infertile and had reduced motility. 
These results indicate that Hsp90 is important in worm fertility and viability. 
Because of the deleterious effects observed with the 300 bp hsp90(RNAi) 
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constuct, a shorter construct was used in subsequent experiments. Worms fed on 
the 75 bp hsp90(hsp90) construct did not show any obvious phenotype but Hsp90 
levels were reduced.  
In the initial RNAi experiments, IVM-6 worms were used but no affect on 
tolerance to ivermectin was observed when Hsp90 levels were reduced using the 
75 bp hsp90(RNAi) construct (data not shown). As IVM-10 worms are significantly 
more resistant to ivermectin, the experiments were repeated using this strain. 
hsp90(RNAi) was carried out and C. elegans N2 and IVM-10 worms were 
subjected to a drug cytotoxicity assay as described in Materials and Methods 
(Section 2.3.2.2) on NGM plates containing ivermectin at increasing 
concentrations (1, 5 or 10 ng/ml ivermectin). However, in all cases, the RNAi-
treated worms crawled off the drug plates. This experiment was repeated 
several times with the same results (data not shown). It remains unclear why the 
RNAi-treated worms should crawl off the plates, but it is possible that a 
reduction in Hsp90 levels affects the ability of C. elegans to sense food, or 
perhaps more likely induces an aversion response of the worm to ivermectin. In 
C. elegans hsp90 was shown to be required for regulation of specific 
chemosensory behaviours (Birnby et al., 2000; Morley & Morimoto, 2004). 
Consequently to overcome this problem, worms were subjected to a motility 
assay in liquid culture containing ivermectin with OP50 as a food source. In the 
RNAi experiments, reducing Hsp90 levels in IVM-10 ivermectin resistant worms 
significantly altered the sensitivity to ivermectin but only at 5 and 10 ng/ml 
ivermectin. It was noteable that only 10-14% of wild-type N2 worms survived 
after 48 h on 10 ng/ml ivermectin, while more than 63% of control IVM-10 worms 
survived this concentration of drug. In contrast, the survival of the IVM-10 worms 
following RNAi was severely compromised. While the results presented in this 
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Chapter do not indicate how a reduction in Hsp90 levels affects the response to 
ivermectin, these results do support the hypothesis that Hsp90 may be involved 
in tolerance of high concentration of ivermection.  
The best explanation of how Hsp90 mediates drug resistance comes from 
studies on yeast (Cowen & Lindquist, 2005; Singh et al., 2009). In azole resistant 
yeast, resistance was suggested to be associated with calcineurin, an Hsp90 
client protein. According to Fox & Heitman (2002), calcineurin acts as a 
regulator for cell cycle progression, morphorgenesis and virulence. Hsp90 binds 
to the catalytic subunit of calcineurin keeping it stable and poised for activation 
(Imai et al., 2000; Kumar et al., 2005).  In the presence of azoles, Hsp90 
regulates membrane responses that are vital for cells to survive. Importantly 
Cowen & Lindquist (2005) showed that the response of azole resistant yeast to 
drug was altered by genetic or chemical inhibition of Hsp90 and that inhibition 
of calcineurin function by Cyclosporin A or FK506 (inhibitor of calcineurin) 
phenocopied Hsp90 inhibition. Thus, Hsp90 potentiates drug resistance in yeast 
via calcineurin.   
There are also several reports that suggest that Hsp90 may have a role in 
drug resistance in tumour cells (Betram et al., 1996; Davies et al., 2002; Xing et 
al., 2008). For example, Xing et al (2008) showed that activation of the 
phosphatidylinositol 3-kinase (PI-3K/Akt2) pathway has a crucial role in inducing 
resistance to docetexal in ovarian and breast cancer cells. The PI-3K/Akt2 
pathway has been shown to be important in promoting cell proliferation and 
inhibiting cell death. Most importantly, Akt is a serine-threonine kinase and an 
Hsp90 client protein, forming a complex with Hsp90 (Sato et al., 2000). Thus, it 
suggests that in some cancer cells, activation of PI-3K/Akt2 pathway which is 
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modulated by Hsp90, is important in docetexal resistance (Xing et al., 2008). In 
another study in cancer chemotherapy, drug resistance was suggested to be 
associated with P-gp and Hsp90β (Betram et al., 1996). Hsp90β was shown to be 
co-precipitated along with P-gp. P-gp is a member of the ATP-binding cassette 
transporter family encoded by the gene MDR1 and previously implicated in the 
multi-drug resistance phenotype (Ueda et al., 1987). The results suggest an 
intracellular co-operation between Hsp90β and P-gp and the involvement of 
Hsp90β in multi-drug resistant colon carcinoma (Betram et al., 1996). In 
addition, a study by Liu et al (1999) showed that reducing Hsp90 levels using 
antisense RNA increased the sensitivity of human gastric and hepatic cancer cells 
to drugs compared to parental cells, which again indicates a possible role of 
Hsp90 in resistance to chemotherapeutic agents in tumour cells.        
 
In conclusion, the role of Hsp90 in acquired drug resistance in nematodes 
deserves further study. The mechanisms of anthelmintic resistance in nematodes 
are not are properly understood but are likely to be complicated. The 
contribution of Hsp90 to drug resistance might be a general mechanism that 
relates the cellular stress response with the stress induced by drug exposure. 
Future investigation of the composition, structure and function of Hsp90 
complexes in nematodes may unlock new possibilities for the treatment of 
anthelmintic resistant nematodes. 
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6 General discussion 
The exposure of any living cell or organism to environmental stress, 
including elevated temperature, chemical or oxidative stress, results in the 
synthesis of proteins known as heat shock proteins (Hsps). Hsps are among the 
most highly conserved of all proteins and are present in most eukaryotic and 
prokaryotic organisms. Consequently the study of Hsps has been of much interest 
in biology. Hsp90, the focus of this thesis, is an essential highly conserved 
protein, which is present in most organisms tested.  
Hsps in host-parasite interactions: What do we know?   
The role of Hsps in host-parasite interactions has received considerable 
attention from both clinical and biological perspectives. From the host point of 
view, Hsps expressed by invading parasites are potent antigens that induce 
immune responses (Polla, 1991; Kaufmann, 1992; Maresca et al., 1994). Thus, 
according to Newport (1991), parasite Hsps are potentially useful in generating 
vaccines. From the parasite point of view, the synthesis of Hsps may represent a 
cellular defense mechanism that favours adaptation of the parasite to different 
environments throughout its life-cycle (Tsuji et al., 1997).  
Parasites that are transmitted to mammalian hosts from the environment 
or from a vector undergo profound changes in temperature during the transition 
to these hosts (with internal temperatures of 37oC or above). The induction of 
Hsps commonly accompanies this transition. Numerous studies have 
demonstrated the developmental regulation of Hsp expression in parasites (Van 
der Ploeg et al., 1985; Devaney & Lewis, 1993; Ernani et al., 1993; Neumann et 
al., 1993; Hartman et al., 2003); expression differs throughout the life-cycle 
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both quantitatively and in the types of Hsps induced. For example Brugia 
pahangi requires two hosts to complete its life-cycle and the temperature shift 
experienced by Mf from 37o C in the mammalian host to 28o C in the mosquito is 
a requirement for development to proceed (Devaney & Lewis, 1993). According 
to Jecock & Devaney (1992), different types of Hsps are expressed in the Mf and 
the L3 of B. pahangi. Their observations show that a range of Hsps were 
expressed in Mf at 37o C and repressed after transfer to 28o C. The most 
abundant proteins identified were small Hsps and these were shown to be 
synthesised only in Mf at 37oC (Devaney et al., 1996). In contrast, in the L3, the 
expression of Hsps is temporary and corresponds with the transition from the 
mosquito to the mammalian host. These studies show that in the Mf and the L3 
of B. pahangi, the transmission between hosts is complemented by alterations in 
gene expression and that temperature induces the expression of certain genes.   
For parasitic species that do not involve a vector in their life-cycle, the 
free-living stage occurs in water or soil. Hsp expression accompanies the 
transition from the environment into the definitive host. In Haemonchus 
contortus, Hsp20 was identified and shown to be constitutively expressed in the 
L3, early L4 and adult stages (Hartman et al., 2003). It was proposed that the 
presence of Hsp20 in the L3 may indicate that this protein plays a role in 
preparation for the transition from pasture to mammalian host (Hartman et al., 
2003). It was also suggested that the presence of Hsp20 in the adult worm may 
be due to its expression in eggs, as an early adaptation to cold shock when eggs 
are passed out of the host onto the pasture. Thus, many Hsps appear to be 
expressed in parasites to co-incide with environmental transitions. In contrast to 
these findings, Hsp90 is expressed constitutively throughout the B. pahangi life-
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cycle. This presumably relates to the fact that some Hsps also play important 
roles under normal conditions of growth.   
Why is there a difference amongst nematodes in GA-binding? 
Much of the work described in this thesis was concerned with 
understanding why some nematode Hsp90s bind to GA, while others do not. The 
variability in GA-binding may relate to differences in nematode life-cycles and 
the environments in which they live. Nematodes are a remarkably successful 
group within the Animal Kingdom. While most nematodes are free-living, 
parasitic species play a significant role in regulating the productivity of wild 
populations, and impact negatively on human agriculture as well as human 
health. Nematodes are abundant and have successfully adapted to nearly every 
habitat from marine to fresh water, from the polar region to the tropics, as well 
as the highest to the lowest of elevations.  
The contradictory affinity of Hsp90 from Caenorhabditis elegans and B. 
pahangi for GA is interesting, given the degree of conservation between the two 
proteins. The first report on the failure of C. elegans Hsp90 to bind to GA came 
from David et al (2003), with similar results reported by Devaney et al (2005). C. 
elegans is a free-living nematode that resides in clade V of the nematode 
phylogeny together with important parasitic nematodes such as H. contortus, 
Teladosargia circumcincta, Heligmosomoides polygyrus etc. The ecology of these 
species is very diverse. According to Kiontke & Sudhaus (2006), the actual niche 
of C. elegans in the environment remains unknown. In the wild, C. elegans is 
usually found as a stress-resistant dauer form, which is non-feeding. The study 
by David et al (2003) demonstrated that C. elegans is insensitive to GA 
treatment as exposure to high concentration of GA did not produce any 
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phenotype. A recent study by Taldone et al (2010) validated this finding using a 
sensitive fluorescence polarisation assay in which GA also failed to bind to C. 
elegans Hsp90. Analysis of hsp90 sequences from a range of nematode species 
demonstrated three separate lineages for hsp90 sequences which correlated 
with the ability to bind GA (Him et al., 2009). However, in that study, no direct 
relationship between amino acid substitutions in Hsp90 and GA binding ability 
was observed. These data suggest that the evolution of hsp90 may correlate with 
key functions other than the ability to bind GA.  
Darwin argued that natural selection causes traits that aid survival to 
become more common, while traits that hinder survival become rare. Over many 
generations, successful random changes are filtered by natural selection and 
retained. In this way an organism can adapt to its environment. C. elegans might 
be adapted to survive exposure to GA in soil. Interestingly, Hsp90 from parasitic 
species that have free-living larvae in the environment also failed to bind GA, 
while Hsp90 from those species that are protected from the environment by an 
egg shell or are permanently parasitic, did bind to GA. The results presented in 
this thesis therefore support the ‘adaptation theory’ as proposed by David et al 
(2003).  
Alternatively there are additional explanations that may explain the 
different sensitivity of B. pahangi and C. elegans to GA. While C. elegans Hsp90 
fails to bind to GA, it retains its ability to bind to ATP. Although differences 
were observed in the level of expression of Hsp90 in B. pahangi and C. elegans, 
both proteins bound to ATP beads in binding assay. However, studies using more 
sophisticated approaches would be necessary to ascertain whether the ATPase 
activity of B. pahangi and C. elegans Hsp90 differs. In addition, Hsp90 is known 
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to be modified significantly, by phosphorylation, acetylation and glycosylation 
(Chiosis et al., 2004; Scroggins and Neckers, 2007; Scroggins et al., 2007; Yang 
et al., 2008). These post-translational modifications alter its activity in a range 
of assays. A recent study on Plasmodium falciparum Hsp90 showed that 
differences in acetylation affected sensitivity to GA (Pallavi et al., 2010). 
However to date, very little is known of the modifications of Hsp90 in 
nematodes. In this thesis, no evidence was produced that post-translational 
modifications are associated with the ability of human Hsp90 to bind to GA, but 
further studies are required to determine the role of such modifications in GA-
binding in nematodes.  
Could Hsp90 be a new target for filarial worms?  
Previous studies by Devaney et al (2005) on B. pahangi showed that GA 
treatment not only kills the Mf but also kills the adult worms in vitro. Both 
male and female worms are susceptible to GA. In addition, the production of 
Mf by adult was inhibited within 24 h of exposure to the drug. While, the 
mechanism by which GA kills the worm is unknown, these results indicate that 
inhibition of Hsp90 activity may represent a novel target for chemotherapy of 
filariasis. The results in Chapter 4 show that only a small amount of cytosolic 
Hsp90 bound to GA in the pull-down assays. This may suggest that inhibition of 
a small proportion of Hsp90 is sufficient to kill the worms. By analogy with its 
effects on mammalian cells, GA most likely kills filarial parasites by disrupting 
interactions between Hsp90 and key client proteins that are required for 
viability. Consequently attempts were made to identify client proteins of 
Hsp90 in adult B. pahangi using a proteomic approach. While key proteins of 
Hsp90 have been identified in mammalian cells and yeast, fewer interactions 
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have been identified in nematodes. In C. elegans, 68 proteins are predicted to 
interact with Hsp90 (www.wormbase.org), but mostly of these interactions 
have not been experimentally validated. In this thesis, several proteins were 
identified in the proteomic analysis, but these were mostly structural proteins. 
Although the 2D-gel analysis did not provide a list of possible Hsp90 client 
protein, further studies should be carried out using the more sensitive DIGE 
method. Recent studies in other organisms have used a similar approach to 
successfully identify a range of client proteins or co-chaperones of Hsp90 
(Tsayler et al., 2009; Garcia-Descalzo et al., 2010). Hsp90 was shown to be 
secreted in the ES product of Brugia malayi (Kumari et al., 1994) and B. 
pahangi (this thesis). It would be interesting in future studies to compare the 
ES proteome of adult worms cultured with or without GA to investigate 
whether any ES products are dependent upon Hsp90 for their activity.   
Does Hsp90 mediate drug resistance in nematodes?  
The role of Hsp90 in anthelmintic resistance remains unresolved. In 
fungi, Hsp90 was shown to be involved in drug resistance. Hsp90 was suggested 
to act as a capacitor of phenotypic variation, buffering genetic variation in 
Drosophila melanogaster (Rutherford & Lindquist, 1998; Sollars et al., 2003) 
and Arabidopsis thaliana (Queitsch et al., 2002). These studies demonstrated 
that challenging Hsp90 function by mutation, pharmacological means or 
environmental stress can produce novel heritable phenotypes. The heritable 
phenotype is passed to the new generation even when Hsp90 levels return to 
normal. Through studies in Drosophila (Rutherford & Lindquist, 1998), a role 
for Hsp90 in evolutionary adaptation was proposed. Hsp90 functions as a 
chaperone for mutant proteins, and allows them to act functionally as normal 
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proteins. These mutations tend to accumulate under the protection of Hsp90. 
When the accumulated mutations surpass the normal Hsp90 threshold as a 
result of environmental stress or inhibition of Hsp90 function, various 
mutations were expressed. Therefore, Hsp90 has the capacity to ‘buffer’ the 
expression of mutations and release these in response to environmental stress. 
The exposure of nematodes to anthelmintic presumably represents a stress and 
induction of Hsps may help nematodes survive that stress. However, whether 
Hsp90 may ‘buffer’ genetic changes in nematodes remains unclear. Results in 
this thesis suggest that Hsp90 might have a role in drug resistance in C. 
elegans, but the mechanism by which Hsp90 might function in resistance in 
nematodes remains to be ascertained. 
Conclusion 
The present study presents a comparative analysis of Hsp90 in nematodes 
and investigates its possible role in drug resistance. Although a high degree of 
sequence similarity is observed when comparing Hsp90 amino acid sequences in 
nematodes, it remains possible that subtle differences in Hsp90 sequence may 
confer differential sensitivity to GA as recently demonstrated in the yeast, 
Humicola fuscoatra, where a single conservative mutation in Hsp90 altered 
sensitivity to radicicol (Prodromou et al., 2009). Additionally, defining the Hsp90 
complexes in B. pahangi and identifying those which are essential for filarial 
viability may provide additional novel targets for the chemotherapy of filariasis.  
Future studies should consider the role of client proteins/co-chaperones in 
Hsp90 activity, the differences in the charged region of Hsp90 and perhaps the 
internal interactions between domains. Further research addressing the possible 
roles of Hsp90 in drug resistance should be carried out. This could be achieved 
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by implementing more sensitive approaches which may be able to identify novel 
targets that might be responsible for acquired drug resistance in nematodes.     
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Appendix 1: Worm materials 
Nematode Source 
 
Trichinella spiralis 
Trichuris muris 
 
Dr. C. Lawrence, University of Strathclyde 
Prof. R. Grencis, University of Manchester 
 
Brugia pahangi 
Dirofilaria immitis 
Onchocerca ochengi 
Acanthocheilonema viteae 
Toxocara cati 
Ascaris suum 
Parascaris equorum 
Anisakis simplex 
Pseudoterranova decipiens 
Anguillicola crassus 
 
Veterinary Infection and Immunity, University of Glasgow 
Dr. J. Foster, New England BioLabs 
Dr. B. Makepeace, Liverpool School of Tropical Medicine 
Prof. W. Harnett, University of Strathclyde 
Mr. J. McGoldrick, Vet School, University of Glasgow 
Prof. A. Maule, Queens University Belfast 
Prof. J. Matthews, Moredun Research Institute 
Dr. S. Martin, University of Aberdeen 
Dr. I. Coombs, University of Glasgow 
Dr. I. Coombs, University of Glasgow 
 
Strongyloides ratti 
Panagrellus redivivus 
Globodera rostochiensis 
Globodera pallida 
Prof. M. Viney, University of Bristol 
Prof. A. Maule, Queens University Belfast 
Dr. J. Jones, Scottish Crop Research Institute 
Dr. C. Fleming, Agri-Food and Bioscience Institute, Belfast 
 
Caenorhabditis elegans 
Caenorhabditis briggsae 
Oscheius tipulae 
Pristionchus pacificus 
Haemonchus contortus 
Heligmosomoides polygyrus 
Teleodorsargia circumcincta 
Nippostrongylus brasiliensis 
C. elegans Genetics Center 
C. elegans Genetics Center 
C. elegans Genetics Center 
C. elegans Genetics Center 
Prof. D. Knox, Moredun Research Institute 
Prof. R. Maizels, Universitiy of Edinburgh 
Prof. D. Knox, Moredun Research Institute 
Prof. R. Maizels, Universitiy of Edinburgh 
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Appendix 2: Buffers and stock solutions 
2.1 Buffers for use in pull-down assays 
2.1.1 TNES buffer 
TNES contains 50 mM Tric-HCl pH 7.4, 100 mM NaCl, 2 mM EDTA, 1% Igepal CA-
630 (SIGMA, UK) in 100 ml ddH2O. Store at room temperature. Add protease 
inhibitor prior to use. 
2.1.2 SkBr3 lysis buffer 
Buffer consists of 50 mM Tris-HCl, pH 7.5, 1% NP40, 2 mM EDTA, 100 MM NaCl. 
Store at room temperature. Add protease inhibitor prior to use. 
2.1.3 GA-biotin lysis buffer 
Buffer consists 20 mM HEPES, 5 nM MgCl2, 1mM EDTA, 100 mM KCl, 0.03% NP-40, 
1% Triton X-100. Store at room temperature. Add protease inhibitor prior to use. 
2.1.4 ATP-binding buffer 
Buffer consists of 20 mm HEPES, 50 mM KCl, 6 mM MgCl2, 0.01% NP40, pH 7.4 in 
100 ml total volume. Store at room temperature.  
2.2 SDS-PAGE and Western blotting buffers and 
solutions 
2.2.1 1x SDS-PAGE sample cocktail  
50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.1% Bromophenol blue, 100 mM 
DTT. Aliquot and store at -20oC before use.   
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2.2.2 10% (w/v) APS 
Dissolve 1000 mg ammonium persulfate (APS) with 10 ml ddH2O. Aliquot and 
store at -20oC.  
2.2.3 10% (w/v) SDS 
Dissolve 10 g SDS in 90 ml ddH2O and bring to 100 ml with ddH2O and store at 
room temperature. 
2.2.4 10x SDS-PAGE running buffer, pH 8.3 (makes 1 L) 
Dissolve 30.3 g Tris-base, 144.0 g Glycine, and 10.0 g SDS with ddH2O up to 1 L 
of total volume and store at 4oC before use. Dilute 50 ml of 10x stock with 450 
ml ddH2O for each electrophoresis.  
2.2.5 Western blotting buffer/Transfer buffer (makes 1 L) 
Dissolve 3.03 g Tris-base, 42.3 g Glycine, add 200 ml Methanol and ddH2O to 
1000 ml. Store buffer at 4oC before use. 
2.2.6 1.5 M Tris-HCl, pH 8.8 
Dissolve 27.23 g Tris-base in 80 ml ddH2O. Adjust to pH 8.8 with HCl. Bring total 
volume to 150 ml with ddH2O and store at 4
oC. 
2.2.7 0.5 M Tris-HCl, pH 6.8 
Dissolve 6 g Tris base in 60 ml ddH2O. Adjust to pH 6.8 with HCl. Bring total 
volume to 100 ml with ddH2O and store at 4
oC. 
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2.2.8 Gel formulation (10% SDS-PAGE gel) 
For 10% resolving gel, add 4.1 ml ddH2O, 3.3 ml 30% Acrylamide/Bis, 2.5 ml 1.5 
M Tris-HCl pH 8.3, 0.1 ml 10% (w/v) SDS, 50 µl 10% (w/v) APS and 5.0 µl TEMED. 
For 5% stacking gel, add 5.7 ml ddH2O, 1.7 ml 30% Acrylamide/Bis, 2.5 ml 0.5 M 
Tris-HCl pH 6.8, 0.1 ml 10% (w/v) SDS, 50 µl 10% (w/v) APS and 10.0 µl TEMED. 
2.2.9 5% (w/v) dried milk solution 
Dissolve 2.5 g of dried milk to 50.0 ml PBS/Tween20. Prepare fresh as required.  
2.2.10 Incubation/blocking buffer for Western blotting 
Add 16.0 ml of PBS/Tween20, 4.0 ml of 5% dried milk and 200 µl of FCS to give 
total volume 20.0 ml. Prepare within 5 min of use.  
2.2.11 Washing buffer 
Dissolve one pack of PBS (Sigma, UK), 500 µl Tween20 in 1 L ddH2O. Store at 4
oC.  
2.3 Staining solutions 
2.3.1 Coomassie blue staining R-250 (makes 2.5 L) 
Dissolve 2.5 g of Coomassie blue in 1.125 L methanol, 1.125 L ddH2O and 250 ml 
acetic acid and keep at room temperature. 
2.3.2 Coomassie blue staining G-250 (makes 500 ml) 
Dissolve 2.5 g of Coomassie blue in 250 ml methanol, 50 ml acetic acid and 200 
ml ddH2O and keep at room temperature.  
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2.3.3 Destaining solution (makes 1.7 L, 10% acetic acid solution) 
Add 175 ml of acetic acid and 500 ml methanol to 1.025 L of ddH2O and store at 
room temperature.  
2.3.4 Silver staining (Bio-Rad, UK. Cat: 161-0449) 
2.3.4.1 Fixative enhancer solution (makes 400 ml)  
Add 200 ml methanol, 40 ml acetic acid and 40 ml fixation enhancer 
concentrate, 120 ml ddH2O to give total volume of 400 ml. 
2.3.4.2 Staining solution (makes 100 ml) 
Add 35 ml ddH2O, 5.0 ml silver complex solution, 5.0 ml reduction moderator 
solution, 5.0 ml image development reagent and 50 ml development accelerator 
solution. Prepare within 5 min of use.   
2.3.4.3 Stop solution (5% (v/v) acetic acid solution) 
Add 50 ml acetic acid and ddH2O up to 1 L and store at room temperature. 
2.3.5 Ponceau S 
Add 3.0 g of TCA (Trichloroacetic acid) to 100 ml of ddH2O and add 0.2 g of 
Ponceau S. Store at room temperature. 
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Appendix 3: Proteomic analysis buffers and stock 
solutions 
3.1 Lysis buffer  
Buffer consists of 8 M urea, 4% CHAPS (w/v) and 100 mM Tris-base in 25 ml. 
Aliquot and store at -20oC before use. Add protease inhibitor prior to use.  
3.2 80% acetone 
Add 80 ml acetone to 20 ml ddH2O (v/v). Store at -20
oC before use. 
3.3 Rehydration buffer 
Buffer consists 6 M urea, 2 M thiourea, 4% CHAPS, 65 mM DTT and trace 
Bromophenol blue. Add 0.5% IPG buffer prior to use. 
3.4 First SDS equilibration buffer solution 
Buffer consists 6 M urea, 75 mM Tris-base, 29.3% Glycerol (v/v), 2% SDS (w/v), 
0.002% Bromophenol blue in 200 ml ddH2O. Aliquot and store at -20
oC. Add 100 
mg DDT/10 ml equilibration buffer prior to use.     
3.5 Second SDS equilibration buffer solution 
Buffer consists 6 M urea, 75 mM Tris-base, 29.3% Glycerol (v/v), 2% SDS (w/v), 
0.002% Bromophenol blue in 200 ml ddH2O. Aliquot and store at -20
oC. Add 250 
mg iodoacetamine/10 ml equilibration buffer prior to use.   
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3.6 Gel formulation (12% SDS-PAGE gel) 
For 100 ml solution, add 42.25 ml ddH2O, 31.25 ml 40% Acrylamide/Bis, 25 ml 
1.5 M Tris-HCl pH 8.8, 1.0 ml 10% (w/v) SDS, 500 µl 10% (w/v) APS and 33 µl 
TEMED. Add APS and TEMED just before casting the gel. 
3.7 1% Bromophenol blue stock solution 
Dissolve 100 mg Bromophenol blue, 60 mg Tris-base with 10 ml ddH2O. Aliquot 
and store at -20oC before use.    
Appendix 4: Bacteria and worm culture 
4.1 L-Broth, pH 7.0 (makes 1 L) 
Dissolve 10 g NaCl, 10 g Tryptone and 5 g yeast to 800 ml ddH2O and bring the 
total volume to 1 L. Sterilise by autoclaving and store at room temperature. 
4.2 L-Broth agar 
Add 7.5 g agar to 500 ml L-Broth and sterilise by autoclaving and store at room 
temperature.  
4.3 NGM agar 
Add 3 g NaCl, 17 g agar, 2.5 g Peptone to 975 ml of ddH2O. Sterilise by 
autoclaving, cool flask to 55oC for 15 min. Then add 1.0 ml of 1 M CaCl2, 1.0 ml 
of 5 mg/ml cholesterol in ethanol, 1.0 ml of 1 M MgSO4 , 25 ml of 1 M KH2PO4. 
Store at 4oC. 
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4.4 Cholesterol-free NGM 
Add 3 g NaCl, 17 g agar, 2.5 g Peptone to 975 ml of ddH2O. Sterilise by 
autoclaving, cool flask to 55oC for 15 min. Then add 1.0 ml of 1 M CaCl2, 1.0 ml 
of 1 M MgSO4 , 25 ml of 1 M KH2PO4. Store at 4
oC. 
4.5 RPMI-1640 medium for B. pahangi culture 
Add 1 ml 50% glucose, 100 units/ml streptomycin, 100 µg/ml penicillin to 100 ml 
RPMI-1640 with containing 5 mM glutamine, 25 mM HEPES (Invitrogen, UK. Cat: 
52400-017). Incubate at 37oC before use.   
4.6 Ivermectin stock solution 
Dissolve 1 mg ivermectin with 1.0 ml of DMSO to give 1 mg/ml concentration. 
Pipette 100 µl and add to 10.0 ml DMSO to give a final concentration of 10 
µg/ml. Store at -20oC before use.     
4.7 Ivermectin plates 
Add 500 µl 25 mg/ml water-soluble cholesterol (Sigma, UK. Cat: C1145-250MG) 
to 500 ml of cholesterol-free NGM. For 10 ng/ml plates (5 x 10 ml), add 50 µl 10 
µg/ml ivermectin to 50 ml NGM to give final concentration of 10 ng/ml. Add 30 
µl 10 µg/ml ivermectin to 50 ml NGM to give final concentration of 6 ng/ml. 
Store plate at room temperature.  
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2Appendix 5: Other buffers and solutions 
5.1 Bleach solution (makes 10 ml) 
Add 625 µl 4 M NaOH, 1500 µl sodium hypochlorite to 7875 µl of ddH2O. Prepare 
fresh as required.   
5.2 M9 buffer (makes 1 L) 
Dissolve 3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 ml MgSO4 in ddH2O and bring up to 
1 L and sterilise by autoclaving and store at room temperature. 
5.3 50% (w/v) glucose stock 
Dissolve 50 g of sucrose to 80 ml ddH2O. Bring up volume to 100 ml with ddH2O 
and store at room temperature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  275 
 
Appendix 6: MASCOT Search Results  
6.1 Down-regulated 
6.1.1 1a - Tropomyosin 
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6.1.2 1b - Myosin regulatory light chain 1  
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6.1.3 1c - Actin-depolymerising factor 1 
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6.1.4 - Actin-depolymerising factor 1 
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6.1.5 - DJ-family protein 
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6.2 Similar in both groups 
6.2.1 2a - Small heat shock protein 
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6.2.2 2b - Alkali myosin light chain 
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6.2.3 2c - Thioredoxin 
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6.2.4 2d - Small heat shock protein 
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6.2.5 2e - Tropomyosin 
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6.3 Up-regulated 
6.3.1 3a - Myosin regulatory light chain 1 
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6.3.2 3b – Tropomyosin 
 
 
